Bristol-Myers Squibb (BMY) 10-K14 Feb 232022 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 31, 2022	Feb. 07, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-01136
Entity Registrant Name	BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-0790350
Entity Address, Address Line One	430 E. 29th Street, 14FL
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	212
Local Phone Number	546-4200
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 164,301,052,839
Entity Common Stock, Shares Outstanding		2,098,775,978
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE: Portions of the definitive proxy statement for the registrant’s Annual Meeting of Shareholders to be filed within 120 days after the conclusion of the registrant's fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.
Entity Central Index Key	0000014272
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Small Business	false
Common Stock, $0.10 Par Value
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.10 Par Value
Trading Symbol	BMY
Security Exchange Name	NYSE
1.000% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2025
Trading Symbol	BMY25
Security Exchange Name	NYSE
1.750% Notes due 2035
Document Information [Line Items]
Title of 12(b) Security	1.750% Notes due 2035
Trading Symbol	BMY35
Security Exchange Name	NYSE
Celgene Contingent Value Rights
Document Information [Line Items]
Title of 12(b) Security	Celgene Contingent Value Rights
Trading Symbol	CELG RT
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Location	Morristown, New Jersey
Auditor Firm ID	34

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions		12 Months Ended
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total Revenues		$ 46,159	$ 46,385	$ 42,518
Cost of products sold	[1]	10,137	9,940	11,773
Marketing, selling and administrative		7,814	7,690	7,661
Research and development		9,509	10,195	10,048
Acquired IPRD		815	1,159	12,533
Amortization of acquired intangible assets		9,595	10,023	9,688
Other (income)/expense, net		576	(720)	(2,314)
Total Expenses		38,446	38,287	49,389
Earnings/(Loss) Before Income Taxes		7,713	8,098	(6,871)
Provision for Income Taxes		1,368	1,084	2,124
Net Earnings/(Loss)		6,345	7,014	(8,995)
Noncontrolling Interest		18	20	20
Net Earnings(Loss) Attributable to BMS		$ 6,327	$ 6,994	$ (9,015)
Earnings per common share attributable to BMS, basic (in usd per share)		$ 2.97	$ 3.15	$ (3.99)
Earnings per common share attributable to BMS, diluted (in usd per share)		$ 2.95	$ 3.12	$ (3.99)
Net product sales
Total Revenues		$ 44,671	$ 45,055	$ 41,321
Alliance and other revenues
Total Revenues		$ 1,488	$ 1,330	$ 1,197

[1]Excludes amortization of acquired intangible assets.

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net Earnings/(Loss)	$ 6,345	$ 7,014	$ (8,995)
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings:
Derivatives qualifying as cash flow hedges	54	415	(256)
Pension and postretirement benefits	145	206	(75)
Marketable debt securities	(2)	(9)	5
Foreign currency translation	(210)	(41)	7
Total Other Comprehensive Income/(Loss)	(13)	571	(319)
Comprehensive Income/(Loss)	6,332	7,585	(9,314)
Comprehensive Income Attributable to Noncontrolling Interest	18	20	20
Comprehensive Income/(Loss) Attributable to BMS	$ 6,314	$ 7,565	$ (9,334)

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 9,123	$ 13,979
Marketable debt securities	130	2,987
Receivables	9,886	9,369
Inventories	2,339	2,095
Other current assets	5,795	4,832
Total Current Assets	27,273	33,262
Property, plant and equipment	6,255	6,049
Goodwill	21,149	20,502
Other intangible assets	35,859	42,527
Deferred income taxes	1,344	1,439
Other non-current assets	4,940	5,535
Total Assets	96,820	109,314
Current Liabilities:
Short-term debt obligations	4,264	4,948
Accounts payable	3,040	2,949
Other current liabilities	14,586	13,971
Total Current Liabilities	21,890	21,868
Deferred income taxes	2,166	4,501
Long-term debt	35,056	39,605
Other non-current liabilities	6,590	7,334
Total Liabilities	65,702	73,308
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021	292	292
Capital in excess of par value of stock	45,165	44,361
Accumulated other comprehensive loss	(1,281)	(1,268)
Retained earnings	25,503	23,820
Less cost of treasury stock — 825 million common shares in 2022 and 747 million common shares in 2021	(38,618)	(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity	31,061	35,946
Noncontrolling interest	57	60
Total Equity	31,118	36,006
Total Liabilities and Equity	$ 96,820	$ 109,314

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share (in usd per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	2,991	3,484
Preferred stock, shares outstanding (in shares)	2,991	3,484
Preferred stock, liquidation preference per share (in usd per share)	$ 50	$ 50
Common stock, par or stated value per share (in usd per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	4,500,000,000	4,500,000,000
Common stock, shares issued (in shares)	2,900,000,000	2,900,000,000
Treasury stock, shares (in shares)	825,000,000	747,000,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities:
Net Earnings/(Loss)	$ 6,345	$ 7,014	$ (8,995)
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization, net	10,276	10,686	10,380
Deferred income taxes	(2,738)	(1,393)	983
Stock-based compensation	457	583	779
Impairment charges	179	1,207	1,203
Divestiture gains and royalties	(1,063)	(684)	(699)
Acquired IPRD	815	1,159	12,533
Equity investment losses/(gains), net	801	(745)	(1,228)
Contingent consideration fair value adjustments	(9)	(542)	(1,757)
Other adjustments	232	183	(134)
Changes in operating assets and liabilities:
Receivables	(663)	(1,054)	(646)
Inventories	(69)	13	2,672
Accounts payable	109	245	188
Rebates and discounts	427	863	1,189
Income taxes payable	(1,423)	(1,063)	(2,305)
Other	(610)	(265)	(111)
Net Cash Provided by Operating Activities	13,066	16,207	14,052
Cash Flows From Investing Activities:
Sale and maturities of marketable debt securities	6,411	4,196	6,280
Purchase of marketable debt securities	(3,592)	(5,478)	(4,172)
Proceeds from sales of equity investment securities	218	2,579	129
Capital expenditures	(1,118)	(973)	(753)
Divestiture and other proceeds	1,305	748	741
Acquisition and other payments, net of cash acquired	(4,286)	(1,610)	(13,084)
Net Cash Used in Investing Activities	(1,062)	(538)	(10,859)
Cash Flows From Financing Activities:
Short-term debt obligations, net	194	(160)	(267)
Issuance of long-term debt	5,926	0	6,945
Repayment of long-term debt	(11,431)	(6,022)	(2,750)
Repurchase of common stock	(8,001)	(6,287)	(1,546)
Dividends	(4,634)	(4,396)	(4,075)
Stock option proceeds and other, net	984	641	542
Net Cash Used in Financing Activities	(16,962)	(16,224)	(1,151)
Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash	(33)	(102)	111
(Decrease)/Increase in Cash, Cash Equivalents and Restricted Cash	(4,991)	(657)	2,153
Cash, Cash Equivalents and Restricted Cash at Beginning of Year	14,316	14,973	12,820
Cash, Cash Equivalents and Restricted Cash at End of Year	$ 9,325	$ 14,316	$ 14,973

ACCOUNTING POLICIES AND RECENTL

ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Accounting Policies and Recently Issued Accounting Standards	ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS Nature of Operations and Basis of Consolidation Bristol-Myers Squibb Company (“BMS”, or “the Company”) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The consolidated financial statements are prepared in conformity with U.S. GAAP, including the accounts of Bristol-Myers Squibb Company and all of its controlled majority-owned subsidiaries and certain variable interest entities. All intercompany balances and transactions are eliminated. Material subsequent events are evaluated and disclosed through the report issuance date. Refer to the Summary of Abbreviated Terms at the end of this 2022 Form 10-K for definitions of capitalized terms used throughout the document. Alliance and license arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of an entity. Entities controlled by means other than a majority voting interest are referred to as variable interest entities and are consolidated when BMS has both the power to direct the activities of the variable interest entity that most significantly impacts its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS ’ s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.” Use of Estimates and Judgments The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of intangible assets; charge-backs, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates. Reclassifications Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Upfront and contingent milestone charges in connection with asset acquisitions or licensing of third-party intellectual property rights previously presented in Research and development are now presented in Acquired IPRD in the consolidated statements of earnings. Cash and Cash Equivalents Cash and cash equivalents include bank deposits, time deposits, commercial paper and money market funds. Cash equivalents consist of highly liquid investments with original maturities of three months or less at the time of purchase and are recognized at cost, which approximates fair value. Marketable Debt Securities Marketable debt securities are classified as “available-for-sale” on the date of purchase and reported at fair value. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit default risk or underlying security and overall capital market liquidity. Marketable debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary, which considers the intent and ability to retain the investment for a period of time sufficient to allow for any anticipated recovery in market value, the duration and extent that the market value has been less than cost and the investee's financial condition. Equity Investments Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in Other (income)/expense, net. Equity investments without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Changes in the estimated fair value of equity investments without readily determinable fair values are recorded in Other (income)/expense, net. BMS holds investments in limited partnerships, which primarily invest in early-stage life sciences companies. Such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. Investments in 50% or less owned companies, as well as limited partnerships, are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The proportional share of the investee's net income or losses of equity investments accounted for using the equity method are included in Other (income)/expense, net. Equity investments without readily determinable fair values and equity investments accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors. Inventory Valuation Inventories are stated at the lower of average cost or net realizable value. Property, Plant and Equipment and Depreciation Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight-line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures. Current facts or circumstances are periodically evaluated to determine if the carrying value of depreciable assets to be held and used may not be recoverable. If such circumstances exist, an estimate of undiscounted future cash flows generated by the long-lived asset, or appropriate grouping of assets, is compared to the carrying value to determine whether an impairment exists at its lowest level of identifiable cash flows. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques using unobservable fair value inputs, such as a discounted value of estimated future cash flows. Capitalized Software Eligible costs to obtain internal use software are capitalized and amortized over the estimated useful life of the software ranging from three Acquisitions Businesses acquired are consolidated upon obtaining control. The fair value of assets acquired and liabilities assumed are recognized at the date of acquisition. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. Business acquisition costs are expensed when incurred. Contingent consideration from potential development, regulatory, approval and sales-based milestones and sales-based royalties are included in the purchase price for business combinations and excluded for asset acquisitions. If the assets acquired do not meet the definition of a business, primarily because no significant processes were acquired or substantially all of the relative fair value was allocated to a single asset, the transaction is accounted for as an asset acquisition rather than a business combination and no goodwill is recorded. In addition, in an asset acquisition, acquired in-process research and development ("IPRD") assets with no alternative future use are charged to Acquired IPRD. Goodwill, IPRD and Other Intangible Assets The fair value of acquired intangible assets is determined using an income-based approach referred to as the excess earnings method utilizing Level 3 fair value inputs. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success. Finite-lived intangible assets, including licenses, marketed product rights and IPRD projects that reach commercialization are amortized on a straight-line basis over their estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. Examples of qualitative factors assessed include BMS ’ s share price, financial performance compared to budgets, long-term financial plans, macroeconomic, industry and market conditions as well as the substantial excess of fair value over the carrying value of net assets from the annual impairment test performed in a prior year. Each relevant factor is assessed both individually and in the aggregate. IPRD is tested for impairment at least annually or more frequently if events occur or circumstances change that would indicate a potential reduction in the fair values of the assets below their carrying value. Impairment charges are recognized to the extent the carrying value of IPRD is determined to exceed its fair value. Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. Derivatives designated as hedges, are assessed at inception and quarterly thereafter, to determine whether they are highly effective in offsetting changes or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in Accumulated other comprehensive loss and are subsequently recognized in earnings consistent with the underlying hedged item. If a derivative is no longer highly effective as a hedge, the Company discontinues hedge accounting prospectively. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from Accumulated other comprehensive loss to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The Company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in foreign currency translation in Accumulated other comprehensive loss. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in investing activities. Restructuring Restructuring charges are recognized as a result of actions to streamline operations, realize synergies from acquisitions and reduce the number of facilities. Estimating the impact of restructuring plans, including future termination benefits, integration expenses and other exit costs, requires judgment. Actual results could vary from these estimates. Restructuring charges are recognized upon meeting certain criteria, including finalization of committed plans, reliable estimates and discussions with local works councils in certain markets. Contingencies Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product and environmental liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Gain contingencies (including contingent proceeds related to the divestitures) are not recognized until realized. Legal fees are expensed as incurred. Revenue Recognition Refer to “—Note 2. Revenue” for a detailed discussion of accounting policies related to revenue recognition, including deferred revenue and royalties. Refer to “—Note 3. Alliances” for further details regarding alliances. Research and Development and Acquired IPRD Research and development costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Research and development costs are presented net of reimbursements from alliance partners. Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid assets and expensed in the period when the services are performed. Acquired IPRD expenses include upfront payments, contingent milestone payments in connection with asset acquisitions or in-license arrangements of third-party intellectual property rights, as well as any upfront and contingent milestones payable by BMS to alliance partners prior to regulatory approval. The Company's Acquired IPRD by type of transaction was as follows: Type of transaction Year ended December 31, Dollars in Millions 2022 2021 2020 Alliance (Note 3) $ 100 $ 730 $ 258 In-license arrangements and other (Note 4) 715 429 659 Asset acquisitions (Note 4) — — 11,616 Acquired IPRD $ 815 $ 1,159 $ 12,533 Advertising and Product Promotion Costs Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $1.3 billion in 2022 and 2021 and $990 million in 2020. Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recognized in Other Comprehensive Income/(Loss). Income Taxes The provision for income taxes includes income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recognized to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. The tax effects of global intangible low-taxed income from certain foreign subsidiaries is recognized in the income tax provision in the period the tax arises. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Recently Issued Accounting Standards Not Yet Adopted Business Combinations In October 2021, the FASB issued amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. The guidance is intended to address inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized. At the acquisition date, an entity should account for the related revenue contracts in accordance with existing revenue recognition guidance generally by assessing how the acquiree applied recognition and measurement in their financial statements. The amended guidance is effective January 1, 2023 on a prospective approach. Fair Value Measurements In June 2022, the FASB issued amended guidance on measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The guidance also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendment requires the following disclosures for equity securities subject to contractual sale restrictions: the fair value of equity securities subject to contractual sale restrictions reflected in the balance sheet; the nature and remaining duration of the restriction(s); and the circumstances that could cause a lapse in the restriction(s). The amended guidance is effective January 1, 2024 on a prospective basis. Early adoption is permitted.

REVENUE

REVENUE	12 Months Ended
REVENUE	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following table summarizes the disaggregation of revenue by nature: Year Ended December 31, Dollars in Millions 2022 2021 2020 Net product sales $ 44,671 $ 45,055 $ 41,321 Alliance revenues 742 716 615 Other revenues 746 614 582 Total Revenues $ 46,159 $ 46,385 $ 42,518 Net product sales represent more than 95% of total revenues for all periods presented. Products are sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, directly to retailers, hospitals, clinics and government agencies. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of control of the product to the customer. The transfer occurs either upon shipment, upon receipt of the product after considering when the customer obtains legal title to the product, or upon infusion for cell therapies and when BMS obtains a right of payment. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product. Gross revenue to the three largest pharmaceutical wholesalers in the U.S. as a percentage of U.S. gross revenues was as follows: Year Ended December 31, 2022 2021 2020 McKesson Corporation 32 % 32 % 31 % AmerisourceBergen Corporation 25 % 25 % 25 % Cardinal Health, Inc. 21 % 20 % 19 % Wholesalers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practices in each country. Revenue is reduced from wholesaler list price at the time of recognition for expected charge-backs, discounts, rebates, sales allowances and product returns ("GTN adjustments"). These GTN adjustments are attributed to various commercial arrangements, managed healthcare organizations and government programs such as Medicare, Medicaid and the 340B program containing various pricing implications, such as mandatory discounts, pricing protection below wholesaler list price or other discounts when Medicare Part D beneficiaries are in the coverage gap. In addition, non-U.S. government programs include different pricing schemes such as cost caps, volume discounts, outcome-based pricing and pricing claw-backs determined on sales of individual companies or an aggregation of companies participating in a specific market. Charge-backs and cash discounts are reflected as a reduction to receivables and settled through the issuance of credits to the customer, typically within one month. All other rebates, discounts and adjustments, including Medicaid and Medicare, are reflected as a liability and settled through cash payments to the customer, typically within various time periods ranging from a few months to one year. Significant judgment is required in estimating GTN adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel. The following table summarizes GTN adjustments: Year Ended December 31, Dollars in Millions 2022 2021 2020 Gross product sales $ 69,633 $ 67,897 $ 60,016 GTN adjustments (a) Charge-backs and cash discounts (7,469) (7,253) (5,827) Medicaid and Medicare rebates (11,362) (9,374) (7,595) Other rebates, returns, discounts and adjustments (6,131) (6,215) (5,273) Total GTN adjustments (24,962) (22,842) (18,695) Net product sales $ 44,671 $ 45,055 $ 41,321 (a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $229 million in 2022, $319 million in 2021 and $106 million in 2020. Alliance and other revenues consist primarily of amounts related to collaborations and out-licensing arrangements. Each of these arrangements are evaluated for whether they represent contracts that are within the scope of the revenue recognition guidance in their entirety or contain aspects that are within the scope of the guidance, either directly or by reference based upon the application of the guidance related to the derecognition of nonfinancial assets (ASC 610). Performance obligations are identified and separated when the other party can benefit directly from the rights, goods or services either on their own or together with other readily available resources and when the rights, goods or services are not highly interdependent or interrelated. Transaction prices for these arrangements may include fixed upfront amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development, regulatory and sales-based milestones because the ultimate outcomes are binary in nature. The expected value method is used to estimate royalties because a broad range of potential outcomes exist, except for instances in which such royalties relate to a license. Variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Significant judgment is required in estimating the amount of variable consideration to recognize when assessing factors outside of BMS’s influence such as likelihood of regulatory success, limited availability of third party information, expected duration of time until resolution, lack of relevant past experience, historical practice of offering fee concessions and a large number and broad range of possible amounts. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price and recognized at a point in time upon the transfer of control. Three types of out-licensing arrangements are typically utilized: (i) arrangements when BMS out-licenses intellectual property to another party and has no further performance obligations; (ii) arrangements that include a license and an additional performance obligation to supply product upon the request of the third party; and (iii) collaboration arrangements, which include transferring a license to a third party to jointly develop and commercialize a product. Most out-licensing arrangements consist of a single performance obligation that is satisfied upon execution of the agreement when the development and commercialization rights are transferred to a third party. Upfront fees are recognized immediately and included in Other (income)/expense, net. Although contingent development and regulatory milestone amounts are assessed each period for the likelihood of achievement, they are typically constrained and recognized when the uncertainty is subsequently resolved for the full amount of the milestone and included in Other (income)/expense, net. Sales-based milestones and royalties are recognized when the milestone is achieved or the subsequent sales occur. Sales-based milestones and royalties are included in Alliance and other revenues. Certain out-licensing arrangements may also include contingent performance obligations to supply commercial product to the third party upon its request. The license and supply obligations are accounted for as separate performance obligations as they are considered distinct because the third party can benefit from the license either on its own or together with other supply resources readily available to it and the obligations are separately identifiable from other obligations in the contract in accordance with the revenue recognition guidance. After considering the standalone selling prices in these situations, upfront fees, contingent development and regulatory milestone amounts and sales-based milestone and royalties are allocated to the license and recognized in the manner described above. Consideration for the supply obligation is usually based upon stipulated cost-plus margin contractual terms which represent a standalone selling price. The supply consideration is recognized at a point in time upon transfer of control of the product to the third party and included in Alliance and other revenues. The above fee allocation between the license and the supply represents the amount of consideration expected to be entitled to for the satisfaction of the separate performance obligations. Although collaboration arrangements are unique in nature, both parties are active participants in the operating activities and are exposed to significant risks and rewards depending on the commercial success of the activities. Performance obligations inherent in these arrangements may include the transfer of certain development or commercialization rights, ongoing development and commercialization services and product supply obligations. Except for certain product supply obligations which are considered distinct and accounted for as separate performance obligations similar to the manner discussed above, all other performance obligations are not considered distinct and are combined into a single performance obligation since the transferred rights are highly integrated and interrelated to the obligation to jointly develop and commercialize the product with the third party. As a result, upfront fees are recognized ratably over time throughout the expected period of the collaboration activities and included in Other (income)/expense, net as the license is combined with other development and commercialization obligations. Contingent development and regulatory milestones that are no longer constrained are recognized in a similar manner on a prospective basis. Royalties and profit sharing are recognized when the underlying sales and profits occur and are included in Alliance and other revenues. Refer to “—Note 3. Alliances” for further information. The following table summarizes the disaggregation of revenue by product and region: Year Ended December 31, Dollars in Millions 2022 2021 2020 In-Line Products Eliquis $ 11,789 $ 10,762 $ 9,168 Opdivo 8,249 7,523 6,992 Pomalyst/Imnovid 3,497 3,332 3,070 Orencia 3,464 3,306 3,157 Sprycel 2,165 2,117 2,140 Yervoy 2,131 2,026 1,682 Empliciti 296 334 381 Mature and other brands 1,749 1,900 2,217 New Product Portfolio Reblozyl 717 551 274 Abecma 388 164 — Opdualag 252 — — Zeposia 250 134 12 Breyanzi 182 87 — Onureg 124 73 17 Inrebic 85 74 55 Camzyos 24 — — Sotyktu 8 — — Recent LOE Products (a) Revlimid 9,978 12,821 12,106 Abraxane 811 1,181 1,247 Total Revenues $ 46,159 $ 46,385 $ 42,518 United States $ 31,828 $ 29,214 $ 26,577 International 13,497 16,319 15,310 Other (b) 834 852 631 Total Revenues $ 46,159 $ 46,385 $ 42,518 (a) Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity. (b) Other include royalties and alliance-related revenues for products not sold by BMS ’ s regional commercial organizations. Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material during the years ended December 31, 2022, 2021 and 2020. Revenue recognized from performance obligations satisfied in prior periods was $556 million in 2022, $561 million in 2021 and $338 million in 2020 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less than one year.

ALLIANCES

ALLIANCES	12 Months Ended
ALLIANCES	Dec. 31, 2022
Supplemental Income Statement Elements [Abstract]
Alliances	ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners. The most common activities between BMS and its alliance partners are presented in results of operations as follows: • When BMS is the principal in the end customer sale, 100% of product sales are included in Net product sales. When BMS's alliance partner is the principal in the end customer sale, BMS’s contractual share of the third-party sales and/or royalty income are included in Alliance revenues as the sale of commercial products are considered part of BMS’s ongoing major or central operations. Refer to “—Note 2. Revenue” for information regarding recognition criteria. • Amounts payable to BMS by alliance partners (who are the principal in the end customer sale) for supply of commercial products are included in Alliance revenues as the sale of commercial products are considered part of BMS’s ongoing major or central operations. • Profit sharing, royalties and other sales-based fees payable by BMS to alliance partners are included in Cost of products sold as incurred. • Cost reimbursements between the parties are recognized as incurred and included in Cost of products sold; Marketing, selling and administrative expenses; or Research and development expenses, based on the underlying nature of the related activities subject to reimbursement. • Upfront and contingent development and regulatory approval milestones payable to BMS by alliance partners for investigational compounds and commercial products are deferred and amortized over the expected period of BMS's development and co-promotion obligation through the market exclusivity period or the periods in which the related compounds or products are expected to contribute to future cash flows. The amortization is presented consistent with the nature of the payment under the arrangement. For example, amounts received for investigational compounds are presented in Other (income)/expense, net as the activities being performed at that time are not related to the sale of commercial products included in BMS’s ongoing major or central operations; amounts received for commercial products are presented in alliance revenue as the sale of commercial products are considered part of BMS’s ongoing major or central operations. • Upfront and contingent regulatory approval milestones payable by BMS to alliance partners for commercial products are capitalized and amortized over the shorter of the contractual term or the periods in which the related products are expected to contribute to future cash flows. • Upfront and contingent milestones payable by BMS to alliance partners prior to regulatory approval are expensed as incurred and included in Acquired IPRD expense. • Royalties and other contingent consideration payable to BMS by alliance partners related to the divestiture of such businesses are included in Other (income)/expense, net when earned. • All payments between BMS and its alliance partners are presented in Cash Flows From Operating Activities except for upfront and milestone payments which are presented in Cash Flows From Investing Activities. Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from alliances: Net product sales $ 12,001 $ 10,840 $ 9,364 Alliance revenues 742 716 615 Total Revenues $ 12,743 $ 11,556 $ 9,979 Payments to/(from) alliance partners: Cost of products sold $ 5,768 $ 5,227 $ 4,485 Marketing, selling and administrative (223) (183) (128) Research and development 49 42 91 Acquired IPRD 100 730 258 Other (income)/expense, net (53) (62) (74) Selected alliance balance sheet information: December 31, Dollars in Millions 2022 2021 Receivables – from alliance partners $ 317 $ 320 Accounts payable – to alliance partners 1,249 1,229 Deferred income from alliances (a) 289 330 (a) Includes unamortized upfront and milestone payments. Specific information pertaining to significant alliances is discussed below, including their nature and purpose; the significant rights and obligations of the parties; specific accounting policy elections; and the statements of earnings classification of and amounts attributable to payments between the parties. Pfizer BMS and Pfizer jointly develop and commercialize Eliquis , an anticoagulant discovered by BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis except in certain countries where Pfizer commercializes Eliquis and pays BMS a sales-based fee. The co-exclusive license rights granted to Pfizer in exchange for an upfront payment and potential milestone payments were recorded to Deferred income and are being amortized in Other (income)/expense, net, as Eliquis was not a commercial product at the commencement of the alliance. The upfront payment and any subsequent contingent milestone proceeds are amortized over the expected period of BMS's co-promotion obligation through the market exclusivity period. Both parties assumed certain obligations to actively participate in a joint executive committee and various other operating committees and have joint responsibilities for the research, development, distribution, sales and marketing activities of the alliance using resources in their own infrastructures. BMS and Pfizer manufacture the product in the alliance and BMS is the principal in the end customer product sales in the U.S., significant countries in Europe, as well as Canada, Australia, China, Japan and South Korea. In certain smaller countries, Pfizer has full commercialization rights and BMS supplies the product to Pfizer at cost plus a percentage of the net sales price to end-customers, which is recorded in full upon transfer of control of the product to Pfizer. Summarized financial information related to this alliance was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from Pfizer alliance: Net product sales $ 11,488 $ 10,431 $ 8,942 Alliance revenues 301 331 226 Total Revenues $ 11,789 $ 10,762 $ 9,168 Payments to/(from) Pfizer: Cost of products sold – Profit sharing $ 5,604 $ 5,064 $ 4,331 Other (income)/expense, net – Amortization of deferred income (42) (36) (55) Selected alliance balance sheet information: December 31, Dollars in Millions 2022 2021 Receivables $ 191 $ 235 Accounts payable 1,208 1,195 Deferred income 222 264 Ono BMS and Ono jointly develop and commercialize Opdivo , Yervoy and several BMS investigational compounds in Japan, South Korea and Taiwan. BMS is responsible for supply of the products. Profits, losses and development costs are shared equally for all combination therapies involving compounds of both parties. Otherwise, sharing is 80% and 20% for activities involving only one of the party’s compounds. BMS and Ono also jointly develop and commercialize Orencia in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. A co-promotion fee of 60% is paid when a sale is made to the other party’s assigned customer. Summarized financial information related to this alliance was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from Ono alliances: Net product sales $ 216 $ 251 $ 194 Alliance revenues 441 385 382 Total Revenues $ 657 $ 636 $ 576 BMS is the principal in the end customer product sales and has the exclusive right to develop, manufacture and commercialize Opdivo worldwide except in Japan, South Korea and Taiwan. Ono is entitled to receive royalties of 4% in North America and 15% in all territories excluding the three countries listed above, subject to customary adjustments. Nektar In 2022, BMS and Nektar discontinued the global clinical development program for bempegaldesleukin (NKTR-214) in combination with Opdivo based on results from pre-planned analyses of three late-stage clinical studies in RCC and bladder cancer. These studies and all other ongoing studies in the program are being discontinued. Research and development cost reimbursements were not material in 2022, 2021 and 2020. BridgeBio In May 2022, BMS and BridgeBio commenced a collaboration to develop and commercialize BBP-398, a SHP2 inhibitor, in oncology. The transaction included an upfront payment of $90 million which was expensed to Acquired IPRD. BridgeBio is eligible to receive contingent development, regulatory and sales-based milestones up to $815 million, as well as royalties on global net sales, excluding certain markets. BridgeBio is responsible for funding and completing ongoing BBP-398 Phase I monotherapy and combination therapy trials. BMS will lead and fund all other development and commercial activities. BridgeBio has an option to co-develop BBP-398 and receive higher royalties in the U.S. 2seventy bio BMS and 2seventy bio jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration includes (i) a right for BMS to license any anti-BCMA products resulting from the collaboration, (ii) a right for 2seventy bio to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to 2seventy bio upon the commercialization of any licensed products resulting from the collaboration should 2seventy bio decline to exercise their co-development and profit sharing rights. The option to license idecabtagene vicleucel ( Abecma ) was exercised in 2016. All profits and losses relating to developing, commercializing and manufacturing ide-cel within the U.S. are shared equally. BMS is exclusively responsible for the development and commercialization of ide-cel outside the U.S. In 2021, the FDA approved Abecma for the treatment of relapsed or refractory multiple myeloma. Net product sales of Abecma were $297 million and $158 million; and the related profit sharing costs were $49 million and $42 million in 2022 and 2021, respectively. Cost reimbursements were not material. In 2020, terms of the collaboration were amended including certain manufacturing obligations. Both parties were also released from future exclusivity related to BCMA-directed T cell therapies. BMS paid $200 million to extinguish its obligation for future ex-U.S. milestones and royalties on ide-cel, which was expensed to Acquired IPRD in 2020. Eisai In 2021, BMS and Eisai commenced an exclusive global strategic collaboration for the co-development and co-commercialization of MORAb-202, a selective folate receptor alpha antibody-drug conjugate being investigated in endometrial, ovarian, lung and breast cancers. MORAb-202 is currently in Phase I/II clinical trials for solid tumors. The parties will jointly develop and commercialize MORAb-202 in the U.S., Canada, Europe, Russia, Japan, China and certain other countries in the Asia-Pacific region (the “collaboration territory”). Eisai will be responsible for the global manufacturing and supply. Profits, research and development and commercialization costs are shared in the collaboration territories. BMS will be responsible for development and commercialization outside of the collaboration territory and will pay a royalty on those sales. A $650 million upfront collaboration fee was expensed to Acquired IPRD in 2021. BMS is also obligated to pay up to $2.5 billion upon the achievement of contingent development, regulatory and sales-based milestones. Cost reimbursements were not material.

ACQUISITIONS, DIVESTITURES, LIC

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS	12 Months Ended
	Dec. 31, 2022
Acquisitions and Divestitures [Abstract]
Acquisitions, divestitures, licensing and other arrangements	ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS Acquisitions Turning Point On August 17, 2022, BMS acquired Turning Point for $4.1 billion of cash (or $3.3 billion net of cash acquired). Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS rights to Turning Point's lead asset, repotrectinib, and other clinical and pre-clinical stage assets. The transaction was accounted for as a business combination requiring all assets acquired and liabilities assumed to be recognized at their fair value as of the acquisition date. The total consideration for the acquisition consisted of the following: Dollars in Millions Total Consideration Cash consideration for outstanding shares $ 3,811 Cash consideration for equity awards 302 Consideration paid 4,113 Less: Unvested stock awards (a) 153 Total consideration to be allocated $ 3,960 (a) Includes unvested equity awards of $73 million expensed in Marketing, selling, and administrative and $80 million expensed in Research and development in 2022. The purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed as of the acquisition date based upon their respective fair values summarized below: Dollars in Millions Purchase Price Allocation Cash and cash equivalents $ 795 Other current assets 14 Intangible assets (a) 2,971 Deferred income tax assets 229 Other non-current assets 10 Deferred income tax liabilities (643) Other current liabilities (111) Identifiable net assets acquired $ 3,265 Goodwill (b) 695 Total consideration allocated $ 3,960 (a) Intangible assets primarily consist of IPRD allocated to repotrectinib ($2.8 billion), a potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers in NSCLC and other advanced solid tumors. Repotrectinib is currently in registrational Phase II study in adults and a Phase I/II study in pediatric patients. The estimated fair value of IPRD assets was determined using an income approach valuation method. (b) Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes. The results of Turning Point's operations were included in the consolidated financial statements commencing August 18, 2022, and were not material. Historical financial results of the acquired entity were not significant. MyoKardia In November 2020, BMS acquired MyoKardia for $13.1 billion, including cash settlements of equity stock awards. MyoKardia was a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. The acquisition provided BMS with rights to MyoKardia’s lead asset, mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy. Mavacamten was approved by FDA in April 2022 under the brand name Camzyos . BMS funded the transaction through a combination of cash on hand from its operations and net proceeds received in connection with the 2020 senior unsecured notes offering. The transaction was accounted for as an asset acquisition since mavacamten represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). As a result, $11.4 billion was expensed to Acquired IPRD during 2020. Additionally, in connection with this acquisition, BMS recorded approximately $1.4 billion of assets primarily consisting of cash, deferred income taxes, licenses; liabilities assumed were $226 million. Total consideration paid also included $482 million of unvested stock awards expensed to Marketing, selling and administrative ($241 million) and Research and development ($241 million). Forbius In 2020, BMS acquired all of the outstanding shares of Forbius for $185 million and contingent development, regulatory and sales-based milestone payments up to $815 million. Forbius was a privately held, clinical-stage protein engineering company that designed and developed biotherapeutics for the treatment of cancer and fibrotic diseases. The acquisition provided BMS with full rights to Forbius' TGF-beta program, including the program’s lead investigational asset, AVID200, which was in Phase I development. BMS accounted for the transaction as an asset acquisition since AVID200 represented substantially all of the fair value of the gross assets acquired. As a result, $178 million was expensed to Acquired IPRD and $7 million was allocated to deferred tax assets. Divestitures The following table summarizes the financial impact of divestitures including royalty income, which is included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses). Net Proceeds (a) Divestiture (Gains)/Losses Royalty Income Dollars in Millions 2022 2021 2020 2022 2021 2020 2022 2021 2020 Diabetes business $ 767 $ 612 $ 558 $ — $ — $ — $ (810) $ (622) $ (567) Mature products and other 390 136 157 (211) (9) (55) (22) (44) (77) Total $ 1,157 $ 748 $ 715 $ (211) $ (9) $ (55) $ (832) $ (666) $ (644) (a) Includes proceeds from royalties received subsequent to the related sale of the asset or business. Diabetes Business In February 2014, BMS and AstraZeneca terminated their diabetes business alliance agreements and BMS sold to AstraZeneca substantially all of the diabetes business comprising the alliance. Consideration for the transaction included tiered royalty payments ranging from 10% to 25% based on net sales through 2025. Royalties were $924 million in 2022, $725 million in 2021 and $673 million in 2020. In 2015 and 2017, BMS transferred a percentage of its future royalty rights on Amelyn , Onglyza* and Farxiga* net product sales to third parties. As a result of these transfers, the royalty income associated with these products was reduced by $114 million in 2022, $103 million in 2021 and $106 million in 2020. Mature Products and Other Manufacturing Operations In January 2023, BMS sold its manufacturing facility in Syracuse, New York to LOTTE Corporation resulting in cash proceeds of $159 million, which was received in December 2022. The business was accounted for as held-for-sale as of December 31, 2022, and its assets were reduced to the estimated relative fair value resulting in a $63 million impairment charge recorded to Cost of products sold in 2022. Assets and liabilities reclassified to held-for-sale and included within Other current assets and Other current liabilities were $172 million and $20 million, respectively, as of December 31, 2022. Other In 2022, product rights to several mature products were sold to Cheplapharm, resulting in cash proceeds of $221 million and a divestiture gain of $211 million. In 2020, the product rights to a mature brand were sold resulting in proceeds of $50 million and divestiture gain of $49 million. Licensing and Other Arrangements Royalty and Licensing Income The following table summarizes the financial impact of Keytruda* royalties, Tecentriq * royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Year Ended December 31, Dollars in Millions 2022 2021 2020 Keytruda * royalties $ (1,001) $ (841) $ (681) Tecentriq * royalties (93) (90) (19) Upfront licensing fees — (34) (30) Contingent milestone income (50) (18) (72) Amortization of deferred income (53) (39) (58) Biohaven sublicense income (55) — — Other royalties (31) (45) (23) Total $ (1,283) $ (1,067) $ (883) Keytruda* Patent License Agreement In 2017, BMS and Ono entered a global patent license agreement with Merck related to Merck's PD-1 antibody Keytruda . In accordance with the agreement, Merck is obligated to pay ongoing royalties on global sales of Keytruda of 6.5% from January 1, 2017 through December 31, 2023, and 2.5% from January 1, 2024 through December 31, 2026. The companies also granted certain rights to each other under their respective patent portfolios pertaining to PD-1. Payments and royalties are shared between BMS and Ono on a 75/25 percent allocation, respectively after adjusting for each parties' legal fees. Tecentriq* Patent License Agreement In 2020, BMS and Ono entered a global patent license agreement with Roche Group related to Tecentriq , Roche’s anti-PD-L1 antibody. Under the agreement, Roche paid $324 million, which included royalties in 2020, and will pay single-digit royalties on worldwide net sales of Tecentriq through December 31, 2026. The upfront payment and royalties are shared between BMS and Ono consistent with existing agreements. BMS recorded $239 million in Other (income)/expense, net for the settlement in 2020. In-license and other arrangements Immatics In 2022, BMS obtained a global exclusive license to Immatics’ TCR bispecific IMA401 program. IMA401 is being studied in oncology and a Clinical Trial Application has been approved by the German federal regulatory authority. The trial commenced in May 2022. BMS and Immatics collaborate on the development and BMS will be responsible for the commercialization of IMA401 worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. Immatics has the option to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA401 in the U.S. The transaction included an upfront payment of $150 million which was expensed to Acquired IPRD in 2022. In addition, Immatics is eligible to receive contingent development, regulatory and sales-based milestones up to $770 million, as well as royalties on global net sales. Agenus In 2021, BMS obtained a global exclusive license to Agenus’ proprietary AGEN1777 bispecific antibody program that blocks TIGIT and an additional target. AGEN1777 is being studied in oncology and a Phase I clinical trial was initiated in October 2021. BMS is responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. The transaction included a payment of $200 million which was included in Acquired IPRD. In addition, Agenus is eligible to receive contingent development, regulatory and sales-based milestones up to $1.4 billion as well as royalties on global net sales. Dragonfly In 2020, BMS obtained a global exclusive license to Dragonfly’s interleukin-12 ("IL-12") investigational immunotherapy program, including its extended half-life cytokine DF6002. BMS is responsible for the development and any subsequent commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. Dragonfly continues to be involved in the development of DF6002 in current and certain future Phase I/II clinical trials. BMS paid $475 million to Dragonfly for the rights in 2020, which was expensed to Acquired IPRD. The payment included $75 million following the commencement of a Phase I combination clinical study. Dragonfly is eligible to receive additional contingent consideration comprised of development, regulatory and sales-based milestone payments up to $2.7 billion and royalties on global net sales. In 2022, a Phase I development milestone for IL-12 was achieved resulting in a $175 million payment to Dragonfly which was included in Acquired IPRD. The parties also amended the terms of three future milestones by requiring the achievement of certain criteria by specified dates unless BMS notifies Dragonfly that it will discontinue development of IL-12. These milestones continue to be considered substantive and contingent because the decision to proceed will be based on an assessment of clinical data prior to the specified dates. In January 2023, BMS notified Dragonfly that it was terminating the global exclusive license that relates to Dragonfly’s IL-12. The termination is effective 90 days after notification at which time all rights will revert back to Dragonfly. Nimbus BMS and Nimbus Therapeutics entered into a settlement resolving all legal claims and business interests pertaining to Nimbus’ TYK2 inhibitor in 2022 resulting in $40 million of income. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory and sales-based milestones upon the occurrence of certain events and approximately 10% of any change in control proceeds received by Nimbus Therapeutics related to its TYK2 inhibitor. In February 2023, Takeda acquired 100% ownership of Nimbus Therapeutics' TYK2 inhibitor for approximately $4.0 billion of upfront proceeds plus contingent sales-based milestones aggregating up to $2.0 billion. Other

OTHER (INCOME)_EXPENSE, NET

OTHER (INCOME)/EXPENSE, NET	12 Months Ended
OTHER (INCOME)/EXPENSE, NET	Dec. 31, 2022
Other Nonoperating Income (Expense) [Abstract]
Other (Income) / Expense, net	OTHER (INCOME)/EXPENSE, NET Year Ended December 31, Dollars in Millions 2022 2021 2020 Interest expense $ 1,232 $ 1,334 $ 1,420 Royalty and licensing income (Note 4) (1,283) (1,067) (883) Royalty income - divestitures (Note 4) (832) (666) (644) Equity investment losses/(income), net (Note 9) 801 (745) (1,228) Integration expenses (Note 6) 440 564 717 Loss on debt redemption (Note 9) 266 281 — Divestiture gains (Note 4) (211) (9) (55) Litigation and other settlements 178 82 (194) Investment income (171) (39) (121) Provision for restructuring (Note 6) 75 169 530 Contingent consideration (9) (542) (1,757) Other 90 (82) (99) Other (income)/expense, net $ 576 $ (720) $ (2,314) Contingent Consideration Contingent consideration in 2021 and 2020 primarily included fair value adjustments resulting from the change in the traded price of contingent value rights issued with the Celgene acquisition. The contractual obligation to pay the contingent value rights terminated in January 2021 because the FDA did not approve liso-cel (JCAR017) by December 31, 2020.

RESTRUCTURING

RESTRUCTURING	12 Months Ended
RESTRUCTURING	Dec. 31, 2022
Restructuring Charges [Abstract]
Restructuring	RESTRUCTURING Celgene Acquisition Plan In 2019, a restructuring and integration plan was implemented as an initiative to realize sustainable run rate synergies resulting from cost savings and avoidance from the Celgene acquisition ("Celgene Acquisition Plan") that have resulted in annual synergies of at least $3.0 billion. The synergies realized are in Cost of products sold, Marketing, selling and administrative expense and Research and development expense. Charges of approximately $3.5 billion are expected to be incurred including cash outlays of approximately $3.1 billion. Cumulative charges of approximately $3.1 billion have been recognized to date including integration planning and execution expenses, employee termination benefit costs and accelerated stock-based compensation, contract termination costs and other shutdown costs associated with site exits. The remaining charges are primarily related to IT system integration which are expected to be incurred through 2024. Employee workforce reductions were approximately 170 in 2022, 405 in 2021 and 1,565 in 2020. Other Restructuring Restructuring and integration plans were initiated to realize expected cost synergies resulting from the Turning Point acquisition on August 17, 2022, the MyoKardia acquisition in 2020 (acquisition-related initiatives), as well as other costs saving initiatives. Charges of approximately $250 million are expected to be incurred through the end of 2023 for the acquisition-related initiatives, and consist of integration planning and execution expenses, employee termination benefit costs and other costs. Cumulative charges of approximately $165 million have been recognized for these actions to date. Company Transformation In 2016, a restructuring plan was announced to evolve and streamline BMS’s operating model. Cumulative charges of approximately $1.5 billion were recognized for these actions since the announcement. Actions under the plan were completed as of December 31, 2020. The following provides the charges related to restructuring initiatives by type of cost: Year Ended December 31, Dollars in Millions 2022 2021 2020 Celgene Acquisition Plan $ 472 $ 673 $ 1,244 Other Restructuring 48 78 39 Company Transformation — — 127 Total charges $ 520 $ 751 $ 1,410 Employee termination costs $ 69 $ 159 $ 457 Other termination costs 6 10 73 Provision for restructuring 75 169 530 Integration expenses 440 564 717 Accelerated depreciation 5 2 53 Asset impairments — 24 103 Other shutdown costs, net — (8) 7 Total charges $ 520 $ 751 $ 1,410 Cost of products sold $ — $ 24 $ 32 Marketing, selling and administrative 5 3 10 Research and development — — 113 Other (income)/expense, net 515 724 1,255 Total charges $ 520 $ 751 $ 1,410 The following summarizes the charges and spending related to restructuring plan activities: Year Ended December 31, Dollars in Millions 2022 2021 Liability at January 1 $ 101 $ 148 Provision for restructuring (a) 75 156 Foreign currency translation and other (7) (4) Payments (122) (199) Liability at December 31 $ 47 $ 101

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The provision/(benefit) for income taxes consisted of: Year Ended December 31, Dollars in Millions 2022 2021 2020 Current: U.S. $ 3,017 $ 1,879 $ 1,245 Non-U.S. 1,089 598 (104) Total current 4,106 2,477 1,141 Deferred: U.S. (2,889) (1,255) 229 Non-U.S. 151 (138) 754 Total deferred (2,738) (1,393) 983 Total Provision for Income Taxes $ 1,368 $ 1,084 $ 2,124 Effective Tax Rate The reconciliation of the effective tax rate to the U.S. statutory Federal income tax rate was as follows: % of Earnings Before Income Taxes Dollars in Millions 2022 2021 2020 Earnings/(Loss) before income taxes: U.S. $ (140) $ 1,593 $ (10,106) Non-U.S. 7,853 6,505 3,235 Total 7,713 8,098 (6,871) U.S. statutory rate 1,620 21.0 % 1,701 21.0 % (1,443) 21.0 % GILTI, net of foreign derived intangible income deduction 634 8.2 % 645 8.0 % 685 (10.0) % Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland (416) (5.4) % (143) (1.8) % (86) 1.3 % Internal transfers of intangible and other assets (93) (1.2) % (983) (12.1) % 853 (12.4) % U.S. Federal, state and foreign contingent tax matters (297) (3.9) % 154 1.9 % 136 (2.0) % U.S. Federal research-based credits (142) (1.8) % (165) (2.0) % (165) 2.4 % Charitable contributions of inventory (94) (1.2) % (42) (0.5) % (36) 0.5 % Contingent value rights — — (108) (1.3) % (363) 5.3 % Non-deductible R&D charges — — — — 2,461 (35.8) % Puerto Rico excise tax credit (144) (1.9) % (152) (1.9) % (147) 2.1 % State and local taxes (net of valuation allowance) 103 1.3 % 33 0.4 % 103 (1.5) % Foreign and other 197 2.6 % 144 1.7 % 126 (1.8) % Total $ 1,368 17.7 % $ 1,084 13.4 % $ 2,124 (30.9) % Internal transfers of intangible and other assets to streamline our legal entity structure subsequent to the Celgene acquisition resulted in a tax benefit in 2022 and 2021 and in a tax charge in 2020 upon adjusting deferred taxes for the book and revalued tax basis differences of the related assets. The 2022 U.S. Federal, state and foreign contingent tax matters include a $522 million tax benefit with respect to lapse of statutes and effectively settled contingent tax matters. Fair value adjustments for contingent value rights are not taxable or tax deductible. Non-deductible R&D charges primarily resulted from the $11.4 billion MyoKardia IPRD charge in 2020. Puerto Rico imposes an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax is recognized in Cost of products sold when the intra-entity sale occurs. For U.S. income tax purposes, the excise tax is not deductible but results in foreign tax credits that are generally recognized in BMS’s provision for income taxes when the excise tax is incurred. As of December 31, 2022, BMS has amended its existing Puerto Rico decree, eliminating the excise tax and increasing its Puerto Rico tax rate to 10.5% effective for the tax year beginning January 1, 2023, and extending BMS’s tax grants an additional 15 years to 2038. Deferred Taxes and Valuation Allowance The components of deferred income tax assets/(liabilities) were as follows: December 31, Dollars in Millions 2022 2021 Deferred tax assets Foreign net operating loss and other carryforwards $ 566 $ 945 State net operating loss and credit carryforwards 329 304 U.S. Federal net operating loss and credit carryforwards 236 226 Milestone payments and license fees 1,030 887 Capitalized research expenditures 1,573 — Other 1,284 1,390 Total deferred tax assets 5,018 3,752 Valuation allowance (873) (1,056) Deferred tax assets net of valuation allowance $ 4,145 $ 2,696 Deferred tax liabilities Acquired intangible assets $ (4,362) $ (4,867) Goodwill and other (605) (891) Total deferred tax liabilities $ (4,967) $ (5,758) Deferred tax liabilities, net $ (822) $ (3,062) Recognized as: Deferred income taxes assets – non-current $ 1,344 $ 1,439 Deferred income taxes liabilities – non-current (2,166) (4,501) Total $ (822) $ (3,062) BMS is not indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign and state income and withholding tax that would apply. BMS remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. The U.S. Federal net operating loss carryforwards were $709 million at December 31, 2022. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue Code. The net operating loss carryforwards expire in varying amounts beginning in 2023. The foreign and state net operating loss carryforwards expire in varying amounts beginning in 2023 (certain amounts have unlimited lives). At December 31, 2022, a valuation allowance of $873 million exists for the following items: $295 million primarily for foreign net operating loss and tax credit carryforwards, $261 million for state deferred tax assets including net operating loss and tax credit carryforwards and $317 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. Changes in the valuation allowance were as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 1,056 $ 2,809 $ 2,844 Provision 213 201 62 Utilization (68) (1,087) (488) Foreign currency translation (59) (157) 212 Acquisitions/(dispositions)/(liquidations), net (271) (720) 179 Non U.S. rate change 2 10 — Balance at end of year $ 873 $ 1,056 $ 2,809 In 2022 and 2021, certain foreign net operating losses and related valuation allowances were utilized or eliminated as a result of internal legal entity restructurings. Income tax payments were $5.4 billion in 2022, $3.5 billion in 2021 and $3.4 billion in 2020. In connection with the enactment of the TCJA, we were required to pay a one-time transition tax and elected to pay over a period of eight years as permitted under the TCJA. The remaining amounts payable are as follows: $567 million in 2023; $799 million in 2024; $1.0 billion in 2025; and $244 million in 2026. Business is conducted in various countries throughout the world and is subject to tax in numerous jurisdictions. A significant number of tax returns that are filed are subject to examination by various federal, state and local tax authorities. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported requiring several years to resolve. Liabilities are established for possible assessments by tax authorities resulting from known tax exposures including, but not limited to, transfer pricing matters, tax credit deductibility of certain expenses, and deemed repatriation transition tax. Such liabilities represent a reasonable provision for taxes ultimately expected to be paid and may need to be adjusted over time as more information becomes known. The effect of changes in estimates related to contingent tax liabilities is included in the effective tax rate reconciliation above. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (excluding interest and penalties): Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 2,042 $ 2,003 $ 1,905 Gross additions to tax positions related to current year 53 66 76 Gross additions to tax positions related to prior years 137 75 325 Gross additions to tax positions assumed in acquisitions 15 — 51 Gross reductions to tax positions related to prior years (381) (22) (352) Settlements (8) (70) (7) Reductions to tax positions related to lapse of statute (83) (5) (5) Cumulative translation adjustment (9) (5) 10 Balance at end of year $ 1,766 $ 2,042 $ 2,003 Additional information regarding unrecognized tax benefits is as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Unrecognized tax benefits that if recognized would impact the effective tax rate $ 1,736 $ 1,957 $ 1,900 Accrued interest 332 424 366 Accrued penalties 25 26 20 Accrued interest and penalties payable for unrecognized tax benefits are included in either current or non-current income taxes payable. Interest and penalties related to unrecognized tax benefits are included in income tax expense. BMS is currently under examination by a number of tax authorities that proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. As previously disclosed, BMS received several notices of proposed adjustments from the IRS related to transfer pricing and other tax issues for the 2008 to 2012 tax years. BMS disagrees with the IRS’s positions and continues to work cooperatively with the IRS to resolve these issues. In December 2022, BMS entered the IRS administrative appeals process to resolve these matters. Timing of the final resolution of these complex matters is uncertain and could have a material impact on BMS’s financial statements. Tax positions for these years unrelated to matters that entered the administrative appeals process are considered effectively settled. It is reasonably possible that new issues will be raised by tax authorities that may increase unrecognized tax benefits; however, an estimate of such increases cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction. It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2022 could decrease in the range of approximately $120 million to $170 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. The following is a summary of major tax jurisdictions for which tax authorities may assert additional taxes based upon tax years currently under audit and subsequent years that will likely be audited: U.S. 2008 to 2012, 2016 to 2022 Canada 2012 to 2022 France 2020 to 2022 Germany 2015 to 2022 Italy 2019 to 2022 Japan 2018 to 2022 UK 2012 to 2022

EARNINGS_(LOSS) PER SHARE

EARNINGS/(LOSS) PER SHARE	12 Months Ended
EARNINGS/(LOSS) PER SHARE	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings/(Loss) Per Share	EARNINGS/(LOSS) PER SHARE Year Ended December 31, Amounts in Millions, Except Per Share Data 2022 2021 2020 Net Earnings/(Loss) Attributable to BMS Used for Basic and Diluted EPS Calculation $ 6,327 $ 6,994 $ (9,015) Weighted-Average Common Shares Outstanding - Basic 2,130 2,221 2,258 Incremental Shares Attributable to Share-Based Compensation Plans 16 24 — Weighted-Average Common Shares Outstanding - Diluted 2,146 2,245 2,258 Earnings/(Loss) per Common Share Basic $ 2.97 $ 3.15 $ (3.99) Diluted 2.95 3.12 (3.99) The total number of potential shares of common stock excluded from the diluted earnings per share computation because of the antidilutive impact was not material in 2022 and 2021 and was 106 million in 2020.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial instruments include cash and cash equivalents, marketable debt securities, equity investments, accounts receivable and payable, debt instruments and derivatives. Changes in exchange rates and interest rates create exposure to market risk. Certain derivative financial instruments are used when available on a cost-effective basis to hedge the underlying economic exposure. These instruments qualify as cash flow, net investment and fair value hedges upon meeting certain criteria, including effectiveness of offsetting hedged exposures. Changes in fair value of derivatives that do not qualify for hedge accounting are recognized in earnings as they occur. Derivative financial instruments are not used for trading purposes. Financial instruments are subject to counterparty credit risk which is considered as part of the overall fair value measurement. Counterparty credit risk is monitored on an ongoing basis and mitigated by limiting amounts outstanding with any individual counterparty, utilizing conventional derivative financial instruments and only entering into agreements with counterparties that meet high credit quality standards. The consolidated financial statements would not be materially impacted if any counterparty failed to perform according to the terms of its agreement. Collateral is not required by any party whether derivatives are in an asset or liability position under the terms of the agreements. Fair Value Measurements — The fair value of financial instruments are classified into one of the following categories: Level 1 inputs utilize unadjusted quoted prices in active markets accessible at the measurement date for identical assets or liabilities. The fair value hierarchy provides the highest priority to Level 1 inputs. Level 2 inputs utilize observable prices for similar instruments and quoted prices for identical or similar instruments in non-active markets. Additionally, certain corporate debt securities utilize a third-party matrix pricing model using significant inputs corroborated by market data for substantially the full term of the assets. Equity and fixed income funds are primarily invested in publicly traded securities valued at the respective NAV of the underlying investments. Level 2 derivative instruments are valued using LIBOR yield curves, less credit valuation adjustments, and observable forward foreign exchange rates at the reporting date. Valuations of derivative contracts may fluctuate considerably from volatility in underlying foreign currencies and underlying interest rates driven by market conditions and the duration of the contract. Level 3 unobservable inputs are used when little or no market data is available. Level 3 financial liabilities consist of other acquisition related contingent consideration and success payments related to undeveloped product rights resulting from the Celgene acquisition. There were no transfers between Levels 1, 2 and 3 during the year ended December 31, 2022. Financial assets and liabilities measured at fair value on a recurring basis are summarized below: December 31, 2022 December 31, 2021 Dollars in Millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents - money market and other securities $ — $ 7,770 $ — $ — $ 12,225 $ — Marketable debt securities: Certificates of deposit — 32 — — 2,264 — Commercial paper — 98 — — 320 — Corporate debt securities — — — — 403 — Derivative assets — 305 — — 206 — Equity investments 424 680 — 1,910 109 — Derivative liabilities — 213 — — 25 — Contingent consideration liability: Contingent value rights 5 — — 8 — — Other acquisition related contingent consideration — — 24 — — 35 Marketable Debt Securities The following table summarizes marketable debt securities: December 31, 2022 December 31, 2021 Dollars in Millions Amortized Gross Unrealized Fair Value Amortized Gross Unrealized Fair Value Gains Losses Gains Losses Certificates of deposit $ 32 $ — $ — $ 32 $ 2,264 $ — $ — $ 2,264 Commercial paper 98 — — 98 320 — — 320 Corporate debt securities — — — — 401 2 — 403 Total marketable debt securities $ 130 $ — $ — $ 130 $ 2,985 $ 2 $ — $ 2,987 Equity Investments The following summarizes the carrying amount of equity investments at December 31, 2022 and 2021: Dollars in Millions 2022 2021 Equity investments with readily determinable fair values $ 1,104 $ 2,019 Equity investments without readily determinable fair values 537 283 Limited partnerships and other equity method investments 546 666 Total equity investments $ 2,187 $ 2,968 The following summarizes the activity related to equity investments. Equity investment (gains)/loss are included in Other (income)/expense, net. Dollars in Millions 2022 2021 2020 Equity investments with readily determined fair values Net loss/(gain) recognized $ 762 $ 403 $ (964) Net loss/(gain) recognized on investments sold (17) (357) 12 Net unrealized loss/(gain) recognized on investments still held 779 760 (976) Equity investments without readily determinable fair values Upward adjustments (80) (918) (388) Impairments and downward adjustments 11 1 204 Equity in net (income)/loss of limited partnerships and other equity method investments 108 (231) (72) Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of December 31, 2022 were $181 million and $61 million, respectively. Qualifying Hedges and Non-Qualifying Derivatives Cash Flow Hedges — Foreign currency forward and purchased local currency put option contracts are used to hedge certain forecasted intercompany inventory purchases and sales transactions and certain foreign currency transactions. The fair value for contracts designated as cash flow hedges is temporarily reported in Accumulated other comprehensive loss and included in earnings when the hedged item affects earnings. The net gain or loss on foreign exchange contracts is expected to be reclassified to net earnings (primarily included in Cost of products sold) within the next 24 months. The notional amount of outstanding foreign currency exchange contracts was primarily attributed to the euro of $5.3 billion and Japanese yen of $1.3 billion as of December 31, 2022. In 2022, BMS entered into cross-currency interest rate swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. The unrealized gains and losses on these contracts are reported in Accumulated other comprehensive loss and reclassified to Other (income)/expense, net, in the same periods during which the hedged debt affects earnings. The notional amount of cross-currency interest rate swap contracts associated with long-term debt denominated in euros was €575 million ($584 million) as of December 31, 2022. In 2020, Treasury lock hedge contracts were entered into with a total notional value of $2.1 billion to hedge future interest rate risk associated with the anticipated issuance of long-term debt to fund the MyoKardia acquisition. The Treasury lock contracts were terminated upon the issuance of the 2020 unsecured senior notes and the $51 million proceeds were included in Other Comprehensive Income/(Loss). Net Investment Hedges — Non-U.S. dollar borrowings of €375 million ($400 million) as of December 31, 2022 are designated as net investment hedges to hedge euro currency exposures of the net investment in certain foreign affiliates and are recognized in long-term debt. The effective portion of foreign exchange gain on the remeasurement of euro debt was included in the foreign currency translation component of Accumulated other comprehensive loss with the related offset in Long-term debt. Cross-currency interest rate swap contracts of $1.2 billion as of December 31, 2022 are designated to hedge currency exposure of BMS’s net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of Accumulated other comprehensive loss with a related offset in Other non-current assets or Other non-current liabilities. The notional amount of outstanding cross-currency interest rate swap contracts was primarily attributed to the Japanese yen of $509 million and euro of $584 million as of December 31, 2022. Fair Value Hedges — Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value. The effective interest rate for the contracts is one-month LIBOR (4.39% as of December 31, 2022) plus an interest rate spread of 4.6%. Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability on the consolidated balance sheet. As a result, there was no net impact in earnings. If the underlying swap is terminated prior to maturity, then the fair value adjustment to the underlying debt is amortized as a reduction to interest expense over the remaining term of the debt. The following summarizes the fair value of outstanding derivatives: December 31, 2022 December 31, 2021 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in Millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts $ — $ — $ 255 $ (18) $ 255 $ 10 $ — $ — Cross-currency interest rate swap contracts 72 1 1,741 (85) 600 26 — — Foreign exchange contracts 5,771 271 2,281 (80) 3,587 161 1,814 (20) Derivatives not designated as hedging instruments: Foreign exchange contracts 1,564 33 1,703 (19) 883 9 568 (5) Total return swap contracts (c) — — 322 (11) — — — — (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities. (c) Total return swap contracts were entered into to hedge changes in fair value of certain deferred compensation liabilities. The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments: Year Ended December 31, 2022 2021 2020 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (27) $ — $ (31) $ — $ (29) Cross-currency interest rate swap contracts — (52) — (11) — (10) Foreign exchange contracts (492) (96) 96 (21) (18) (23) The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive Income/(Loss): Year Ended December 31, Dollars in Millions 2022 2021 2020 Derivatives qualifying as cash flow hedges Foreign exchange contracts gain/(loss): Recognized in Other Comprehensive Income/(Loss) $ 592 $ 364 $ (267) Reclassified to Cost of products sold (492) 96 (54) Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive Income (7) — — Reclassified to Other (income)/expense, net (29) — — Forward starting interest rate swap contract loss: Reclassified to Other (income)/expense, net (3) — — Treasury lock hedge contracts gain: Recognized in Other Comprehensive Income/(Loss) — — 51 Derivatives qualifying as net investment hedges Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive Income/(Loss) 30 38 (11) Non-derivatives qualifying as net investment hedges Non U.S. dollar borrowings gain/(loss): Recognized in Other Comprehensive Income/(Loss) 91 83 (105)

Financing Arrangements

Financing Arrangements	12 Months Ended
Financing Arrangements	Dec. 31, 2022
Debt Disclosure [Abstract]
Financing Arrangements	FINANCING ARRANGEMENTS Short-term debt obligations include: December 31, Dollars in Millions 2022 2021 Non-U.S. short-term borrowings $ 176 $ 105 Current portion of long-term debt 3,897 4,764 Other 191 79 Total $ 4,264 $ 4,948 Long-term debt and the current portion of long-term debt includes: December 31, Dollars in Millions 2022 2021 Principal Value: Floating Rate Notes due 2022 $ — $ 500 2.000% Notes due 2022 — 750 2.600% Notes due 2022 — 1,500 3.250% Notes due 2022 — 1,000 3.550% Notes due 2022 — 1,000 0.537% Notes due 2023 1,500 1,500 2.750% Notes due 2023 750 750 3.250% Notes due 2023 500 500 3.250% Notes due 2023 890 890 7.150% Notes due 2023 239 239 2.900% Notes due 2024 2,478 2,478 3.625% Notes due 2024 395 395 0.750% Notes due 2025 1,000 1,000 1.000% Euro Notes due 2025 613 651 3.875% Notes due 2025 229 1,925 3.200% Notes due 2026 1,750 2,250 6.800% Notes due 2026 256 256 1.125% Notes due 2027 1,000 1,000 3.250% Notes due 2027 512 750 3.450% Notes due 2027 534 1,000 3.900% Notes due 2028 1,500 1,500 3.400% Notes due 2029 2,400 4,000 1.450% Notes due 2030 1,250 1,250 2.950% Notes due 2032 1,750 — 1.750% Euro Notes due 2035 613 651 5.875% Notes due 2036 279 279 6.125% Notes due 2038 219 219 4.125% Notes due 2039 2,000 2,000 2.350% Notes due 2040 750 750 5.700% Notes due 2040 153 193 3.550% Notes due 2042 1,250 — 3.250% Notes due 2042 500 500 5.250% Notes due 2043 226 280 4.500% Notes due 2044 342 500 4.625% Notes due 2044 748 748 5.000% Notes due 2045 758 1,768 4.350% Notes due 2047 1,250 1,250 4.550% Notes due 2048 1,272 1,486 4.250% Notes due 2049 3,750 3,750 2.550% Notes due 2050 1,500 1,500 3.700% Notes due 2052 2,000 — 3.900% Notes due 2062 1,000 — 6.875% Notes due 2097 63 86 0.13% - maturing through 2023 15 51 Total $ 38,234 $ 43,095 December 31, Dollars in Millions 2022 2021 Principal Value $ 38,234 $ 43,095 Adjustments to Principal Value: Fair value of interest rate swap contracts (18) 10 Unamortized basis adjustment from swap terminations 97 119 Unamortized bond discounts and issuance costs (284) (263) Unamortized purchase price adjustments of Celgene debt 924 1,408 Total $ 38,953 $ 44,369 Current portion of long-term debt $ 3,897 $ 4,764 Long-term debt 35,056 39,605 Total $ 38,953 $ 44,369 The fair value of long-term debt was $34.9 billion and $49.1 billion at December 31, 2022 and 2021, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. In 2022, BMS issued an aggregate principal amount of $6.0 billion of fixed rate unsecured senior notes with net proceeds of $5.9 billion. In 2020, BMS issued an aggregate principal amount of $7.0 billion of fixed rate unsecured senior notes with proceeds, net of discount and deferred loan issuance costs, of $6.9 billion. The notes rank equally in right of payment with all of BMS’s existing and future senior unsecured indebtedness and are redeemable at any time, in whole, or in part, at varying specified redemption prices plus accrued and unpaid interest. In 2022, BMS purchased aggregate principal amount of $6.0 billion of certain of its debt securities for $6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. In 2021, BMS purchased aggregate principal amount of $3.5 billion of certain of its debt securities for approximately $4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. Repayment of notes at maturity aggregated $4.8 billion in 2022, $2.0 billion in 2021 and $2.8 billion in 2020. Interest payments were $1.4 billion in 2022, $1.5 billion in 2021 and $1.6 billion in 2020. The aggregate maturities of long-term debt for each of the next five years are as follows: $3.9 billion in 2023; $2.9 billion in 2024; $1.8 billion in 2025; $2.0 billion in 2026; $2.0 billion in 2027. Interest payments related to long-term debt for each of the next five years are as follows: $1.2 billion in 2023; $1.1 billion in 2024; $1.1 billion in 2025; $1.0 billion in 2026; $977 million in 2027. Credit Facilities As of December 31, 2022, BMS had a five-year $5.0 billion facility expiring in January 2027 and extendable annually by one year with the consent of the lenders. This facility provides for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’ commercial paper borrowings. No borrowings were outstanding under any revolving credit facility as of December 31, 2022 or 2021. Available financial guarantees provided in the form of bank overdraft facilities, stand-by letters of credit and performance bonds were $1.4 billion as of December 31, 2022. Stand-by letters of credit and guarantees are issued through financial institutions in support of various obligations, including sale of products to hospitals and foreign ministries of health, bonds for customs, and duties and value added tax.

RECEIVABLES

RECEIVABLES	12 Months Ended
RECEIVABLES	Dec. 31, 2022
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Receivables	RECEIVABLES December 31, Dollars in Millions 2022 2021 Trade receivables $ 8,848 $ 8,723 Less charge-backs and cash discounts (675) (723) Less allowance for expected credit loss (22) (21) Net trade receivables 8,151 7,979 Alliance, royalties, VAT and other 1,735 1,390 Receivables $ 9,886 $ 9,369 Non-U.S. receivables sold on a nonrecourse basis were $1.0 billion in 2022, $1.5 billion in 2021 and $1.2 billion in 2020. In the aggregate, receivables from three pharmaceutical wholesalers in the U.S. represented approximately 66% and 59% of total trade receivables at December 31, 2022 and 2021, respectively. Changes to the allowances for expected credit loss, charge-backs and cash discounts were as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 744 $ 663 $ 412 Provision (a) 7,476 7,257 5,839 Utilization (7,521) (7,170) (5,601) Other (2) (6) 13 Balance at end of year $ 697 $ 744 $ 663 (a) Includes provision for expected credit loss of $7 million in 2022, $4 million in 2021 and $12 million in 2020.

INVENTORIES

INVENTORIES	12 Months Ended
INVENTORIES	Dec. 31, 2022
Inventory, Net [Abstract]
Inventories	INVENTORIES December 31, Dollars in Millions 2022 2021 Finished goods $ 509 $ 543 Work in process 1,850 2,111 Raw and packaging materials 464 350 Total Inventories $ 2,823 $ 3,004 Inventories $ 2,339 $ 2,095 Other non-current assets 484 909 Total inventories include fair value adjustments resulting from the Celgene acquisition of approximately $84 million as of December 31, 2022 and $508 million as of December 31, 2021.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT AND EQUIPMENT December 31, Dollars in Millions 2022 2021 Land $ 162 $ 169 Buildings 5,920 5,897 Machinery, equipment and fixtures 3,284 3,252 Construction in progress 1,053 764 Gross property, plant and equipment 10,419 10,082 Less accumulated depreciation (4,164) (4,033) Property, plant and equipment $ 6,255 $ 6,049 United States $ 4,833 $ 4,710 International 1,422 1,339 Total $ 6,255 $ 6,049 Depreciation expense was $587 million in 2022, $559 million in 2021 and $586 million in 2020.

LEASES

LEASES	12 Months Ended
LEASES	Dec. 31, 2022
Leases [Abstract]
Leases	LEASES Leased facilities for office, research and development, storage and distribution purposes comprise approximately 95% of the total lease obligation. Lease terms vary based on the nature of operations and the market dynamics in each country; however, all leased facilities are classified as operating leases with remaining lease terms between one year and 15 years. Most leases contain specific renewal options for periods ranging between one year and 10 years where notice to renew must be provided in advance of lease expiration or automatic renewals where no advance notice is required. Periods covered by an option to extend the lease were included in the non-cancellable lease term when exercise of the option was determined to be reasonably certain. Certain leases also contain termination options that provide the flexibility to terminate the lease ahead of its expiration with sufficient advance notice. Periods covered by an option to terminate the lease were included in the non-cancellable lease term when exercise of the option was determined not to be reasonably certain. Judgment is required in assessing whether renewal and termination options are reasonably certain to be exercised. Factors are considered such as contractual terms compared to current market rates, leasehold improvements expected to have significant value, costs to terminate a lease and the importance of the facility to operations. Costs determined to be variable and not based on an index or rate were not included in the measurement of real estate lease liabilities. These variable costs include real estate taxes, insurance, utilities, common area maintenance and other operating costs. As the implicit rate on most leases is not readily determinable, an incremental borrowing rate was applied on a portfolio approach to discount its real estate lease liabilities. The remaining 5% of lease obligations are comprised of vehicles and a research and development facility operated by a third party under management’s direction. Vehicle lease terms vary by country with terms generally between one year and four years. The following table summarizes the components of lease expense: Year Ended December 31, Dollars in Millions 2022 2021 2020 Operating lease cost $ 224 $ 220 $ 194 Variable lease cost 55 44 50 Short-term lease cost 20 17 19 Sublease income (6) (7) (4) Total operating lease expense $ 293 $ 274 $ 259 Operating lease right-of-use assets and liabilities were as follows: December 31, Dollars in Millions 2022 2021 Other non-current assets $ 1,220 $ 919 Other current liabilities $ 136 $ 169 Other non-current liabilities 1,261 874 Total liabilities $ 1,397 $ 1,043 Future lease payments for non-cancellable operating leases as of December 31, 2022 were as follows: Dollars in Millions 2023 $ 187 2024 191 2025 169 2026 149 2027 145 Thereafter 933 Total future lease payments 1,774 Less imputed interest (377) Total lease liability $ 1,397 Right-of-use assets obtained in exchange for new operating lease obligations were $492 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $203 million in 2022, $189 million in 2021 and $164 million in 2020. Undiscounted lease obligations for operating leases not yet commenced were $754 million as of December 31, 2022. The obligation primarily relates to a research and development facility that is being constructed by the lessor and is expected to be ready for use in 2025. A right-of-use asset impairment charge of $31 million was incurred during 2020 due to a site vacancy and partial sublease. The fair value of the right-of-use asset was determined using an income approach incorporating potential future cash flows associated with the sublease of the building. Supplemental balance sheet information related to leases was as follows: December 31, 2022 2021 Weighted average remaining lease term 11 years 10 years Weighted average discount rate 4 % 3 %

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill The changes in the carrying amounts in Goodwill were as follows: December 31, Dollars in Millions 2022 2021 Beginning balance $ 20,502 $ 20,547 Turning Point acquisition 695 — Currency translation and other adjustments (48) (45) Ending balance $ 21,149 $ 20,502 Other Intangible Assets Other intangible assets consisted of the following: December 31, Dollars in Millions Estimated 2022 2021 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Other intangible assets (a) : Licenses 5 – 15 years $ 400 $ (128) $ 272 $ 307 $ (102) $ 205 Acquired marketed product rights 3 – 15 years 60,477 (31,949) 28,528 60,454 (22,380) 38,074 Capitalized software 3 – 10 years 1,555 (1,056) 499 1,499 (1,001) 498 IPRD (a) 6,560 — 6,560 3,750 — 3,750 Total Other intangible assets $ 68,992 $ (33,133) $ 35,859 $ 66,010 $ (23,483) $ 42,527 (a) Includes other intangible assets recognized as part of the Turning Point acquisition in 2022. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for further information related to the Turning Point acquisition. Amortization expense of Other intangible assets was $9.7 billion in 2022, $10.2 billion in 2021 and $9.9 billion in 2020. Future annual amortization expense of Other intangible assets is expected to be approximately $9.2 billion in 2023, $8.4 billion in 2024, $2.9 billion in 2025, $1.4 billion in 2026 and $1.3 billion in 2027. Other intangible asset impairment charges were $101 million in 2022, $1.2 billion in 2021 and $1.1 billion in 2020. In 2022, $98 million IPRD impairment charges were recorded in Research and development expense resulting from decisions to discontinue development of investigational compounds in connection with the prioritization of current pipeline opportunities. The charges represented full write-downs. In 2021, a $610 million IPRD impairment charge for an investigational compound was recorded in Research and development expense primarily resulting from changes in clinical timelines, expected launch dates and competitive landscape. The compound is being studied as a potential treatment for hematologic diseases and was acquired in the acquisition of Celgene. The charge represented a partial write-down of its carrying value based on the estimated fair value determined using discounted cash flow projections. Additionally, a $230 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of current pipeline opportunities. The compound was being studied as a potential treatment for fibrotic diseases and was acquired in the acquisition of Celgene. The charge represented a full write-down based on the estimated fair value determined using discounted cash flow projections. In 2021, Inrebic EU regulatory approval milestones of $300 million were achieved resulting in a $385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. In 2020, a $575 million impairment charge was recorded in Cost of products sold resulting from the lower cash flow projections reflecting revised commercial forecasts for Inrebic , resulting in the full impairment of the asset. Additionally, a $470 million impairment charge was recorded in Research and development expense following a decision to discontinue the orva-cel program development. Inrebic and orva-cel were obtained in connection with the acquisition of Celgene.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	12 Months Ended
SUPPLEMENTAL FINANCIAL INFORMATION	Dec. 31, 2022
Supplemental Financial Information [Abstract]
Supplemental Financial Information	SUPPLEMENTAL FINANCIAL INFORMATION December 31, Dollars in Millions 2022 2021 Income taxes $ 3,547 $ 2,786 Research and development 579 514 Contract assets 504 361 Equity investments — 255 Restricted cash (a) 148 140 Other 1,017 776 Other current assets $ 5,795 $ 4,832 December 31, Dollars in Millions 2022 2021 Equity investments $ 2,187 $ 2,713 Inventories 484 909 Operating leases 1,220 919 Pension and postretirement 285 317 Research and development 496 248 Restricted cash (a) 54 197 Other 214 232 Other non-current assets $ 4,940 $ 5,535 (a) Restricted cash consists of funds restricted for annual Company contributions to the defined contribution plan in the U.S. and escrow for litigation settlements. Cash is restricted when withdrawal or general use is contractually or legally restricted. December 31, Dollars in Millions 2022 2021 Rebates and discounts $ 6,702 $ 6,399 Income taxes 942 754 Employee compensation and benefits 1,425 1,375 Research and development 1,359 1,373 Dividends 1,196 1,186 Interest 321 378 Royalties 431 410 Operating leases 136 169 Other 2,074 1,927 Other current liabilities $ 14,586 $ 13,971 December 31, Dollars in Millions 2022 2021 Income taxes $ 3,992 $ 4,835 Pension and postretirement 402 654 Operating leases 1,261 874 Deferred income 283 326 Deferred compensation 349 427 Other 303 218 Other non-current liabilities $ 6,590 $ 7,334

EQUITY

EQUITY	12 Months Ended
EQUITY	Dec. 31, 2022
Equity [Abstract]
Equity	EQUITY Common Stock Capital in Excess Accumulated Other Comprehensive Loss Retained Treasury Stock Noncontrolling Dollars and Shares in Millions Shares Par Value Shares Cost Balance at January 1, 2020 2,923 $ 292 $ 43,709 $ (1,520) $ 34,474 672 $ (25,357) $ 100 Net loss — — — — (9,015) — — 20 Other Comprehensive Income/(Loss) — — — (319) — — — — Cash dividends declared (a) — — — — (4,178) — — — Share repurchase program — — 1,400 — — 43 (2,993) — Stock compensation — — (784) — — (36) 2,113 — Distributions — — — — — — — (60) Balance at December 31, 2020 2,923 292 44,325 (1,839) 21,281 679 (26,237) 60 Net earnings — — — — 6,994 — — 20 Other Comprehensive Income/(Loss) — — — 571 — — — — Cash dividends declared (a) — — — — (4,455) — — — Share repurchase program — — — — — 102 (6,240) — Stock compensation — — 36 — — (34) 1,218 — Distributions — — — — — — — (20) Balance at December 31, 2021 2,923 292 44,361 (1,268) 23,820 747 (31,259) 60 Net earnings — — — — 6,327 — — 18 Other Comprehensive Income/(Loss) — — — (13) — — — — Cash dividends declared (a) — — — — (4,644) — — — Share repurchase program — — — — — 109 (8,001) — Stock compensation — — 804 — — (31) 642 — Distributions — — — — — — — (21) Balance at December 31, 2022 2,923 $ 292 $ 45,165 $ (1,281) $ 25,503 825 $ (38,618) $ 57 (a) Cash dividends declared per common share were $2.19 in 2022, $2.01 in 2021 and $1.84 in 2020. BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares, effected in the open market or through privately negotiated transactions in compliance with Rule 10b-18 under the Exchange Act, including through Rule 10b5-1 trading plans. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method. The outstanding share repurchase authorization under the program was $15.2 billion as of December 31, 2021. In 2022, BMS entered into accelerated share repurchase ("ASR") agreements to repurchase an aggregate amount of $5.0 billion of the Company's common stock. The ASR agreements were funded with cash on-hand. The Company received approximately 69 million shares of common stock during the year which were included in treasury stock. The total number of shares repurchased under the ASR agreements was based on volume-weighted average prices of BMS's common stock during the terms of the ASR transactions less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. In addition, as part of its share repurchase program, BMS repurchased approximately 40 million shares of its common stock for $3.0 billion during the year ended December 31, 2022. The remaining share repurchase capacity under the share repurchase program was $7.2 billion as of December 31, 2022. The components of Other Comprehensive Income/(Loss) were as follows: Year Ended December 31, 2022 2021 2020 Dollars in Millions Pretax Tax After Tax Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges: Unrealized gains/(losses) $ 585 $ (79) $ 506 $ 364 $ (34) $ 330 $ (216) $ 7 $ (209) Reclassified to net earnings (a) (524) 72 (452) 95 (10) 85 (54) 7 (47) Derivatives qualifying as cash flow hedges 61 (7) 54 459 (44) 415 (270) 14 (256) Pension and postretirement benefits: Actuarial gains/(losses) 146 (25) 121 220 (40) 180 (134) 25 (109) Amortization (b) 21 (6) 15 41 (10) 31 33 (6) 27 Settlements (b) 11 (2) 9 (6) 1 (5) 10 (3) 7 Pension and postretirement benefits 178 (33) 145 255 (49) 206 (91) 16 (75) Marketable debt securities: Unrealized (losses)gains (2) — (2) (11) 2 (9) 7 (1) 6 Realized (gains)/losses (b) — — — — — — (1) — (1) Marketable debt securities (2) — (2) (11) 2 (9) 6 (1) 5 Foreign currency translation (183) (27) (210) (14) (27) (41) (19) 26 7 Other Comprehensive Income/(Loss) $ 54 $ (67) $ (13) $ 689 $ (118) $ 571 $ (374) $ 55 $ (319) (a) Included in Cost of products sold and Other (income)/expense, net. Refer to “—Note 9.Financial Instruments and Fair Value Measurements“ for further information. (b) Included in Other (income)/expense, net. The accumulated balances related to each component of Other Comprehensive Income/(Loss), net of taxes, were as follows: December 31, Dollars in Millions 2022 2021 Derivatives qualifying as cash flow hedges $ 232 $ 178 Pension and postretirement benefits (623) (768) Marketable debt securities — 2 Foreign currency translation (a) (890) (680) Accumulated other comprehensive loss $ (1,281) $ (1,268) (a) Included in foreign currency are net investment hedges gains of $125 million and $30 million as of December 31, 2022 and December 31, 2021.

RETIREMENT BENEFITS

RETIREMENT BENEFITS	12 Months Ended
RETIREMENT BENEFITS	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Benefits	RETIREMENT BENEFITS BMS sponsors defined benefit pension plans, defined contribution plans and termination indemnity plans for certain employees. Defined Benefit Pension Plans The net periodic benefit cost of defined benefit pension plans was $27 million, $28 million, and $42 million during the years ended December 31, 2022, 2021 and 2020, respectively. Changes in defined benefit pension plan obligations, assets, funded status and amounts recognized in the consolidated balance sheets were as follows: Year Ended December 31, Dollars in Millions 2022 2021 Benefit obligations at beginning of year $ 2,935 $ 3,242 Service cost—benefits earned during the year 36 51 Interest cost 42 35 Settlements and curtailments (58) (101) Actuarial (gains)/losses (760) (153) Benefits paid (68) (46) Foreign currency and other (151) (93) Benefit obligations at end of year $ 1,976 $ 2,935 Fair value of plan assets at beginning of year $ 2,815 $ 2,807 Actual return on plan assets (570) 125 Employer contributions 76 87 Settlements (53) (83) Benefits paid (68) (46) Foreign currency and other (173) (75) Fair value of plan assets at end of year $ 2,027 $ 2,815 Funded status $ 51 $ (120) Assets/(Liabilities) recognized: Other non-current assets $ 285 $ 317 Other current liabilities (21) (24) Other non-current liabilities (213) (413) Funded status $ 51 $ (120) Recognized in Accumulated other comprehensive loss: Net actuarial losses $ 869 $ 1,015 Prior service credit (25) (29) Total $ 844 $ 986 The accumulated benefit obligation for defined benefit pension plans was $2.0 billion and $2.9 billion at December 31, 2022 and 2021, respectively. Additional information related to pension plans was as follows: December 31, Dollars in Millions 2022 2021 Pension plans with projected benefit obligations in excess of plan assets: Projected benefit obligation $ 728 $ 1,274 Fair value of plan assets 495 836 Pension plans with accumulated benefit obligations in excess of plan assets : Accumulated benefit obligation 728 1,245 Fair value of plan assets 495 832 Actuarial Assumptions Weighted-average assumptions used to determine defined benefit pension plan obligations were as follows: December 31, 2022 2021 Discount rate 4.0 % 1.6 % Rate of compensation increase 1.2 % 1.0 % Interest crediting rate 2.5 % 2.1 % Weighted-average actuarial assumptions used to determine defined benefit pension plan net periodic benefit cost were as follows: Year Ended December 31, 2022 2021 2020 Discount rate 1.6 % 1.2 % 1.6 % Expected long-term return on plan assets 3.6 % 3.6 % 4.1 % Rate of compensation increase 1.0 % 1.3 % 1.3 % Interest crediting rate 2.1 % 2.2 % 2.2 % The yield on high quality corporate bonds matching the duration of the benefit obligations is used in determining the discount rate. The FTSE Pension Discount Curve is used in developing the discount rate for the U.S. plans. The expected return on plan assets assumption for each plan is based on management’s expectations of long-term average rates of return to be achieved by the underlying investment portfolio. Several factors are considered in developing the expected return on plan assets, including long-term historical returns and input from external advisors. Individual asset class return forecasts were developed based upon market conditions, for example, price-earnings levels and yields and long-term growth expectations. The expected long-term rate of return is the weighted-average of the target asset allocation of each individual asset class. Actuarial gains and losses resulted from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates) and from differences between assumed and actual experience (such as differences between actual and expected return on plan assets). Actuarial gains and losses related to plan benefit obligations primarily resulted from changes in discount rates. Postretirement Benefit Plans Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $187 million and $237 million at December 31, 2022 and 2021, respectively. The weighted-average discount rate used to determine benefit obligations was 5.0% and 2.5% at December 31, 2022 and 2021, respectively. The net periodic benefit credits were not material. As a result of the Bristol Myers Squibb Retirement Income Plan's termination in 2019, $381 million of assets held in a separate account within the Pension Trust used to fund retiree medical plan payments was reverted back to the Company in 2020, resulting in an excise tax of $76 million. Plan Assets The fair value of pension plan assets by asset category at December 31, 2022 and 2021 was as follows: December 31, 2022 December 31, 2021 Dollars in Millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Plan Assets Equity securities $ 1 $ — $ — $ 1 $ 44 $ — $ — $ 44 Equity funds — 368 — 368 — 625 — 625 Fixed income funds — 697 — 697 — 815 — 815 Corporate debt securities — 376 — 376 — 485 — 485 U.S. Treasury and agency securities — 75 — 75 — 67 — 67 Insurance contracts — — 123 123 — — 130 130 Cash and cash equivalents 43 — — 43 47 — — 47 Other — 15 35 50 — 224 42 266 Plan assets subject to leveling $ 44 $ 1,531 $ 158 $ 1,733 $ 91 $ 2,216 $ 172 $ 2,479 Plan assets measured at NAV as a practical expedient 294 336 Net plan assets $ 2,027 $ 2,815 The investment valuation policies per investment class are as follows: Level 1 inputs utilize unadjusted quoted prices in active markets accessible at the measurement date for identical assets or liabilities. The fair value hierarchy provides the highest priority to Level 1 inputs. These instruments include equity securities, equity funds and fixed income funds publicly traded on a national securities exchange, and cash and cash equivalents. Cash and cash equivalents are highly liquid investments with original maturities of three months or less at the time of purchase and are recognized at cost, which approximates fair value. Pending trade sales and purchases are included in cash and cash equivalents until final settlement. Level 2 inputs utilize observable prices for similar instruments, quoted prices for identical or similar instruments in non-active markets, and other observable inputs that can be corroborated by market data for substantially the full term of the assets or liabilities. Equity funds and fixed income funds classified as Level 2 within the fair value hierarchy are valued at the NAV of their shares held at year end, which represents fair value. Corporate debt securities and U.S. Treasury and agency securities classified as Level 2 within the fair value hierarchy are valued utilizing observable prices for similar instruments and quoted prices for identical or similar instruments in markets that are not active. Level 3 unobservable inputs are used when little or no market data is available. Insurance contracts are held by certain foreign pension plans and are carried at contract value, which approximates the estimated fair value and is based on the fair value of the underlying investment of the insurance company. There were no transfers between Levels 1, 2 and 3 during the year ended December 31, 2022. Investments using the practical expedient consist primarily of multi-asset funds which are redeemable on either a daily, weekly, or monthly basis. The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2022 was broadly characterized as an allocation between equity securities (23%), debt securities (66%) and other investments (11%). Contributions and Estimated Future Benefit Payments The Company's estimated annual contributions and future benefits payments are not expected to be material. Savings Plans The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $360 million in 2022, $350 million in 2021 and $290 million in 2020.

EMPLOYEE STOCK BENEFIT PLANS

EMPLOYEE STOCK BENEFIT PLANS	12 Months Ended
EMPLOYEE STOCK BENEFIT PLANS	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Employee Stock Benefit Plans	EMPLOYEE STOCK BENEFIT PLANS On May 4, 2021, the shareholders approved the 2021 Stock Award and Incentive Plan (the “2021 Plan”) replacing our previous equity plans. The 2021 Plan authorizes awards in the form of incentive stock options, nonqualified stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), dividend equivalents, performance share units ("PSUs"), market share units ("MSUs") and other stock-based awards. As of December 31, 2022, the 2021 Plan was the only plan under which we were authorized to grant equity awards. The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2022, 81 million shares were available for award and 44 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. Under the 2021 Plan, executive officers and other employees may be granted options to purchase common stock at no less than the market price on the date the option is granted. Options generally become exercisable ratably over four years and have a maximum term of 10 years. The 2021 Plan provides for the granting of SARs whereby the grantee may surrender exercisable rights and receive common stock and/or cash measured by the excess of the market price of the common stock over the award's exercise price. BMS did not grant stock options or SARs during the years ended December 31, 2022, 2021 and 2020. Options that were outstanding during those years generally vested ratably over four years (some options granted as replacements for options held by Celgene option holders upon the acquisition of Celgene in 2019 provided for cliff vesting and/or longer or shorter vesting periods). RSUs are granted to executive officers and other employees, subject to restrictions as to continuous employment. Generally, vesting occurs ratably over a three MSUs are granted to executive officers. Vesting is conditioned upon continuous employment and occurs ratably over four years, subject to accelerated vesting in specified circumstances. The number of shares issued upon vesting of MSUs is determined based on a specified payout factor requiring that the market price per share at a specified measurement date be at least 80% of the grant-date share price (market condition) for awards granted in 2022 (60% prior to 2022). Attainment of a higher payout factor, calculated as the share price on measurement date divided by share price on award date, results in a higher percentage payout of MSUs, up to a maximum of 225% of the target number of MSUs for awards granted in 2022 (200% prior to 2022). The share price used in the payout factor is calculated using an average of the closing prices on the grant date or measurement date, and the nine trading days immediately preceding the grant date or measurement date. PSUs are granted to executive officers, have a three-year performance cycle and are granted as a target number of stock units subject to adjustment. The number of shares issued when PSUs vest is determined based on the achievement of specified performance goals (a performance condition) and based on BMS’s three-year total shareholder return relative to a peer group of companies (a market condition) and can range from 0% to a maximum of 200% of the target number of PSUs. Vesting is conditioned upon continuous employment and occurs on the third anniversary of the grant date, subject to accelerated vesting in specified circumstances. Stock-based compensation expense for awards ultimately expected to vest is recognized over the vesting period. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Cost of products sold $ 41 $ 57 $ 37 Marketing, selling and administrative 195 241 332 Research and development 221 272 339 Other (income)/expense, net — 13 71 Total stock-based compensation expense $ 457 $ 583 $ 779 Income tax benefit (a) $ 91 $ 120 $ 158 (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $74 million in 2022, $38 million in 2021 and $35 million in 2020. The total stock-based compensation expense for the years ended December 31, 2022, 2021 and 2020 includes $96 million, $192 million and $382 million, respectively, related to Celgene post-combination service period. The expense for the accelerated vesting of awards related to the Celgene acquisition was not material in 2022 and was $13 million and $71 million in 2021 and 2020, respectively. The following table summarizes the stock compensation activity for the year ended December 31, 2022: Stock Options RSUs MSUs PSUs Shares in Millions Number of Options Weighted-Average Exercise Price of Shares Number of Nonvested RSUs Weighted-Average Grant-Date Fair Value Number of Nonvested MSUs Weighted-Average Grant-Date Fair Value Number of Nonvested PSUs Weighted-Average Grant-Date Fair Value Balance at January 1, 2022 47.0 $ 53.00 19.1 $ 54.92 1.8 $ 56.51 3.4 $ 55.38 Granted — — 8.7 64.12 1.0 60.74 1.4 66.76 Released/Exercised (24.3) 50.79 (8.2) 55.12 (0.8) 56.95 (1.3) 49.99 Adjustments for actual payout — — — — 0.1 54.26 0.4 49.99 Forfeited/Canceled (0.8) 58.70 (2.7) 57.43 (0.3) 57.63 (0.4) 60.26 Balance at December 31, 2022 21.9 55.25 16.9 59.17 1.8 58.25 3.5 60.88 Expected to vest 14.9 58.97 1.6 58.12 3.2 60.45 Dollars in Millions Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 734 $ 49 $ 89 Expected weighted-average period in years of compensation cost to be recognized 2.5 2.8 1.7 Amounts in Millions, except per share data 2022 2021 2020 Weighted-average grant date fair value (per share): RSUs $ 64.12 $ 56.58 $ 53.65 MSUs 60.74 58.04 53.92 PSUs 66.76 59.04 55.61 Fair value of awards that vested: RSUs - replacement awards $ 152 $ 519 $ 777 RSUs 300 246 122 MSUs 44 37 37 PSUs 68 61 59 Total intrinsic value of stock options exercised 526 512 556 The fair value of RSUs approximates the closing market price of BMS’s common stock on the grant date after adjusting for the units not eligible for accrual of dividend equivalents. The fair value of MSUs is estimated as of the grant date using a Monte Carlo simulation. The fair value of PSUs is estimated as of the grant date for the portion related to the relative total shareholder return measure, using a Monte Carlo simulation and, for the remaining portion, based on the closing market price of BMS’s common stock on the grant date after adjusting for the units not eligible for accrual of dividend equivalents, and taking into account the probability of satisfying the performance condition as of the grant date. The following table summarizes significant outstanding and exercisable options at December 31, 2022: Range of Exercise Prices Number of Options (in millions) Weighted-Average Remaining Contractual Life (in years) Weighted-Average Exercise Price Per Share Aggregate Intrinsic Value (in millions) $10 - $40 2.2 1.0 $ 35.02 $ 80 $40 - $55 7.7 3.3 48.92 177 $55 - $65 8.0 2.7 59.45 100 $65 + 4.0 3.2 70.02 9 Outstanding 21.9 2.8 55.25 $ 366 Exercisable 21.9 2.8 55.25 $ 366 The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing stock price of $71.95 on December 30, 2022, which was the last trading day of 2022.

LEGAL PROCEEDINGS AND CONTINGEN

LEGAL PROCEEDINGS AND CONTINGENCIES	12 Months Ended
LEGAL PROCEEDINGS AND CONTINGENCIES	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	LEGAL PROCEEDINGS AND CONTINGENCIES BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below. While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS’s legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS’s financial position, results of operations or cash flows for a particular period. Furthermore, failure to successfully enforce BMS’s patent rights would likely result in substantial decreases in the respective product revenues from generic competition. Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see “—Note 7. Income Taxes.” INTELLECTUAL PROPERTY Anti-PD-1 and Anti-PD-L1 — U.S. In September 2015, Dana-Farber Cancer Institute (“Dana-Farber”) filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD-1 and PD-L1 antibodies. Specifically, Dana-Farber sought to add two scientists as inventors to these patents. In October 2017, Pfizer was allowed to intervene in the case alleging that one of the scientists identified by Dana-Farber was employed by a company eventually acquired by Pfizer during the relevant period. In May 2019, the District Court issued a decision ruling that the two scientists should be added as inventors to the patents, which decision was affirmed on appeal. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss that complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber’s claims for damages before May 17, 2019—the date of the District Court’s ruling that Dana-Farber was a co-inventor of the patents—are preempted by federal patent law. On January 25, 2023, the Court held a hearing on a motion filed by BMS requesting that the Court enter summary judgment in BMS' favor. A trial has been scheduled for May 2023. On March 17, 2022, BMS filed a lawsuit in U.S. District Court for the District of Delaware against AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd (collectively, “AZ”) alleging that AZ's marketing of the PD-L1 antibody Imfinzi infringes certain claims of U.S. Patent Nos. 9,580,505, 9,580,507, 10,138,299, 10,308,714, 10,266,594, 10,266,595, 10,266,596 and 10,323,092. A trial has been scheduled to begin on April 22, 2024. CAR-T — U.S. In October 2017, Juno and Sloan Kettering Institute for Cancer Research (“SKI”) filed a complaint for patent infringement against Kite Pharma, Inc. (“Kite”) in the U.S. District Court for the Central District of California. The complaint alleged that Kite’s Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the “’190 Patent”) concerning CAR-T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the ’190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite’s defenses, finding that Kite willfully infringed the ’190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million upfront payment and a 27.6% running royalty on Kite’s sales of Yescarta* through the expiration of the ’190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite’s motions in their entirety. In April 2020, the Court granted in part Juno’s motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest and enhanced damages and a 27.6% running royalty on Kite’s sales of Yescarta * from December 13, 2019 through the expiration of the ’190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the ’190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit for panel and en banc rehearing, which the Federal Circuit denied on January 14, 2022. On June 13, 2022, Juno and SKI filed a petition for a writ of certiorari with the U.S. Supreme Court, which the Court denied on November 7, 2022. On November 23, 2022, Juno and SKI filed a petition for rehearing with the Court, which the Court denied on January 9, 2023. CTLA-4 — U.S. On January 23, 2023, BMS filed a lawsuit in U.S. District Court for the District of Delaware against AstraZeneca Pharmaceuticals LP and AstraZeneca AB (collectively, "AZ AB") alleging that AZ AB's marketing of the CTLA-4 antibody Imjudo infringes certain claims of U.S. Patent Nos. 9,320,811 and 9,273, 135. No trial date has been scheduled. Eliquis - Europe In November 2020 and January 2021, Sandoz Limited (“Sandoz”) and Teva Pharmaceutical Industries Ltd. (“Teva Limited”), respectively, filed lawsuits in the United Kingdom seeking revocation of the UK apixaban composition of matter patent and related Supplementary Protection Certificate (“SPC”). BMS subsequently filed counterclaims for infringement in both actions. A trial took place in February 2022 and in a judgment issued on April 7, 2022, the judge found the UK apixaban composition of matter patent and related SPC invalid. On November 2, 2022, BMS was granted permission from the Court of Appeal to appeal the judgment and a hearing is scheduled to take place on April 18-19, 2023. Similar lawsuits have been filed in various other countries in Europe seeking revocation of our composition of matter patents and SPCs relating to Eliquis, and trials have been scheduled in certain of those cases, including in Norway and France in early 2023. In May 2022, a Dutch court issued a decision denying a request by BMS for a preliminary injunction that would have prevented an at-risk generic launch in the Netherlands by Sandoz prior to a full trial on the validity of the Dutch composition of matter patent and SPC. Following the above decisions in the UK and the Netherlands, generic manufacturers have begun marketing generic versions of Eliquis in the UK and the Netherlands, and may seek to market generic versions of Eliquis in additional countries in Europe, prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe. In September 2022, a trial was held in Sweden regarding Teva's challenge to the validity of the Swedish apixaban composition of matter patent and related SPC, and a decision was issued on November 2, 2022, confirming their validity and rejecting Teva's claims. In September 2022, BMS filed a request for a preliminary injunction against Teva in Denmark, but the request was denied in December 2022, based on the finding that there is no imminent threat of a launch by Teva in Denmark. In December 2022, BMS filed a request for a preliminary injunction in Finland against Teva, which request was granted in January 2023, prohibiting Teva from offering, storing or selling generic Eliquis products in Finland that have obtained price and reimbursement. BMS has also requested that a preliminary injunction be entered against Teva in Ireland, for which a hearing occurred in February 2023. Onureg – U.S. In November 2021, BMS received a Notice Letter from Accord notifying BMS that Accord had filed an ANDA containing a paragraph IV certification seeking approval of a generic version of Onureg in the U.S. and challenging the one FDA Orange Book-listed formulation patent expiring in 2030. In response, BMS filed a patent infringement action against Accord in the U.S. District Court for the District of Delaware. A trial has been scheduled to begin on March 18, 2024. Plavix* - Australia Sanofi was notified that, in August 2007, GenRx Proprietary Limited (“GenRx”) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex (“GenRx-Apotex”). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi’s injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (“Full Court”) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($304 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government’s claim for damages. In May 2020, the Australian government appealed the Federal Court’s decision and an appeal hearing concluded in February 2021. Sprycel - U.S. In January 2022, BMS received a Notice Letter from Xspray Pharma AB (“Xspray”), Nanocopoeia, LLC ("Nanocopoeia") and Handa Oncology, LLC ("Handa"), respectively, notifying BMS that each had filed a 505(b)(2) NDA application containing paragraph IV certifications seeking approval of a dasatinib product in the U.S. and challenging two FDA Orange Book-listed monohydrate form patents expiring in 2025 and 2026. In February 2022, BMS filed a patent infringement action against Xspray in the U.S. District Court for the District of New Jersey. In May 2022, BMS filed a patent infringement action against Nanocopoeia in the U.S. District Court for the District of Minnesota. In November 2022, BMS filed a patent infringement action against Handa in the U.S. District Court for the Northern District of California. No trial dates have been scheduled in any of these actions. Both Xspray and Nanocopoeia have filed motions for a judgment based on the pleadings, and a hearing on Nanocopoeia's motion took place on January 5, 2023. Zeposia - U.S. On October 15, 2021, Actelion Pharmaceuticals LTD and Actelion Pharmaceuticals US, INC (“Actelion”) filed a complaint for patent infringement in the United States District Court for the District of New Jersey against BMS and Celgene for alleged infringement of U.S. Patent No. 10,251,867 (the “’867 Patent”). The Complaint alleges that the sale of Zeposia infringes certain claims of the ’867 Patent and Actelion is seeking damages and injunctive relief. No trial date has been scheduled. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits BMS and certain Sanofi entities are defendants in consumer protection actions brought by the attorneys general of Hawaii and New Mexico relating to the labeling, sales and/or promotion of Plavix . A trial in the Hawaii matter occurred in 2020. In February 2021, the Court issued a decision against Sanofi and BMS, imposing penalties in the total amount of $834 million, with $417 million attributed to BMS. Sanofi and BMS disagree with the decision and are appealing it. An oral argument before the Hawaii Supreme Court occurred in December 2022. BMS remains confident in the merits of its case and its likelihood of success on appeal and does not believe establishing a reserve is warranted for this matter. In September 2022, the parties settled the New Mexico matter. PRODUCT LIABILITY LITIGATION BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products. Abilify BMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. Cases have been filed in state and federal courts and additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation consolidated the federal court cases for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master settlement agreement establishing a proposed settlement program to resolve all Abilify* compulsivity claims filed as of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders and all remaining cases in the U.S. MDL litigation have since been resolved. Three inactive cases remain in New Jersey State court. There are eleven cases pending in Canada (four class actions, seven individual injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario), both of which class actions have now been certified. Byetta* Amylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta , primarily pancreatic cancer and in some cases claiming alleged wrongful death. The majority of cases were pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (“JCCP”). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The MDL and JCCP decisions are both final and all claims in the MDL and JCCP have since been dismissed. All thyroid cancer claims that were pending in these courts have been dismissed as well. Onglyza* BMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . In February 2018, the Judicial Panel on Multidistrict Litigation ordered all the federal Onglyza* cases to be transferred to an MDL in the U.S. District Court for the Eastern District of Kentucky. A significant majority of the claims are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco (“JCCP”). On September 24, 2021, the JCCP court granted defendants’ motion to exclude plaintiffs’ only general causation expert and on January 5, 2022, the MDL court likewise granted defendants’ motion to exclude plaintiffs’ expert. On March 30, 2022, the JCCP court granted summary judgment to defendants, thus effectively dismissing the 18 claims previously pending in California state court. Plaintiffs have filed an appeal. Defendants filed a summary judgment motion in the MDL as well, which the MDL court granted on August 2, 2022. Plaintiffs in the MDL then moved to alter or amend the MDL court’s order, and defendants opposed. On November 3, 2022, the MDL court denied plaintiffs motion to alter or amend its summary judgment order. Plaintiffs filed their Notice of Appeal on December 2, 2022. As part of BMS’s global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca. SECURITIES LITIGATION Celgene Securities Litigations Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the “Celgene Securities Class Action”). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene’s 2020 outlook and projected sales of Otezla* , and (3) the new drug application for Zeposia . The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiff’s amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. In November 2020, the Court granted class certification with respect to the remaining claims. In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action (the “Schwab Action”). In July 2020, the defendants filed a motion to dismiss the plaintiffs’ complaint in full. In March 2021, the Court granted in part and denied in part defendants’ motion to dismiss consistent with its decision in the Celgene Securities Class Action. The California Public Employees’ Retirement System in April 2021 (the “CalPERS Action”); DFA Investment Dimensions Group Inc., on behalf of certain of its funds; and American Century Mutual Funds, Inc., on behalf of certain of its funds, in July 2021 (respectively the “DFA Action” and the “American Century Action”), and GIC Private Limited in September 2021 (the “GIC Action”), filed separate individual actions in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action and the Schwab individual action against the same remaining defendants in those actions. In October 2021, these actions were consolidated for pre-trial proceedings with the Schwab Action. The court also consolidated any future direct actions raising common questions of law and fact with the Schwab Action. No trial dates have been scheduled in any of the above Celgene Securities Litigations. Contingent Value Rights Litigations In June 2021, an action was filed against BMS in the U.S. District Court for the Southern District of New York asserting claims of alleged breaches of a Contingent Value Rights Agreement (“CVR Agreement”) entered into in connection with the closing of BMS’s acquisition of Celgene Corporation in November 2019. The successor trustee under the CVR Agreement alleges that BMS breached the CVR Agreement by allegedly failing to use “diligent efforts” to obtain FDA approval of liso-cel ( Breyanzi ) before a contractual milestone date, thereby avoiding a $6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the successor trustee. The successor trustee seeks damages in an amount to be determined at trial and other relief, including interest and attorneys’ fees. BMS disputes the successor trustee’s allegations and filed a motion to dismiss on July 23, 2021. On June 24, 2022, the court denied BMS’s motion to dismiss. In October 2021, alleged former Celgene stockholders filed a complaint in the U.S. District Court for the Southern District of New York asserting claims on behalf of a putative class of Celgene stockholders who received CVRs in the BMS merger with Celgene for violations of sections 14(a) and 20(a) of the Securities Exchange Act of 1934 relating to the joint proxy statement. That action later was consolidated with another action filed in the same court, and a consolidated complaint thereafter was filed asserting claims on behalf of a class of CVR acquirers, whether in the BMS merger with Celgene or otherwise, for violations of sections 11, 12(a)(2), and 15 of the Securities Act of 1933 and sections 10(b), 14(a) and 20(2) of the Securities Exchange Act of 1934. The complaint alleges that the February 22, 2019 joint proxy statement was materially false or misleading because it failed to disclose that BMS allegedly had no intention to obtain FDA approval for liso-cel ( Breyanzi ) by the applicable milestone date in the CVR Agreement and that certain statements made by BMS or certain BMS officers in periodic SEC filings, earnings calls, press releases, and investor presentations between December 2019 and November 2020 were materially false or misleading for the same reason. Defendants have moved to dismiss the complaint. In November 2021, an alleged purchaser of CVRs filed a complaint in the Supreme Court of the State of New York for New York County asserting claims on behalf of a putative class of CVR acquirers for violations of sections 11(a) and 12(a)(2) of the Securities Act of 1933. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel ( Breyanzi ) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, and certain BMS officers who signed the registration statement. BMS removed the action to the U.S. District Court for the Southern District of New York. The plaintiff filed a motion to remand the action to the state court, which the court granted on September 19, 2022. Defendants have moved to stay the action pending resolution of the federal action and, in the alternative, to dismiss the complaint. In November 2021, an alleged Celgene stockholder filed a complaint in the Superior Court of New Jersey, Union County asserting claims on behalf of two separate putative classes, one of acquirers of CVRs and one of acquirers of BMS common stock, for violations of sections 11(a), 12(a)(2), and 15 of the Securities Act of 1933. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel ( Breyanzi ) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, certain BMS officers who signed the registration statement and Celgene’s former chairman and chief executive officer. BMS removed the action to the U.S. District Court for the District of New Jersey and filed a motion to transfer the action to the U.S. District Court for the Southern District of New York. The plaintiff filed a motion to remand the action to the state court, which the court granted on September 22, 2022. Defendants have moved to stay the action pending resolution of the federal action and, in the alternative, to dismiss the complaint. No trial dates have been scheduled in any of the above CVR Litigations. OTHER LITIGATION HIV Medication Antitrust Litigations BMS was sued with three other manufacturers of HIV medications in related lawsuits in the Northern District of California. The initial lawsuits, filed on behalf of indirect purchasers, alleged that the defendants’ agreements to develop and sell fixed-dose combination products for the treatment of HIV, including Atripla* and Evotaz , violate antitrust laws. In July 2020, the Court granted in part defendants’ motion to dismiss, including dismissing with prejudice plaintiffs’ claims as to an overarching conspiracy and plaintiffs’ theories based on the alleged payment of royalties after patent expiration. Other claims, however, remained. In October 2021, BMS entered a settlement agreement with the indirect purchasers. On May 6, 2022, the Court granted final approval of that settlement. In September and October 2020, two purported class actions were also filed asserting similar claims on behalf of direct purchasers. In March 2021, the Court dismissed one of the direct purchaser cases and limited the claims of the remaining direct purchaser case to those arising in 2016 or later. However, the Court gave plaintiffs leave to amend their complaints, and one plaintiff filed an amended complaint on March 16, 2021. In March 2022, BMS entered into a settlement agreement with the direct purchasers (excluding the retailers discussed below). On November 18, 2022, the Court granted final approval of that settlement. On September 22, 2021, two additional non-class action direct purchaser complaints were filed by a number of retail pharmacy and grocery store chains against BMS and two other manufacturers of HIV medications. Those complaints made allegations similar to those raised in the other federal court cases and the New Mexico state court case described below. In January 2022, BMS entered into an agreement to settle the cases filed against it by the retail pharmacy and grocery store chains, and those cases were dismissed. In February 2021, BMS and two other manufacturers of HIV medications were sued in State Court in New Mexico by the Attorney General of the State of New Mexico in a case alleging that the defendants’ agreements to develop and sell various fixed-dose combination products for the treatment of HIV, including Atripla* , and agreements to settle certain patent litigation violate the antitrust laws of the State of New Mexico. On October 26, 2022, BMS and the State of New Mexico entered into an agreement to settle New Mexico’s case against BMS. The case against BMS was dismissed by stipulation on November 7, 2022. In December 2021, five additional non-class-action indirect purchaser cases were filed in the Northern District of California, and one additional non-class-action indirect purchaser case was filed in California state court naming BMS and two other manufacturers as defendants. Those complaints made allegations similar to those in the other federal court cases. In February 2022, BMS reached a settlement agreement with one of the non-class-action indirect purchaser plaintiffs and that case was dismissed. In April 2022, two additional indirect purchaser plaintiffs filed non-class suits against BMS and other defendants. In July 2022, BMS entered into a settlement agreement resolving these seven remaining indirect purchaser cases. Accordingly, all of the HIV Medication Antitrust Litigations that were pending against BMS have been resolved. Thalomid and Revlimid Litigations Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for ANDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid , and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, sought injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In March 2020, Celgene reached a settlement with the class plaintiffs. In October 2020, the Court entered a final order approving the settlement and dismissed the matter. That settlement did not resolve the claims of certain entities that opted out of the settlement. In March 2019, Humana Inc. (“Humana”), which opted out of the above settlement, filed a lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana’s complaint makes largely the same claims and allegations as were made in the now settled Thalomid and Revlimid antitrust class action litigation. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. In May 2019, Celgene filed a motion to dismiss Humana’s complaint. In April 2022, the Court issued an order denying Celgene’s motion to dismiss. That order addressed only Celgene’s argument that certain of

ACCOUNTING POLICIES AND RECEN_2

ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of Operations and Basis of Consolidation	Nature of Operations and Basis of Consolidation Bristol-Myers Squibb Company (“BMS”, or “the Company”) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The consolidated financial statements are prepared in conformity with U.S. GAAP, including the accounts of Bristol-Myers Squibb Company and all of its controlled majority-owned subsidiaries and certain variable interest entities. All intercompany balances and transactions are eliminated. Material subsequent events are evaluated and disclosed through the report issuance date. Refer to the Summary of Abbreviated Terms at the end of this 2022 Form 10-K for definitions of capitalized terms used throughout the document. Alliance and license arrangements are assessed to determine whether the terms provide economic or other control over the entity requiring consolidation of an entity. Entities controlled by means other than a majority voting interest are referred to as variable interest entities and are consolidated when BMS has both the power to direct the activities of the variable interest entity that most significantly impacts its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity.
Business Segment Information	Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS ’ s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.”
Use of Estimates and Judgments	Use of Estimates and Judgments The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of intangible assets; charge-backs, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates.
Reclassifications	Reclassifications Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Upfront and contingent milestone charges in connection with asset acquisitions or licensing of third-party intellectual property rights previously presented in Research and development are now presented in Acquired IPRD in the consolidated statements of earnings.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include bank deposits, time deposits, commercial paper and money market funds. Cash equivalents consist of highly liquid investments with original maturities of three months or less at the time of purchase and are recognized at cost, which approximates fair value.
Marketable Debt Securities and Investments in Equity Securities	Marketable Debt Securities Marketable debt securities are classified as “available-for-sale” on the date of purchase and reported at fair value. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit default risk or underlying security and overall capital market liquidity. Marketable debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary, which considers the intent and ability to retain the investment for a period of time sufficient to allow for any anticipated recovery in market value, the duration and extent that the market value has been less than cost and the investee's financial condition. Equity Investments Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in Other (income)/expense, net. Equity investments without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Changes in the estimated fair value of equity investments without readily determinable fair values are recorded in Other (income)/expense, net. BMS holds investments in limited partnerships, which primarily invest in early-stage life sciences companies. Such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. Investments in 50% or less owned companies, as well as limited partnerships, are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The proportional share of the investee's net income or losses of equity investments accounted for using the equity method are included in Other (income)/expense, net. Equity investments without readily determinable fair values and equity investments accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.
Inventory Valuation	Inventory Valuation Inventories are stated at the lower of average cost or net realizable value.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight-line method based on the estimated useful lives of the related assets ranging from 20 to 50 years for buildings and 3 to 20 years for machinery, equipment and fixtures.
Impairment or Disposal of Property, Plant and Equipment	Current facts or circumstances are periodically evaluated to determine if the carrying value of depreciable assets to be held and used may not be recoverable. If such circumstances exist, an estimate of undiscounted future cash flows generated by the long-lived asset, or appropriate grouping of assets, is compared to the carrying value to determine whether an impairment exists at its lowest level of identifiable cash flows. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques using unobservable fair value inputs, such as a discounted value of estimated future cash flows.
Capitalized Software	Capitalized SoftwareEligible costs to obtain internal use software are capitalized and amortized over the estimated useful life of the software ranging from three
Acquisitions	Acquisitions Businesses acquired are consolidated upon obtaining control. The fair value of assets acquired and liabilities assumed are recognized at the date of acquisition. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. Business acquisition costs are expensed when incurred. Contingent consideration from potential development, regulatory, approval and sales-based milestones and sales-based royalties are included in the purchase price for business combinations and excluded for asset acquisitions. If the assets acquired do not meet the definition of a business, primarily because no significant processes were acquired or substantially all of the relative fair value was allocated to a single asset, the transaction is accounted for as an asset acquisition rather than a business combination and no goodwill is recorded. In addition, in an asset acquisition, acquired in-process research and development ("IPRD") assets with no alternative future use are charged to Acquired IPRD.
Goodwill, Acquired In-Process Research and Development and Other Intangible Assets	Goodwill, IPRD and Other Intangible Assets The fair value of acquired intangible assets is determined using an income-based approach referred to as the excess earnings method utilizing Level 3 fair value inputs. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success.
Impairment or Disposal of Intangible Assets	If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. Examples of qualitative factors assessed include BMS ’ s share price, financial performance compared to budgets, long-term financial plans, macroeconomic, industry and market conditions as well as the substantial excess of fair value over the carrying value of net assets from the annual impairment test performed in a prior year. Each relevant factor is assessed both individually and in the aggregate. IPRD is tested for impairment at least annually or more frequently if events occur or circumstances change that would indicate a potential reduction in the fair values of the assets below their carrying value. Impairment charges are recognized to the extent the carrying value of IPRD is determined to exceed its fair value.
Derivatives	Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. Derivatives designated as hedges, are assessed at inception and quarterly thereafter, to determine whether they are highly effective in offsetting changes or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in Accumulated other comprehensive loss and are subsequently recognized in earnings consistent with the underlying hedged item. If a derivative is no longer highly effective as a hedge, the Company discontinues hedge accounting prospectively. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from Accumulated other comprehensive loss to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The Company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in foreign currency translation in Accumulated other comprehensive loss. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in investing activities.
Restructuring	Restructuring Restructuring charges are recognized as a result of actions to streamline operations, realize synergies from acquisitions and reduce the number of facilities. Estimating the impact of restructuring plans, including future termination benefits, integration expenses and other exit costs, requires judgment. Actual results could vary from these estimates. Restructuring charges are recognized upon meeting certain criteria, including finalization of committed plans, reliable estimates and discussions with local works councils in certain markets.
Contingencies	Contingencies Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product and environmental liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Gain contingencies (including contingent proceeds related to the divestitures) are not recognized until realized. Legal fees are expensed as incurred.
Revenue Recognition	Revenue Recognition Refer to “—Note 2. Revenue” for a detailed discussion of accounting policies related to revenue recognition, including deferred revenue and royalties. Refer to “—Note 3. Alliances” for further details regarding alliances. Alliance and other revenues consist primarily of amounts related to collaborations and out-licensing arrangements. Each of these arrangements are evaluated for whether they represent contracts that are within the scope of the revenue recognition guidance in their entirety or contain aspects that are within the scope of the guidance, either directly or by reference based upon the application of the guidance related to the derecognition of nonfinancial assets (ASC 610). Performance obligations are identified and separated when the other party can benefit directly from the rights, goods or services either on their own or together with other readily available resources and when the rights, goods or services are not highly interdependent or interrelated. Transaction prices for these arrangements may include fixed upfront amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development, regulatory and sales-based milestones because the ultimate outcomes are binary in nature. The expected value method is used to estimate royalties because a broad range of potential outcomes exist, except for instances in which such royalties relate to a license. Variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Significant judgment is required in estimating the amount of variable consideration to recognize when assessing factors outside of BMS’s influence such as likelihood of regulatory success, limited availability of third party information, expected duration of time until resolution, lack of relevant past experience, historical practice of offering fee concessions and a large number and broad range of possible amounts. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price and recognized at a point in time upon the transfer of control. Three types of out-licensing arrangements are typically utilized: (i) arrangements when BMS out-licenses intellectual property to another party and has no further performance obligations; (ii) arrangements that include a license and an additional performance obligation to supply product upon the request of the third party; and (iii) collaboration arrangements, which include transferring a license to a third party to jointly develop and commercialize a product. Most out-licensing arrangements consist of a single performance obligation that is satisfied upon execution of the agreement when the development and commercialization rights are transferred to a third party. Upfront fees are recognized immediately and included in Other (income)/expense, net. Although contingent development and regulatory milestone amounts are assessed each period for the likelihood of achievement, they are typically constrained and recognized when the uncertainty is subsequently resolved for the full amount of the milestone and included in Other (income)/expense, net. Sales-based milestones and royalties are recognized when the milestone is achieved or the subsequent sales occur. Sales-based milestones and royalties are included in Alliance and other revenues. Certain out-licensing arrangements may also include contingent performance obligations to supply commercial product to the third party upon its request. The license and supply obligations are accounted for as separate performance obligations as they are considered distinct because the third party can benefit from the license either on its own or together with other supply resources readily available to it and the obligations are separately identifiable from other obligations in the contract in accordance with the revenue recognition guidance. After considering the standalone selling prices in these situations, upfront fees, contingent development and regulatory milestone amounts and sales-based milestone and royalties are allocated to the license and recognized in the manner described above. Consideration for the supply obligation is usually based upon stipulated cost-plus margin contractual terms which represent a standalone selling price. The supply consideration is recognized at a point in time upon transfer of control of the product to the third party and included in Alliance and other revenues. The above fee allocation between the license and the supply represents the amount of consideration expected to be entitled to for the satisfaction of the separate performance obligations. Although collaboration arrangements are unique in nature, both parties are active participants in the operating activities and are exposed to significant risks and rewards depending on the commercial success of the activities. Performance obligations inherent in these arrangements may include the transfer of certain development or commercialization rights, ongoing development and commercialization services and product supply obligations. Except for certain product supply obligations which are considered distinct and accounted for as separate performance obligations similar to the manner discussed above, all other performance obligations are not considered distinct and are combined into a single performance obligation since the transferred rights are highly integrated and interrelated to the obligation to jointly develop and commercialize the product with the third party. As a result, upfront fees are recognized ratably over time throughout the expected period of the collaboration activities and included in Other (income)/expense, net as the license is combined with other development and commercialization obligations. Contingent development and regulatory milestones that are no longer constrained are recognized in a similar manner on a prospective basis. Royalties and profit sharing are recognized when the underlying sales and profits occur and are included in Alliance and other revenues. Refer to “—Note 3. Alliances” for further information.
Research and Development	Research and Development and Acquired IPRD Research and development costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Research and development costs are presented net of reimbursements from alliance partners. Nonrefundable advance payments for services to be received in the future for use in research and development activities are recorded as prepaid assets and expensed in the period when the services are performed.
Advertising and Product Promotion Costs	Advertising and Product Promotion Costs Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $1.3 billion in 2022 and 2021 and $990 million in 2020.
Foreign Currency Translation	Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recognized in Other Comprehensive Income/(Loss).
Income Taxes	Income Taxes The provision for income taxes includes income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recognized to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. The tax effects of global intangible low-taxed income from certain foreign subsidiaries is recognized in the income tax provision in the period the tax arises. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted Business Combinations In October 2021, the FASB issued amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. The guidance is intended to address inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized. At the acquisition date, an entity should account for the related revenue contracts in accordance with existing revenue recognition guidance generally by assessing how the acquiree applied recognition and measurement in their financial statements. The amended guidance is effective January 1, 2023 on a prospective approach. Fair Value Measurements In June 2022, the FASB issued amended guidance on measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The guidance also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendment requires the following disclosures for equity securities subject to contractual sale restrictions: the fair value of equity securities subject to contractual sale restrictions reflected in the balance sheet; the nature and remaining duration of the restriction(s); and the circumstances that could cause a lapse in the restriction(s). The amended guidance is effective January 1, 2024 on a prospective basis. Early adoption is permitted.
Alliances	The most common activities between BMS and its alliance partners are presented in results of operations as follows: • When BMS is the principal in the end customer sale, 100% of product sales are included in Net product sales. When BMS's alliance partner is the principal in the end customer sale, BMS’s contractual share of the third-party sales and/or royalty income are included in Alliance revenues as the sale of commercial products are considered part of BMS’s ongoing major or central operations. Refer to “—Note 2. Revenue” for information regarding recognition criteria. • Amounts payable to BMS by alliance partners (who are the principal in the end customer sale) for supply of commercial products are included in Alliance revenues as the sale of commercial products are considered part of BMS’s ongoing major or central operations. • Profit sharing, royalties and other sales-based fees payable by BMS to alliance partners are included in Cost of products sold as incurred. • Cost reimbursements between the parties are recognized as incurred and included in Cost of products sold; Marketing, selling and administrative expenses; or Research and development expenses, based on the underlying nature of the related activities subject to reimbursement. • Upfront and contingent development and regulatory approval milestones payable to BMS by alliance partners for investigational compounds and commercial products are deferred and amortized over the expected period of BMS's development and co-promotion obligation through the market exclusivity period or the periods in which the related compounds or products are expected to contribute to future cash flows. The amortization is presented consistent with the nature of the payment under the arrangement. For example, amounts received for investigational compounds are presented in Other (income)/expense, net as the activities being performed at that time are not related to the sale of commercial products included in BMS’s ongoing major or central operations; amounts received for commercial products are presented in alliance revenue as the sale of commercial products are considered part of BMS’s ongoing major or central operations. • Upfront and contingent regulatory approval milestones payable by BMS to alliance partners for commercial products are capitalized and amortized over the shorter of the contractual term or the periods in which the related products are expected to contribute to future cash flows. • Upfront and contingent milestones payable by BMS to alliance partners prior to regulatory approval are expensed as incurred and included in Acquired IPRD expense. • Royalties and other contingent consideration payable to BMS by alliance partners related to the divestiture of such businesses are included in Other (income)/expense, net when earned. • All payments between BMS and its alliance partners are presented in Cash Flows From Operating Activities except for upfront and milestone payments which are presented in Cash Flows From Investing Activities.

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
Accounting Policies (Tables)	Dec. 31, 2022
Accounting Policies [Abstract]
Acquired IPRD by type of transaction	The Company's Acquired IPRD by type of transaction was as follows: Type of transaction Year ended December 31, Dollars in Millions 2022 2021 2020 Alliance (Note 3) $ 100 $ 730 $ 258 In-license arrangements and other (Note 4) 715 429 659 Asset acquisitions (Note 4) — — 11,616 Acquired IPRD $ 815 $ 1,159 $ 12,533

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
REVENUE (Tables)	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes the disaggregation of revenue by nature: Year Ended December 31, Dollars in Millions 2022 2021 2020 Net product sales $ 44,671 $ 45,055 $ 41,321 Alliance revenues 742 716 615 Other revenues 746 614 582 Total Revenues $ 46,159 $ 46,385 $ 42,518
Schedule of Revenue by Major Customers	Gross revenue to the three largest pharmaceutical wholesalers in the U.S. as a percentage of U.S. gross revenues was as follows: Year Ended December 31, 2022 2021 2020 McKesson Corporation 32 % 32 % 31 % AmerisourceBergen Corporation 25 % 25 % 25 % Cardinal Health, Inc. 21 % 20 % 19 %
Reconciliation of Gross Product Sales to Net Product Sales	The following table summarizes GTN adjustments: Year Ended December 31, Dollars in Millions 2022 2021 2020 Gross product sales $ 69,633 $ 67,897 $ 60,016 GTN adjustments (a) Charge-backs and cash discounts (7,469) (7,253) (5,827) Medicaid and Medicare rebates (11,362) (9,374) (7,595) Other rebates, returns, discounts and adjustments (6,131) (6,215) (5,273) Total GTN adjustments (24,962) (22,842) (18,695) Net product sales $ 44,671 $ 45,055 $ 41,321
Disaggregation of Revenue by Product and Region	The following table summarizes the disaggregation of revenue by product and region: Year Ended December 31, Dollars in Millions 2022 2021 2020 In-Line Products Eliquis $ 11,789 $ 10,762 $ 9,168 Opdivo 8,249 7,523 6,992 Pomalyst/Imnovid 3,497 3,332 3,070 Orencia 3,464 3,306 3,157 Sprycel 2,165 2,117 2,140 Yervoy 2,131 2,026 1,682 Empliciti 296 334 381 Mature and other brands 1,749 1,900 2,217 New Product Portfolio Reblozyl 717 551 274 Abecma 388 164 — Opdualag 252 — — Zeposia 250 134 12 Breyanzi 182 87 — Onureg 124 73 17 Inrebic 85 74 55 Camzyos 24 — — Sotyktu 8 — — Recent LOE Products (a) Revlimid 9,978 12,821 12,106 Abraxane 811 1,181 1,247 Total Revenues $ 46,159 $ 46,385 $ 42,518 United States $ 31,828 $ 29,214 $ 26,577 International 13,497 16,319 15,310 Other (b) 834 852 631 Total Revenues $ 46,159 $ 46,385 $ 42,518 (a) Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity. (b) Other include royalties and alliance-related revenues for products not sold by BMS ’ s regional commercial organizations.

ALLIANCES (Tables)

ALLIANCES (Tables)	12 Months Ended
ALLIANCES (Tables)	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Financial Information Pertaining to Alliances	Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from alliances: Net product sales $ 12,001 $ 10,840 $ 9,364 Alliance revenues 742 716 615 Total Revenues $ 12,743 $ 11,556 $ 9,979 Payments to/(from) alliance partners: Cost of products sold $ 5,768 $ 5,227 $ 4,485 Marketing, selling and administrative (223) (183) (128) Research and development 49 42 91 Acquired IPRD 100 730 258 Other (income)/expense, net (53) (62) (74) Selected alliance balance sheet information: December 31, Dollars in Millions 2022 2021 Receivables – from alliance partners $ 317 $ 320 Accounts payable – to alliance partners 1,249 1,229 Deferred income from alliances (a) 289 330 (a) Includes unamortized upfront and milestone payments.
Alliance revenues \| Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Financial Information Pertaining to Alliances	Summarized financial information related to this alliance was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from Pfizer alliance: Net product sales $ 11,488 $ 10,431 $ 8,942 Alliance revenues 301 331 226 Total Revenues $ 11,789 $ 10,762 $ 9,168 Payments to/(from) Pfizer: Cost of products sold – Profit sharing $ 5,604 $ 5,064 $ 4,331 Other (income)/expense, net – Amortization of deferred income (42) (36) (55) Selected alliance balance sheet information: December 31, Dollars in Millions 2022 2021 Receivables $ 191 $ 235 Accounts payable 1,208 1,195 Deferred income 222 264
Alliance revenues \| Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Financial Information Pertaining to Alliances	Summarized financial information related to this alliance was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Revenues from Ono alliances: Net product sales $ 216 $ 251 $ 194 Alliance revenues 441 385 382 Total Revenues $ 657 $ 636 $ 576

ACQUISITIONS, DIVESTITURES, L_2

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2022
Acquisitions and Divestitures [Abstract]
Total Consideration for the Acquisition	The total consideration for the acquisition consisted of the following: Dollars in Millions Total Consideration Cash consideration for outstanding shares $ 3,811 Cash consideration for equity awards 302 Consideration paid 4,113 Less: Unvested stock awards (a) 153 Total consideration to be allocated $ 3,960 (a) Includes unvested equity awards of $73 million expensed in Marketing, selling, and administrative and $80 million expensed in Research and development in 2022.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed as of the acquisition date based upon their respective fair values summarized below: Dollars in Millions Purchase Price Allocation Cash and cash equivalents $ 795 Other current assets 14 Intangible assets (a) 2,971 Deferred income tax assets 229 Other non-current assets 10 Deferred income tax liabilities (643) Other current liabilities (111) Identifiable net assets acquired $ 3,265 Goodwill (b) 695 Total consideration allocated $ 3,960 (a) Intangible assets primarily consist of IPRD allocated to repotrectinib ($2.8 billion), a potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers in NSCLC and other advanced solid tumors. Repotrectinib is currently in registrational Phase II study in adults and a Phase I/II study in pediatric patients. The estimated fair value of IPRD assets was determined using an income approach valuation method. (b) Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes.
Divestitures	Divestitures The following table summarizes the financial impact of divestitures including royalty income, which is included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses). Net Proceeds (a) Divestiture (Gains)/Losses Royalty Income Dollars in Millions 2022 2021 2020 2022 2021 2020 2022 2021 2020 Diabetes business $ 767 $ 612 $ 558 $ — $ — $ — $ (810) $ (622) $ (567) Mature products and other 390 136 157 (211) (9) (55) (22) (44) (77) Total $ 1,157 $ 748 $ 715 $ (211) $ (9) $ (55) $ (832) $ (666) $ (644) (a) Includes proceeds from royalties received subsequent to the related sale of the asset or business.
Royalty and Licensing Income	The following table summarizes the financial impact of Keytruda* royalties, Tecentriq * royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Year Ended December 31, Dollars in Millions 2022 2021 2020 Keytruda * royalties $ (1,001) $ (841) $ (681) Tecentriq * royalties (93) (90) (19) Upfront licensing fees — (34) (30) Contingent milestone income (50) (18) (72) Amortization of deferred income (53) (39) (58) Biohaven sublicense income (55) — — Other royalties (31) (45) (23) Total $ (1,283) $ (1,067) $ (883)

OTHER (INCOME)_EXPENSE, NET (Ta

OTHER (INCOME)/EXPENSE, NET (Tables)	12 Months Ended
OTHER (INCOME)/EXPENSE, NET (Tables)	Dec. 31, 2022
Other Nonoperating Income (Expense) [Abstract]
Schedule Of Other Income Expense	Year Ended December 31, Dollars in Millions 2022 2021 2020 Interest expense $ 1,232 $ 1,334 $ 1,420 Royalty and licensing income (Note 4) (1,283) (1,067) (883) Royalty income - divestitures (Note 4) (832) (666) (644) Equity investment losses/(income), net (Note 9) 801 (745) (1,228) Integration expenses (Note 6) 440 564 717 Loss on debt redemption (Note 9) 266 281 — Divestiture gains (Note 4) (211) (9) (55) Litigation and other settlements 178 82 (194) Investment income (171) (39) (121) Provision for restructuring (Note 6) 75 169 530 Contingent consideration (9) (542) (1,757) Other 90 (82) (99) Other (income)/expense, net $ 576 $ (720) $ (2,314)

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	12 Months Ended
RESTRUCTURING (Tables)	Dec. 31, 2022
Restructuring Charges [Abstract]
Schedule of Charges Related to Restructuring Initiatives By Type of Cost	The following provides the charges related to restructuring initiatives by type of cost: Year Ended December 31, Dollars in Millions 2022 2021 2020 Celgene Acquisition Plan $ 472 $ 673 $ 1,244 Other Restructuring 48 78 39 Company Transformation — — 127 Total charges $ 520 $ 751 $ 1,410 Employee termination costs $ 69 $ 159 $ 457 Other termination costs 6 10 73 Provision for restructuring 75 169 530 Integration expenses 440 564 717 Accelerated depreciation 5 2 53 Asset impairments — 24 103 Other shutdown costs, net — (8) 7 Total charges $ 520 $ 751 $ 1,410 Cost of products sold $ — $ 24 $ 32 Marketing, selling and administrative 5 3 10 Research and development — — 113 Other (income)/expense, net 515 724 1,255 Total charges $ 520 $ 751 $ 1,410
Summary of Charges and Spending Related to Restructuring Plan Activities	The following summarizes the charges and spending related to restructuring plan activities: Year Ended December 31, Dollars in Millions 2022 2021 Liability at January 1 $ 101 $ 148 Provision for restructuring (a) 75 156 Foreign currency translation and other (7) (4) Payments (122) (199) Liability at December 31 $ 47 $ 101

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Provision/(Benefit) for Income Taxes	The provision/(benefit) for income taxes consisted of: Year Ended December 31, Dollars in Millions 2022 2021 2020 Current: U.S. $ 3,017 $ 1,879 $ 1,245 Non-U.S. 1,089 598 (104) Total current 4,106 2,477 1,141 Deferred: U.S. (2,889) (1,255) 229 Non-U.S. 151 (138) 754 Total deferred (2,738) (1,393) 983 Total Provision for Income Taxes $ 1,368 $ 1,084 $ 2,124
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of the effective tax rate to the U.S. statutory Federal income tax rate was as follows: % of Earnings Before Income Taxes Dollars in Millions 2022 2021 2020 Earnings/(Loss) before income taxes: U.S. $ (140) $ 1,593 $ (10,106) Non-U.S. 7,853 6,505 3,235 Total 7,713 8,098 (6,871) U.S. statutory rate 1,620 21.0 % 1,701 21.0 % (1,443) 21.0 % GILTI, net of foreign derived intangible income deduction 634 8.2 % 645 8.0 % 685 (10.0) % Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland (416) (5.4) % (143) (1.8) % (86) 1.3 % Internal transfers of intangible and other assets (93) (1.2) % (983) (12.1) % 853 (12.4) % U.S. Federal, state and foreign contingent tax matters (297) (3.9) % 154 1.9 % 136 (2.0) % U.S. Federal research-based credits (142) (1.8) % (165) (2.0) % (165) 2.4 % Charitable contributions of inventory (94) (1.2) % (42) (0.5) % (36) 0.5 % Contingent value rights — — (108) (1.3) % (363) 5.3 % Non-deductible R&D charges — — — — 2,461 (35.8) % Puerto Rico excise tax credit (144) (1.9) % (152) (1.9) % (147) 2.1 % State and local taxes (net of valuation allowance) 103 1.3 % 33 0.4 % 103 (1.5) % Foreign and other 197 2.6 % 144 1.7 % 126 (1.8) % Total $ 1,368 17.7 % $ 1,084 13.4 % $ 2,124 (30.9) %
Schedule of Deferred Income Tax Assets/(Liabilities)	The components of deferred income tax assets/(liabilities) were as follows: December 31, Dollars in Millions 2022 2021 Deferred tax assets Foreign net operating loss and other carryforwards $ 566 $ 945 State net operating loss and credit carryforwards 329 304 U.S. Federal net operating loss and credit carryforwards 236 226 Milestone payments and license fees 1,030 887 Capitalized research expenditures 1,573 — Other 1,284 1,390 Total deferred tax assets 5,018 3,752 Valuation allowance (873) (1,056) Deferred tax assets net of valuation allowance $ 4,145 $ 2,696 Deferred tax liabilities Acquired intangible assets $ (4,362) $ (4,867) Goodwill and other (605) (891) Total deferred tax liabilities $ (4,967) $ (5,758) Deferred tax liabilities, net $ (822) $ (3,062) Recognized as: Deferred income taxes assets – non-current $ 1,344 $ 1,439 Deferred income taxes liabilities – non-current (2,166) (4,501) Total $ (822) $ (3,062)
Changes in the Valuation Allowance	Changes in the valuation allowance were as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 1,056 $ 2,809 $ 2,844 Provision 213 201 62 Utilization (68) (1,087) (488) Foreign currency translation (59) (157) 212 Acquisitions/(dispositions)/(liquidations), net (271) (720) 179 Non U.S. rate change 2 10 — Balance at end of year $ 873 $ 1,056 $ 2,809
Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (excluding interest and penalties): Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 2,042 $ 2,003 $ 1,905 Gross additions to tax positions related to current year 53 66 76 Gross additions to tax positions related to prior years 137 75 325 Gross additions to tax positions assumed in acquisitions 15 — 51 Gross reductions to tax positions related to prior years (381) (22) (352) Settlements (8) (70) (7) Reductions to tax positions related to lapse of statute (83) (5) (5) Cumulative translation adjustment (9) (5) 10 Balance at end of year $ 1,766 $ 2,042 $ 2,003
Summary of Unrecognized Tax Benefits	Additional information regarding unrecognized tax benefits is as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Unrecognized tax benefits that if recognized would impact the effective tax rate $ 1,736 $ 1,957 $ 1,900 Accrued interest 332 424 366 Accrued penalties 25 26 20

EARNINGS_(LOSS) PER SHARE (Tabl

EARNINGS/(LOSS) PER SHARE (Tables)	12 Months Ended
EARNINGS/(LOSS) PER SHARE (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Year Ended December 31, Amounts in Millions, Except Per Share Data 2022 2021 2020 Net Earnings/(Loss) Attributable to BMS Used for Basic and Diluted EPS Calculation $ 6,327 $ 6,994 $ (9,015) Weighted-Average Common Shares Outstanding - Basic 2,130 2,221 2,258 Incremental Shares Attributable to Share-Based Compensation Plans 16 24 — Weighted-Average Common Shares Outstanding - Diluted 2,146 2,245 2,258 Earnings/(Loss) per Common Share Basic $ 2.97 $ 3.15 $ (3.99) Diluted 2.95 3.12 (3.99)

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	Financial assets and liabilities measured at fair value on a recurring basis are summarized below: December 31, 2022 December 31, 2021 Dollars in Millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents - money market and other securities $ — $ 7,770 $ — $ — $ 12,225 $ — Marketable debt securities: Certificates of deposit — 32 — — 2,264 — Commercial paper — 98 — — 320 — Corporate debt securities — — — — 403 — Derivative assets — 305 — — 206 — Equity investments 424 680 — 1,910 109 — Derivative liabilities — 213 — — 25 — Contingent consideration liability: Contingent value rights 5 — — 8 — — Other acquisition related contingent consideration — — 24 — — 35
Summary of Marketable Debt Securities	The following table summarizes marketable debt securities: December 31, 2022 December 31, 2021 Dollars in Millions Amortized Gross Unrealized Fair Value Amortized Gross Unrealized Fair Value Gains Losses Gains Losses Certificates of deposit $ 32 $ — $ — $ 32 $ 2,264 $ — $ — $ 2,264 Commercial paper 98 — — 98 320 — — 320 Corporate debt securities — — — — 401 2 — 403 Total marketable debt securities $ 130 $ — $ — $ 130 $ 2,985 $ 2 $ — $ 2,987
Summary of Equity Investments Carrying Amount	The following summarizes the carrying amount of equity investments at December 31, 2022 and 2021: Dollars in Millions 2022 2021 Equity investments with readily determinable fair values $ 1,104 $ 2,019 Equity investments without readily determinable fair values 537 283 Limited partnerships and other equity method investments 546 666 Total equity investments $ 2,187 $ 2,968
Schedule of Equity Investments	The following summarizes the activity related to equity investments. Equity investment (gains)/loss are included in Other (income)/expense, net. Dollars in Millions 2022 2021 2020 Equity investments with readily determined fair values Net loss/(gain) recognized $ 762 $ 403 $ (964) Net loss/(gain) recognized on investments sold (17) (357) 12 Net unrealized loss/(gain) recognized on investments still held 779 760 (976) Equity investments without readily determinable fair values Upward adjustments (80) (918) (388) Impairments and downward adjustments 11 1 204 Equity in net (income)/loss of limited partnerships and other equity method investments 108 (231) (72)
Summary of Fair Value of Outstanding Derivatives	The following summarizes the fair value of outstanding derivatives: December 31, 2022 December 31, 2021 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in Millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts $ — $ — $ 255 $ (18) $ 255 $ 10 $ — $ — Cross-currency interest rate swap contracts 72 1 1,741 (85) 600 26 — — Foreign exchange contracts 5,771 271 2,281 (80) 3,587 161 1,814 (20) Derivatives not designated as hedging instruments: Foreign exchange contracts 1,564 33 1,703 (19) 883 9 568 (5) Total return swap contracts (c) — — 322 (11) — — — — (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities. (c) Total return swap contracts were entered into to hedge changes in fair value of certain deferred compensation liabilities.
Derivative Instruments	The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments: Year Ended December 31, 2022 2021 2020 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (27) $ — $ (31) $ — $ (29) Cross-currency interest rate swap contracts — (52) — (11) — (10) Foreign exchange contracts (492) (96) 96 (21) (18) (23) The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive Income/(Loss): Year Ended December 31, Dollars in Millions 2022 2021 2020 Derivatives qualifying as cash flow hedges Foreign exchange contracts gain/(loss): Recognized in Other Comprehensive Income/(Loss) $ 592 $ 364 $ (267) Reclassified to Cost of products sold (492) 96 (54) Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive Income (7) — — Reclassified to Other (income)/expense, net (29) — — Forward starting interest rate swap contract loss: Reclassified to Other (income)/expense, net (3) — — Treasury lock hedge contracts gain: Recognized in Other Comprehensive Income/(Loss) — — 51 Derivatives qualifying as net investment hedges Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive Income/(Loss) 30 38 (11) Non-derivatives qualifying as net investment hedges Non U.S. dollar borrowings gain/(loss): Recognized in Other Comprehensive Income/(Loss) 91 83 (105)

Financing Arrangements (Tables)

Financing Arrangements (Tables)	12 Months Ended
Financing Arrangements (Tables)	Dec. 31, 2022
Debt Disclosure [Abstract]
Short-term debt obligations	Short-term debt obligations include: December 31, Dollars in Millions 2022 2021 Non-U.S. short-term borrowings $ 176 $ 105 Current portion of long-term debt 3,897 4,764 Other 191 79 Total $ 4,264 $ 4,948
Schedule of long-term debt	Long-term debt and the current portion of long-term debt includes: December 31, Dollars in Millions 2022 2021 Principal Value: Floating Rate Notes due 2022 $ — $ 500 2.000% Notes due 2022 — 750 2.600% Notes due 2022 — 1,500 3.250% Notes due 2022 — 1,000 3.550% Notes due 2022 — 1,000 0.537% Notes due 2023 1,500 1,500 2.750% Notes due 2023 750 750 3.250% Notes due 2023 500 500 3.250% Notes due 2023 890 890 7.150% Notes due 2023 239 239 2.900% Notes due 2024 2,478 2,478 3.625% Notes due 2024 395 395 0.750% Notes due 2025 1,000 1,000 1.000% Euro Notes due 2025 613 651 3.875% Notes due 2025 229 1,925 3.200% Notes due 2026 1,750 2,250 6.800% Notes due 2026 256 256 1.125% Notes due 2027 1,000 1,000 3.250% Notes due 2027 512 750 3.450% Notes due 2027 534 1,000 3.900% Notes due 2028 1,500 1,500 3.400% Notes due 2029 2,400 4,000 1.450% Notes due 2030 1,250 1,250 2.950% Notes due 2032 1,750 — 1.750% Euro Notes due 2035 613 651 5.875% Notes due 2036 279 279 6.125% Notes due 2038 219 219 4.125% Notes due 2039 2,000 2,000 2.350% Notes due 2040 750 750 5.700% Notes due 2040 153 193 3.550% Notes due 2042 1,250 — 3.250% Notes due 2042 500 500 5.250% Notes due 2043 226 280 4.500% Notes due 2044 342 500 4.625% Notes due 2044 748 748 5.000% Notes due 2045 758 1,768 4.350% Notes due 2047 1,250 1,250 4.550% Notes due 2048 1,272 1,486 4.250% Notes due 2049 3,750 3,750 2.550% Notes due 2050 1,500 1,500 3.700% Notes due 2052 2,000 — 3.900% Notes due 2062 1,000 — 6.875% Notes due 2097 63 86 0.13% - maturing through 2023 15 51 Total $ 38,234 $ 43,095 December 31, Dollars in Millions 2022 2021 Principal Value $ 38,234 $ 43,095 Adjustments to Principal Value: Fair value of interest rate swap contracts (18) 10 Unamortized basis adjustment from swap terminations 97 119 Unamortized bond discounts and issuance costs (284) (263) Unamortized purchase price adjustments of Celgene debt 924 1,408 Total $ 38,953 $ 44,369 Current portion of long-term debt $ 3,897 $ 4,764 Long-term debt 35,056 39,605 Total $ 38,953 $ 44,369

RECEIVABLES (Tables)

RECEIVABLES (Tables)	12 Months Ended
RECEIVABLES (Tables)	Dec. 31, 2022
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	December 31, Dollars in Millions 2022 2021 Trade receivables $ 8,848 $ 8,723 Less charge-backs and cash discounts (675) (723) Less allowance for expected credit loss (22) (21) Net trade receivables 8,151 7,979 Alliance, royalties, VAT and other 1,735 1,390 Receivables $ 9,886 $ 9,369
Receivables Allowance	Changes to the allowances for expected credit loss, charge-backs and cash discounts were as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Balance at beginning of year $ 744 $ 663 $ 412 Provision (a) 7,476 7,257 5,839 Utilization (7,521) (7,170) (5,601) Other (2) (6) 13 Balance at end of year $ 697 $ 744 $ 663 (a) Includes provision for expected credit loss of $7 million in 2022, $4 million in 2021 and $12 million in 2020.

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
INVENTORIES (Tables)	Dec. 31, 2022
Inventory, Net [Abstract]
Schedule of Inventories	December 31, Dollars in Millions 2022 2021 Finished goods $ 509 $ 543 Work in process 1,850 2,111 Raw and packaging materials 464 350 Total Inventories $ 2,823 $ 3,004 Inventories $ 2,339 $ 2,095 Other non-current assets 484 909

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	December 31, Dollars in Millions 2022 2021 Land $ 162 $ 169 Buildings 5,920 5,897 Machinery, equipment and fixtures 3,284 3,252 Construction in progress 1,053 764 Gross property, plant and equipment 10,419 10,082 Less accumulated depreciation (4,164) (4,033) Property, plant and equipment $ 6,255 $ 6,049 United States $ 4,833 $ 4,710 International 1,422 1,339 Total $ 6,255 $ 6,049

LEASES (Tables)

LEASES (Tables)	12 Months Ended
LEASES (Tables)	Dec. 31, 2022
Leases [Abstract]
Summary of Components of Lease Expense	The following table summarizes the components of lease expense: Year Ended December 31, Dollars in Millions 2022 2021 2020 Operating lease cost $ 224 $ 220 $ 194 Variable lease cost 55 44 50 Short-term lease cost 20 17 19 Sublease income (6) (7) (4) Total operating lease expense $ 293 $ 274 $ 259 Supplemental balance sheet information related to leases was as follows: December 31, 2022 2021 Weighted average remaining lease term 11 years 10 years Weighted average discount rate 4 % 3 %
Operating lease Right-Of-Use Assets and Liabilities	Operating lease right-of-use assets and liabilities were as follows: December 31, Dollars in Millions 2022 2021 Other non-current assets $ 1,220 $ 919 Other current liabilities $ 136 $ 169 Other non-current liabilities 1,261 874 Total liabilities $ 1,397 $ 1,043
Future Lease Payments For Non-Cancellable Operating Leases	Future lease payments for non-cancellable operating leases as of December 31, 2022 were as follows: Dollars in Millions 2023 $ 187 2024 191 2025 169 2026 149 2027 145 Thereafter 933 Total future lease payments 1,774 Less imputed interest (377) Total lease liability $ 1,397

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amounts in Goodwill were as follows: December 31, Dollars in Millions 2022 2021 Beginning balance $ 20,502 $ 20,547 Turning Point acquisition 695 — Currency translation and other adjustments (48) (45) Ending balance $ 21,149 $ 20,502
Schedule of Intangible Assets	Other intangible assets consisted of the following: December 31, Dollars in Millions Estimated 2022 2021 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Other intangible assets (a) : Licenses 5 – 15 years $ 400 $ (128) $ 272 $ 307 $ (102) $ 205 Acquired marketed product rights 3 – 15 years 60,477 (31,949) 28,528 60,454 (22,380) 38,074 Capitalized software 3 – 10 years 1,555 (1,056) 499 1,499 (1,001) 498 IPRD (a) 6,560 — 6,560 3,750 — 3,750 Total Other intangible assets $ 68,992 $ (33,133) $ 35,859 $ 66,010 $ (23,483) $ 42,527 (a) Includes other intangible assets recognized as part of the Turning Point acquisition in 2022. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for further information related to the Turning Point acquisition.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	12 Months Ended
SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	Dec. 31, 2022
Supplemental Financial Information [Abstract]
Schedule of Other Current Assets	December 31, Dollars in Millions 2022 2021 Income taxes $ 3,547 $ 2,786 Research and development 579 514 Contract assets 504 361 Equity investments — 255 Restricted cash (a) 148 140 Other 1,017 776 Other current assets $ 5,795 $ 4,832
Schedule of Other Assets, Noncurrent	December 31, Dollars in Millions 2022 2021 Equity investments $ 2,187 $ 2,713 Inventories 484 909 Operating leases 1,220 919 Pension and postretirement 285 317 Research and development 496 248 Restricted cash (a) 54 197 Other 214 232 Other non-current assets $ 4,940 $ 5,535 (a) Restricted cash consists of funds restricted for annual Company contributions to the defined contribution plan in the U.S. and escrow for litigation settlements. Cash is restricted when withdrawal or general use is contractually or legally restricted.
Schedule of Accrued Liabilities	December 31, Dollars in Millions 2022 2021 Rebates and discounts $ 6,702 $ 6,399 Income taxes 942 754 Employee compensation and benefits 1,425 1,375 Research and development 1,359 1,373 Dividends 1,196 1,186 Interest 321 378 Royalties 431 410 Operating leases 136 169 Other 2,074 1,927 Other current liabilities $ 14,586 $ 13,971
Other Noncurrent Liabilities	December 31, Dollars in Millions 2022 2021 Income taxes $ 3,992 $ 4,835 Pension and postretirement 402 654 Operating leases 1,261 874 Deferred income 283 326 Deferred compensation 349 427 Other 303 218 Other non-current liabilities $ 6,590 $ 7,334

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
EQUITY (Tables)	Dec. 31, 2022
Equity [Abstract]
Schedule of Stockholders Equity	Common Stock Capital in Excess Accumulated Other Comprehensive Loss Retained Treasury Stock Noncontrolling Dollars and Shares in Millions Shares Par Value Shares Cost Balance at January 1, 2020 2,923 $ 292 $ 43,709 $ (1,520) $ 34,474 672 $ (25,357) $ 100 Net loss — — — — (9,015) — — 20 Other Comprehensive Income/(Loss) — — — (319) — — — — Cash dividends declared (a) — — — — (4,178) — — — Share repurchase program — — 1,400 — — 43 (2,993) — Stock compensation — — (784) — — (36) 2,113 — Distributions — — — — — — — (60) Balance at December 31, 2020 2,923 292 44,325 (1,839) 21,281 679 (26,237) 60 Net earnings — — — — 6,994 — — 20 Other Comprehensive Income/(Loss) — — — 571 — — — — Cash dividends declared (a) — — — — (4,455) — — — Share repurchase program — — — — — 102 (6,240) — Stock compensation — — 36 — — (34) 1,218 — Distributions — — — — — — — (20) Balance at December 31, 2021 2,923 292 44,361 (1,268) 23,820 747 (31,259) 60 Net earnings — — — — 6,327 — — 18 Other Comprehensive Income/(Loss) — — — (13) — — — — Cash dividends declared (a) — — — — (4,644) — — — Share repurchase program — — — — — 109 (8,001) — Stock compensation — — 804 — — (31) 642 — Distributions — — — — — — — (21) Balance at December 31, 2022 2,923 $ 292 $ 45,165 $ (1,281) $ 25,503 825 $ (38,618) $ 57 (a) Cash dividends declared per common share were $2.19 in 2022, $2.01 in 2021 and $1.84 in 2020.
Schedule of Comprehensive Income (Loss)	The components of Other Comprehensive Income/(Loss) were as follows: Year Ended December 31, 2022 2021 2020 Dollars in Millions Pretax Tax After Tax Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges: Unrealized gains/(losses) $ 585 $ (79) $ 506 $ 364 $ (34) $ 330 $ (216) $ 7 $ (209) Reclassified to net earnings (a) (524) 72 (452) 95 (10) 85 (54) 7 (47) Derivatives qualifying as cash flow hedges 61 (7) 54 459 (44) 415 (270) 14 (256) Pension and postretirement benefits: Actuarial gains/(losses) 146 (25) 121 220 (40) 180 (134) 25 (109) Amortization (b) 21 (6) 15 41 (10) 31 33 (6) 27 Settlements (b) 11 (2) 9 (6) 1 (5) 10 (3) 7 Pension and postretirement benefits 178 (33) 145 255 (49) 206 (91) 16 (75) Marketable debt securities: Unrealized (losses)gains (2) — (2) (11) 2 (9) 7 (1) 6 Realized (gains)/losses (b) — — — — — — (1) — (1) Marketable debt securities (2) — (2) (11) 2 (9) 6 (1) 5 Foreign currency translation (183) (27) (210) (14) (27) (41) (19) 26 7 Other Comprehensive Income/(Loss) $ 54 $ (67) $ (13) $ 689 $ (118) $ 571 $ (374) $ 55 $ (319) (a) Included in Cost of products sold and Other (income)/expense, net. Refer to “—Note 9.Financial Instruments and Fair Value Measurements“ for further information. (b) Included in Other (income)/expense, net.
Schedule of Accumulated Other Comprehensive Income (Loss)	The accumulated balances related to each component of Other Comprehensive Income/(Loss), net of taxes, were as follows: December 31, Dollars in Millions 2022 2021 Derivatives qualifying as cash flow hedges $ 232 $ 178 Pension and postretirement benefits (623) (768) Marketable debt securities — 2 Foreign currency translation (a) (890) (680) Accumulated other comprehensive loss $ (1,281) $ (1,268) (a) Included in foreign currency are net investment hedges gains of $125 million and $30 million as of December 31, 2022 and December 31, 2021.

RETIREMENT BENEFITS (Tables)

RETIREMENT BENEFITS (Tables)	12 Months Ended
RETIREMENT BENEFITS (Tables)	Dec. 31, 2022
Retirement Benefits [Abstract]
Schedule Of Defined Benefit Obligations And Assets	Changes in defined benefit pension plan obligations, assets, funded status and amounts recognized in the consolidated balance sheets were as follows: Year Ended December 31, Dollars in Millions 2022 2021 Benefit obligations at beginning of year $ 2,935 $ 3,242 Service cost—benefits earned during the year 36 51 Interest cost 42 35 Settlements and curtailments (58) (101) Actuarial (gains)/losses (760) (153) Benefits paid (68) (46) Foreign currency and other (151) (93) Benefit obligations at end of year $ 1,976 $ 2,935 Fair value of plan assets at beginning of year $ 2,815 $ 2,807 Actual return on plan assets (570) 125 Employer contributions 76 87 Settlements (53) (83) Benefits paid (68) (46) Foreign currency and other (173) (75) Fair value of plan assets at end of year $ 2,027 $ 2,815 Funded status $ 51 $ (120) Assets/(Liabilities) recognized: Other non-current assets $ 285 $ 317 Other current liabilities (21) (24) Other non-current liabilities (213) (413) Funded status $ 51 $ (120) Recognized in Accumulated other comprehensive loss: Net actuarial losses $ 869 $ 1,015 Prior service credit (25) (29) Total $ 844 $ 986
Schedule Of Accumulated And Projected Benefit Obligation In Excess Of Fair Value Of Plan Assets	Additional information related to pension plans was as follows: December 31, Dollars in Millions 2022 2021 Pension plans with projected benefit obligations in excess of plan assets: Projected benefit obligation $ 728 $ 1,274 Fair value of plan assets 495 836 Pension plans with accumulated benefit obligations in excess of plan assets : Accumulated benefit obligation 728 1,245 Fair value of plan assets 495 832
Schedule Of Defined Benefit Actuarial Assumptions Benefit Obligations	Weighted-average assumptions used to determine defined benefit pension plan obligations were as follows: December 31, 2022 2021 Discount rate 4.0 % 1.6 % Rate of compensation increase 1.2 % 1.0 % Interest crediting rate 2.5 % 2.1 %
Schedule Of Defined Benefit Actuarial Assumptions Net Periodic Benefit Cost	Weighted-average actuarial assumptions used to determine defined benefit pension plan net periodic benefit cost were as follows: Year Ended December 31, 2022 2021 2020 Discount rate 1.6 % 1.2 % 1.6 % Expected long-term return on plan assets 3.6 % 3.6 % 4.1 % Rate of compensation increase 1.0 % 1.3 % 1.3 % Interest crediting rate 2.1 % 2.2 % 2.2 %
Fair Value of Pension Plan Assets by Asset Category	The fair value of pension plan assets by asset category at December 31, 2022 and 2021 was as follows: December 31, 2022 December 31, 2021 Dollars in Millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Plan Assets Equity securities $ 1 $ — $ — $ 1 $ 44 $ — $ — $ 44 Equity funds — 368 — 368 — 625 — 625 Fixed income funds — 697 — 697 — 815 — 815 Corporate debt securities — 376 — 376 — 485 — 485 U.S. Treasury and agency securities — 75 — 75 — 67 — 67 Insurance contracts — — 123 123 — — 130 130 Cash and cash equivalents 43 — — 43 47 — — 47 Other — 15 35 50 — 224 42 266 Plan assets subject to leveling $ 44 $ 1,531 $ 158 $ 1,733 $ 91 $ 2,216 $ 172 $ 2,479 Plan assets measured at NAV as a practical expedient 294 336 Net plan assets $ 2,027 $ 2,815

EMPLOYEE STOCK BENEFIT PLANS (T

EMPLOYEE STOCK BENEFIT PLANS (Tables)	12 Months Ended
EMPLOYEE STOCK BENEFIT PLANS (Tables)	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation Expense	Stock-based compensation expense was as follows: Year Ended December 31, Dollars in Millions 2022 2021 2020 Cost of products sold $ 41 $ 57 $ 37 Marketing, selling and administrative 195 241 332 Research and development 221 272 339 Other (income)/expense, net — 13 71 Total stock-based compensation expense $ 457 $ 583 $ 779 Income tax benefit (a) $ 91 $ 120 $ 158 (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $74 million in 2022, $38 million in 2021 and $35 million in 2020.
Summary of Stock Compensation Activity	The following table summarizes the stock compensation activity for the year ended December 31, 2022: Stock Options RSUs MSUs PSUs Shares in Millions Number of Options Weighted-Average Exercise Price of Shares Number of Nonvested RSUs Weighted-Average Grant-Date Fair Value Number of Nonvested MSUs Weighted-Average Grant-Date Fair Value Number of Nonvested PSUs Weighted-Average Grant-Date Fair Value Balance at January 1, 2022 47.0 $ 53.00 19.1 $ 54.92 1.8 $ 56.51 3.4 $ 55.38 Granted — — 8.7 64.12 1.0 60.74 1.4 66.76 Released/Exercised (24.3) 50.79 (8.2) 55.12 (0.8) 56.95 (1.3) 49.99 Adjustments for actual payout — — — — 0.1 54.26 0.4 49.99 Forfeited/Canceled (0.8) 58.70 (2.7) 57.43 (0.3) 57.63 (0.4) 60.26 Balance at December 31, 2022 21.9 55.25 16.9 59.17 1.8 58.25 3.5 60.88 Expected to vest 14.9 58.97 1.6 58.12 3.2 60.45 Dollars in Millions Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 734 $ 49 $ 89 Expected weighted-average period in years of compensation cost to be recognized 2.5 2.8 1.7 Amounts in Millions, except per share data 2022 2021 2020 Weighted-average grant date fair value (per share): RSUs $ 64.12 $ 56.58 $ 53.65 MSUs 60.74 58.04 53.92 PSUs 66.76 59.04 55.61 Fair value of awards that vested: RSUs - replacement awards $ 152 $ 519 $ 777 RSUs 300 246 122 MSUs 44 37 37 PSUs 68 61 59 Total intrinsic value of stock options exercised 526 512 556
Summary of Significant Outstanding and Exercisable Options	The following table summarizes significant outstanding and exercisable options at December 31, 2022: Range of Exercise Prices Number of Options (in millions) Weighted-Average Remaining Contractual Life (in years) Weighted-Average Exercise Price Per Share Aggregate Intrinsic Value (in millions) $10 - $40 2.2 1.0 $ 35.02 $ 80 $40 - $55 7.7 3.3 48.92 177 $55 - $65 8.0 2.7 59.45 100 $65 + 4.0 3.2 70.02 9 Outstanding 21.9 2.8 55.25 $ 366 Exercisable 21.9 2.8 55.25 $ 366

ACCOUNTING POLICIES AND RECEN_3

ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Advertising and product promotion costs	$ 1,300	$ 1,300	$ 990
Minimum \| Buildings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	20 years
Minimum \| Machinery equipment and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	3 years
Minimum \| Capitalized Software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	3 years
Maximum \| Buildings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	50 years
Maximum \| Machinery equipment and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	20 years
Maximum \| Capitalized Software
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of property, plant and equipment (in years)	10 years

ACCOUNTING POLICIES AND RECEN_4

ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS - Acquired IPRD By Type of Transaction (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Acquired IPRD	$ 815	$ 1,159	$ 12,533
Alliance revenues
Property, Plant and Equipment [Line Items]
Alliance (Note 3)	100	730	258
In-license arrangements and other (Note 4)	715	429	659
Asset acquisitions (Note 4)	$ 0	$ 0	$ 11,616

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total Revenues	$ 46,159	$ 46,385	$ 42,518
Net product sales
Disaggregation of Revenue [Line Items]
Total Revenues	44,671	45,055	41,321
Alliance revenues
Disaggregation of Revenue [Line Items]
Total Revenues	742	716	615
Other revenues
Disaggregation of Revenue [Line Items]
Total Revenues	$ 746	$ 614	$ 582

REVENUE - Additional Informatio

REVENUE - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Revenue recognized from performance obligation satisfied in prior period	$ 556	$ 561	$ 338
Total revenues \| Revenue \| Net product sales
Product Information [Line Items]
Concentration risk, percentage	95%

REVENUE - Schedule of Revenue b

REVENUE - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
McKesson Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	32%	32%	31%
AmerisourceBergen Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	25%	25%	25%
Cardinal Health, Inc.
Revenue, Major Customer [Line Items]
Concentration risk, percentage	21%	20%	19%

REVENUE - Reconciliation of Gro

REVENUE - Reconciliation of Gross Product Sales to Net Product Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Gross to Net Adjustments [Line Items]
Total Revenues	$ 46,159	$ 46,385	$ 42,518
Gross to net adjustments	(24,962)	(22,842)	(18,695)
Prior period gross to net adjustment impacted by new accounting pronouncement	229	319	106
Gross product sales
Gross to Net Adjustments [Line Items]
Total Revenues	69,633	67,897	60,016
Net product sales
Gross to Net Adjustments [Line Items]
Total Revenues	44,671	45,055	41,321
Charge-backs and cash discounts
Gross to Net Adjustments [Line Items]
Gross to net adjustments	(7,469)	(7,253)	(5,827)
Medicaid and Medicare rebates
Gross to Net Adjustments [Line Items]
Gross to net adjustments	(11,362)	(9,374)	(7,595)
Other rebates, returns, discounts and adjustments
Gross to Net Adjustments [Line Items]
Gross to net adjustments	$ (6,131)	$ (6,215)	$ (5,273)

REVENUE - Disaggregation of R_2

REVENUE - Disaggregation of Revenue by Product and Region (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from External Customer [Line Items]
Total Revenues	$ 46,159	$ 46,385	$ 42,518
United States
Revenue from External Customer [Line Items]
Total Revenues	31,828	29,214	26,577
International
Revenue from External Customer [Line Items]
Total Revenues	13,497	16,319	15,310
Other
Revenue from External Customer [Line Items]
Total Revenues	834	852	631
Eliquis
Revenue from External Customer [Line Items]
Total Revenues	11,789	10,762	9,168
Opdivo
Revenue from External Customer [Line Items]
Total Revenues	8,249	7,523	6,992
Pomalyst/Imnovid
Revenue from External Customer [Line Items]
Total Revenues	3,497	3,332	3,070
Orencia
Revenue from External Customer [Line Items]
Total Revenues	3,464	3,306	3,157
Sprycel
Revenue from External Customer [Line Items]
Total Revenues	2,165	2,117	2,140
Yervoy
Revenue from External Customer [Line Items]
Total Revenues	2,131	2,026	1,682
Empliciti
Revenue from External Customer [Line Items]
Total Revenues	296	334	381
Mature and other brands
Revenue from External Customer [Line Items]
Total Revenues	1,749	1,900	2,217
Reblozyl
Revenue from External Customer [Line Items]
Total Revenues	717	551	274
Abecma
Revenue from External Customer [Line Items]
Total Revenues	388	164	0
Opdualag
Revenue from External Customer [Line Items]
Total Revenues	252	0	0
Zeposia
Revenue from External Customer [Line Items]
Total Revenues	250	134	12
Breyanzi
Revenue from External Customer [Line Items]
Total Revenues	182	87	0
Onureg
Revenue from External Customer [Line Items]
Total Revenues	124	73	17
Inrebic
Revenue from External Customer [Line Items]
Total Revenues	85	74	55
Camzyos
Revenue from External Customer [Line Items]
Total Revenues	24	0	0
Sotyktu
Revenue from External Customer [Line Items]
Total Revenues	8	0	0
Revlimid
Revenue from External Customer [Line Items]
Total Revenues	9,978	12,821	12,106
Abraxane
Revenue from External Customer [Line Items]
Total Revenues	$ 811	$ 1,181	$ 1,247

ALLIANCES - Financial Informati

ALLIANCES - Financial Information Pertaining to Alliances (Total) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 46,159	$ 46,385	$ 42,518
Cost of products sold	[1]	10,137	9,940	11,773
Marketing, selling and administrative		(7,814)	(7,690)	(7,661)
Other (income)/expense, net		576	(720)	(2,314)
Receivables – from alliance partners		9,886	9,369
Accounts payable – to alliance partners		3,040	2,949
Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		44,671	45,055	41,321
Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		12,743	11,556	9,979
Cost of products sold		5,768	5,227	4,485
Marketing, selling and administrative		(223)	(183)	(128)
Research and development		49	42	91
Acquired IPRD		100	730	258
Other (income)/expense, net		(53)	(62)	(74)
Receivables – from alliance partners		317	320
Accounts payable – to alliance partners		1,249	1,229
Deferred income from alliances		289	330
Alliance revenues \| Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 12,001	$ 10,840	$ 9,364

[1]Excludes amortization of acquired intangible assets.

ALLIANCES - Financial Informa_2

ALLIANCES - Financial Information Pertaining to Alliances (Pfizer) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 46,159	$ 46,385	$ 42,518
Cost of products sold – Profit sharing	[1]	10,137	9,940	11,773
Other (income)/expense, net		576	(720)	(2,314)
Receivables		9,886	9,369
Accounts payable		3,040	2,949
Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		44,671	45,055	41,321
Eliquis
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		11,789	10,762	9,168
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		11,789	10,762	9,168
Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		12,743	11,556	9,979
Cost of products sold – Profit sharing		5,768	5,227	4,485
Other (income)/expense, net		(53)	(62)	(74)
Receivables		317	320
Accounts payable		1,249	1,229
Deferred income		289	330
Alliance revenues \| Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		12,001	10,840	9,364
Alliance revenues \| Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		301	331	226
Cost of products sold – Profit sharing		5,604	5,064	4,331
Other (income)/expense, net		(42)	(36)	(55)
Receivables		191	235
Accounts payable		1,208	1,195
Deferred income		222	264
Alliance revenues \| Pfizer \| Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 11,488	$ 10,431	$ 8,942
Alliance revenues \| Pfizer \| Eliquis \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursement for development costs from alliance partner		60%
Alliance revenues \| Pfizer \| Eliquis \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursement for development costs from alliance partner		50%

[1]Excludes amortization of acquired intangible assets.

ALLIANCES - Financial Informa_3

ALLIANCES - Financial Information Pertaining to Alliances (Ono) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 46,159	$ 46,385	$ 42,518
Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	657	636	576
Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 12,743	11,556	9,979
Alliance revenues \| Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Co-promotion fee percentage	60%
Total Revenues	$ 441	385	382
Alliance revenues \| Ono \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit sharing involving only one compound	80%
Alliance revenues \| Ono \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Profit sharing involving only one compound	20%
Alliance revenues \| North America \| Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate due to regulatory approvals	4%
Alliance revenues \| Rest of World Except Japan, South Korea and Taiwan \| Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty rate due to regulatory approvals	15%
Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 44,671	45,055	41,321
Net product sales \| Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	12,001	10,840	9,364
Net product sales \| Alliance revenues \| Ono
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 216	$ 251	$ 194

ALLIANCES - Financial Informa_4

ALLIANCES - Financial Information Pertaining to Alliances (Nektar) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development	$ 9,509	$ 10,195	$ 10,048

ALLIANCES - Financial Informa_5

ALLIANCES - Financial Information Pertaining to Alliances (2seventy bio) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 46,159	$ 46,385	$ 42,518
Cost of products sold	[1]	10,137	9,940	11,773
Upfront payment related to the collaboration agreement				200
Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		44,671	45,055	41,321
Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		12,743	11,556	9,979
Cost of products sold		5,768	5,227	4,485
Alliance revenues \| Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		12,001	10,840	$ 9,364
2seventy bio \| Alliance revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of products sold		49	42
2seventy bio \| Alliance revenues \| Net product sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		$ 297	$ 158

[1]Excludes amortization of acquired intangible assets.

ALLIANCES - Financial Informa_6

ALLIANCES - Financial Information Pertaining to Alliances (BridgeBio) (Details) - BridgeBio $ in Millions	1 Months Ended
	May 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments for licensing and alliance arrangements	$ 90
Consideration for contingent development and regulatory approval	$ 815

ALLIANCES - Financial Informa_7

ALLIANCES - Financial Information Pertaining to Alliances (Eisai) (Details) - Eisai - Alliance revenues $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments for licensing and alliance arrangements	$ 650
Consideration for contingent development and regulatory approval	$ 2,500

ACQUISITIONS, DIVESTITURES, L_3

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Consideration Transferred (Details) - Turning Point $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Cash consideration for outstanding shares	$ 4,113
Total consideration to be allocated	3,960
Common Stock
Business Acquisition [Line Items]
Cash consideration for outstanding shares	3,811
Equity
Business Acquisition [Line Items]
Cash consideration for outstanding shares	302
Unvested Equity Awards
Business Acquisition [Line Items]
Cash consideration for outstanding shares	153
Equity securities \| Unvested Equity Awards
Business Acquisition [Line Items]
Cash consideration for outstanding shares	73
Research and development \| Unvested Equity Awards
Business Acquisition [Line Items]
Cash consideration for outstanding shares	$ 80

ACQUISITIONS, DIVESTITURES, L_4

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 21,149	$ 20,502	$ 20,547
In Process Research and Development
Business Acquisition [Line Items]
Identifiable assets acquired, indefinite-lived intangible assets	2,800
Turning Point
Business Acquisition [Line Items]
Cash and cash equivalents	795
Other current assets	14
Intangible assets	2,971
Deferred income tax assets	229
Other non-current assets	10
Deferred income tax liabilities	(643)
Other current liabilities	(111)
Identifiable net assets acquired	3,265
Goodwill	695
Total consideration allocated	$ 3,960

ACQUISITIONS, DIVESTITURES, L_5

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended			36 Months Ended	84 Months Ended
	Feb. 14, 2023	Feb. 28, 2014	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2026	Dec. 31, 2023	Jan. 31, 2023	Mar. 31, 2022	Nov. 30, 2020
Business Acquisition [Line Items]
Acquired IPRD			$ 815	$ 1,159	$ 12,533
Marketing, selling and administrative			7,814	7,690	7,661
Research and development			9,509	10,195	10,048
Royalty Income			832	666	644
Proceeds from divestiture of businesses, net of cash divested			1,157	748	715
Divestiture gain			211	9	55
Turning Point
Business Acquisition [Line Items]
Payments to acquire businesses, gross			4,113
Acquisition, net of cash acquired			3,300
Keytruda Royalties \| Forecast
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner							6.50%
Keytruda Royalties \| Subsequent Event \| Forecast
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner						2.50%
Tecentriq Royalties
Business Acquisition [Line Items]
Proceeds from out-licensed arrangements				324
Patent settlement income				239
Dragonfly
Business Acquisition [Line Items]
Upfront payments for licensing and alliance arrangements					475
Payment for additional targets made to collaborative partner					75
Collaborative arrangement contingent payments maximum exposure					2,700
Dragonfly \| Subsequent Event
Business Acquisition [Line Items]
Termination of license								90 days
Nimbus Therapuetics TYK2 Inhibitor
Business Acquisition [Line Items]
Income from settlement			40
Nimbus Therapuetics TYK2 Inhibitor \| Subsequent Event
Business Acquisition [Line Items]
Collaborative arrangement contingent payments maximum exposure	$ 2,000
Mavacamten
Business Acquisition [Line Items]
Payment to extinguish future royalty obligation			(295)
Diabetes business
Business Acquisition [Line Items]
Royalty Income			810	622	567
Proceeds from divestiture of businesses, net of cash divested			767	612	558
Divestiture gain			0	0	0
Diabetes business \| Minimum
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner		10%
Diabetes business \| Maximum
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner		25%
Diabetes business \| Supply Agreements
Business Acquisition [Line Items]
Royalty Income			924	725	673
Diabetes business \| Amelyn, Onglyza, and Farxiga
Business Acquisition [Line Items]
Business sale royalty expense			114	103	106
Mature Brands and Other
Business Acquisition [Line Items]
Divestiture gain			211
Mature Brands and Other \| Discontinued Operations, Held-for-sale
Business Acquisition [Line Items]
Assets held for sale			172
Liabilities held for sale			20
Mature Brands and Other \| Cost of products sold
Business Acquisition [Line Items]
Asset impairment charges			63
Mature brand, Teofarma
Business Acquisition [Line Items]
Proceeds from divestiture of businesses, net of cash divested				50
Divestiture gain				49
LOTTE Corporation \| Mature Brands and Other
Business Acquisition [Line Items]
Sales price			159
Immatics
Business Acquisition [Line Items]
Contingent and regulatory milestone payments			770
License and other arrangements upfront payments									$ 150
Dragonfly
Business Acquisition [Line Items]
License and other arrangements upfront payments			(175)
Agenus
Business Acquisition [Line Items]
Contingent and regulatory milestone payments				1,400
License and other arrangements upfront payments				$ 200
Cheplapharm \| Mature Brands and Other
Business Acquisition [Line Items]
Proceeds from divestiture of businesses, net of cash divested			$ 221
MyoKardia Acquisition
Business Acquisition [Line Items]
Consideration paid										$ 13,100
Acquired IPRD					11,400
Assets assumed					1,400
Liabilities assumed					226
Unvested stock awards expensed to marketing, selling and administrative expense and research and development					482
Marketing, selling and administrative					241
Research and development					241
Forbius
Business Acquisition [Line Items]
Consideration paid					185
Contingent and regulatory milestone payments					815
Upfront payment, acquired IPRD					178
Deferred income taxes acquired through an asset acquisition					$ 7
Bristol-Myers Squibb \| Keytruda Royalties \| Subsequent Event \| Forecast
Business Acquisition [Line Items]
Payment and royalty allocation						75%
Ono \| Keytruda Royalties \| Subsequent Event \| Forecast
Business Acquisition [Line Items]
Payment and royalty allocation						25%
Nimbus Therapeutics \| Subsequent Event
Business Acquisition [Line Items]
License and other arrangements upfront payments	$ 4,000
Nimbus Therapeutics \| Nimbus Therapuetics TYK2 Inhibitor
Business Acquisition [Line Items]
Change in control proceeds			10%
Nimbus Therapeutics \| Nimbus Therapuetics TYK2 Inhibitor \| Subsequent Event
Business Acquisition [Line Items]
Percentage of ownership acquired	100%

ACQUISITIONS, DIVESTITURES, L_6

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Divestitures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	$ 1,157	$ 748	$ 715
Divestiture gains (Note 4)	(211)	(9)	(55)
Royalty Income	(832)	(666)	(644)
Diabetes business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	767	612	558
Divestiture gains (Note 4)	0	0	0
Royalty Income	(810)	(622)	(567)
Mature products and other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture proceeds	390	136	157
Divestiture gains (Note 4)	(211)	(9)	(55)
Royalty Income	(22)	(44)	(77)
Not all inclusive
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture gains (Note 4)	$ (211)	$ (9)	$ (55)

ACQUISITIONS, DIVESTITURES, L_7

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Licensing and Other Arrangements (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront licensing fees	$ 0	$ (34)	$ (30)
Contingent regulatory milestone income	(50)	(18)	(72)
Amortization of deferred income	(53)	(39)	(58)
Total	(1,283)	(1,067)	(883)
Keytruda Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty income, nonoperating	(1,001)	(841)	(681)
Tecentriq Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty income, nonoperating	(93)	(90)	(19)
Biohaven
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Biohaven sublicense income	(55)	0	0
Other Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty income, nonoperating	$ (31)	$ (45)	$ (23)

OTHER (INCOME)_EXPENSE, NET - S

OTHER (INCOME)/EXPENSE, NET - Schedule Of Other Income Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Nonoperating Income (Expense) [Abstract]
Interest expense	$ 1,232	$ 1,334	$ 1,420
Royalty and licensing income (Note 4)	1,283	1,067	883
Royalty income - divestitures (Note 4)	(832)	(666)	(644)
Equity investment losses/(income), net (Note 9)	801	(745)	(1,228)
Integration expenses (Note 6)	440	564	717
Loss on debt redemption (Note 9)	266	281	0
Divestiture gains (Note 4)	(211)	(9)	(55)
Litigation and other settlements	178	82	(194)
Investment income	(171)	(39)	(121)
Provision for restructuring	75	169	530
Contingent consideration	(9)	(542)	(1,757)
Other	90	(82)	(99)
Other (income)/expense, net	$ 576	$ (720)	$ (2,314)

RESTRUCTURING - Additional Info

RESTRUCTURING - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) employee	Dec. 31, 2021 employee	Dec. 31, 2020 USD ($) employee	Dec. 31, 2019 USD ($)
Celgene Acquisition Plan
Restructuring Cost and Reserve [Line Items]
Expected cost savings and avoidance				$ 3,000
Expected restructuring and related charges				3,500
Restructuring and related charges incurred to date				3,100
Cash outlays				$ 3,100
Workforce reduction of manufacturing, selling, administrative, and research and development personnel \| employee	170	405	1,565
Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring and related charges	$ 250
Restructuring and related charges incurred to date	$ 165
Company Transformation
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges incurred to date			$ 1,500

RESTRUCTURING - Schedule of Res

RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Total charges	$ 520	$ 751	$ 1,410
Employee termination costs	69	159	457
Other termination costs	6	10	73
Provision for restructuring	75	169	530
Integration expenses	440	564	717
Accelerated depreciation	5	2	53
Asset impairments	0	24	103
Other shutdown costs, net	0	(8)	7
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Total charges	0	24	32
Marketing, selling and administrative
Restructuring Cost and Reserve [Line Items]
Total charges	5	3	10
Research and development
Restructuring Cost and Reserve [Line Items]
Total charges	0	0	113
Other (income)/expense, net
Restructuring Cost and Reserve [Line Items]
Total charges	515	724	1,255
Celgene Acquisition Plan
Restructuring Cost and Reserve [Line Items]
Total charges	472	673	1,244
Other Restructuring
Restructuring Cost and Reserve [Line Items]
Total charges	48	78	39
Company Transformation
Restructuring Cost and Reserve [Line Items]
Total charges	$ 0	$ 0	$ 127

RESTRUCTURING - Schedule of R_2

RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve [Roll Forward]
Liability, beginning of period	$ 101	$ 148
Provision for restructuring	75	156
Foreign currency translation and other	(7)	(4)
Payments	(122)	(199)
Liability, end of period	47	101	$ 148
Liability, accrual adjustment	7	19
Accelerated stock-based compensation	$ 75	169	$ 530
Accelerated Stock Based Compensation \| Celgene Acquisition Plan
Restructuring Reserve [Roll Forward]
Accelerated stock-based compensation		$ 13

INCOME TAXES - Schedule of Prov

INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
U.S.	$ 3,017	$ 1,879	$ 1,245
Non-U.S.	1,089	598	(104)
Total current	4,106	2,477	1,141
Deferred:
U.S.	(2,889)	(1,255)	229
Non-U.S.	151	(138)	754
Total deferred	(2,738)	(1,393)	983
Total Provision for Income Taxes	$ 1,368	$ 1,084	$ 2,124

INCOME TAXES - Schedule of Effe

INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings/(Loss) before income taxes:
U.S.	$ (140)	$ 1,593	$ (10,106)
Non-U.S.	7,853	6,505	3,235
Earnings/(Loss) Before Income Taxes	7,713	8,098	(6,871)
Effective Income Tax Rate Reconciliation, Amount
U.S. statutory rate	1,620	1,701	(1,443)
GILTI, net of foreign derived intangible income deduction	634	645	685
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland	(416)	(143)	(86)
Internal transfers of intangible and other assets	(93)	(983)	853
U.S. Federal, state and foreign contingent tax matters	(297)	154	136
U.S. Federal research-based credits	(142)	(165)	(165)
Charitable contributions of inventory	(94)	(42)	(36)
Contingent value rights	0	(108)	(363)
Non-deductible R&D charges	0	0	2,461
Puerto Rico excise tax credit	(144)	(152)	(147)
State and local taxes (net of valuation allowance)	103	33	103
Foreign and other	197	144	126
Total Provision for Income Taxes	$ 1,368	$ 1,084	$ 2,124
Effective Income Tax Rate Reconciliation, Percent
U.S. statutory rate	21%	21%	21%
GILTI, net of foreign derived intangible income deduction	8.20%	8%	(10.00%)
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland	(5.40%)	(1.80%)	1.30%
Internal transfers of intangible and other assets	(1.20%)	(12.10%)	(12.40%)
U.S. Federal, state and foreign contingent tax matters	(3.90%)	1.90%	(2.00%)
U.S. Federal research-based credits	(1.80%)	(2.00%)	2.40%
Charitable contributions of inventory	(1.20%)	(0.50%)	0.50%
Contingent value rights	0%	(1.30%)	5.30%
Non-deductible R&D charges	0%	0%	(35.80%)
Puerto Rico excise tax credit	(1.90%)	(1.90%)	2.10%
State and local taxes (net of valuation allowance)	1.30%	0.40%	(1.50%)
Foreign and other	2.60%	1.70%	(1.80%)
Total	17.70%	13.40%	(30.90%)

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ in Millions		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Valuation Allowance [Line Items]
GILTI, net of foreign derived intangible income deduction		$ 634	$ 645	$ 685
Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations, including interest accrued		522
Acquired IPRD		$ 815	$ 1,159	$ 12,533
Puerto Rico tax rate		(5.40%)	(1.80%)	1.30%
Valuation allowance	$ 873	$ 873	$ 1,056
Income tax payments		5,400	$ 3,500	$ 3,400
Transition tax due 2022	567	567
Transition tax due 2023	799	799
Transition tax due 2024	1,000	1,000
Transition tax due 2025	244	244
MyoKardia Acquisition
Valuation Allowance [Line Items]
Acquired IPRD				$ 11,400
Foreign Net Operating Loss And Tax Credit Carryforwards
Valuation Allowance [Line Items]
Valuation allowance	295	295
State Net Operating Loss And Tax Credit Carryforwards
Valuation Allowance [Line Items]
Valuation allowance	261	261
SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward
Valuation Allowance [Line Items]
Valuation allowance	317	317
Domestic Tax Authority
Valuation Allowance [Line Items]
Operating loss carryforwards	$ 709	709
PUERTO RICO
Valuation Allowance [Line Items]
Puerto Rico tax rate	10.50%
Minimum
Valuation Allowance [Line Items]
Reasonably possible decrease in unrecognized tax benefits	$ 120	120
Maximum
Valuation Allowance [Line Items]
Reasonably possible decrease in unrecognized tax benefits	$ 170	$ 170

INCOME TAXES - Schedule of Defe

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Foreign net operating loss and other carryforwards	$ 566	$ 945
State net operating loss and credit carryforwards	329	304
U.S. Federal net operating loss and credit carryforwards	236	226
Milestone payments and license fees	1,030	887
Capitalized research expenditures	1,573	0
Other	1,284	1,390
Total deferred tax assets	5,018	3,752
Valuation allowance	(873)	(1,056)
Deferred tax assets net of valuation allowance	4,145	2,696
Deferred tax liabilities
Acquired intangible assets	(4,362)	(4,867)
Goodwill and other	(605)	(891)
Total deferred tax liabilities	(4,967)	(5,758)
Deferred tax liabilities, net	(822)	(3,062)
Deferred income taxes assets – non-current	1,344	1,439
Deferred income taxes liabilities – non-current	$ (2,166)	$ (4,501)

INCOME TAXES - Summary of Valua

INCOME TAXES - Summary of Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$ 744	$ 663	$ 412
Provision	7,476	7,257	5,839
Utilization	(7,521)	(7,170)	(5,601)
Foreign currency translation	(2)	(6)	13
Balance at end of year	697	744	663
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	1,056	2,809	2,844
Provision	213	201	62
Utilization	(68)	(1,087)	(488)
Foreign currency translation	(59)	(157)	212
Acquisitions/(dispositions)/(liquidations), net	(271)	(720)	179
Non U.S. rate change	2	10	0
Balance at end of year	$ 873	$ 1,056	$ 2,809

INCOME TAXES - Summary of Incom

INCOME TAXES - Summary of Income Tax Contingencies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 2,042	$ 2,003	$ 1,905
Gross additions to tax positions related to current year	53	66	76
Gross additions to tax positions related to prior years	137	75	325
Gross additions to tax positions assumed in acquisitions	15	0	51
Gross reductions to tax positions related to prior years	(381)	(22)	(352)
Settlements	(8)	(70)	(7)
Reductions to tax positions related to lapse of statute	(83)	(5)	(5)
Cumulative translation adjustment, increase			10
Cumulative translation adjustment, decrease	(9)	(5)
Balance at end of year	$ 1,766	$ 2,042	$ 2,003

INCOME TAXES - Summary of Inc_2

INCOME TAXES - Summary of Income Tax Examinations (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefits that if recognized would impact the effective tax rate	$ 1,736	$ 1,957	$ 1,900
Accrued interest	332	424	366
Accrued penalties	$ 25	$ 26	$ 20

EARNINGS_(LOSS) PER SHARE (Deta

EARNINGS/(LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Earnings/(Loss) Attributable to BMS Used for Basic and Diluted EPS Calculation	$ 6,327	$ 6,994	$ (9,015)
Weighted-average common shares outstanding - basic (in shares)	2,130,000,000	2,221,000,000	2,258,000,000
Incremental shares attributable to share-based compensation plans (in shares)	16,000,000	24,000,000	0
Weighted-average common shares outstanding - diluted (in shares)	2,146,000,000	2,245,000,000	2,258,000,000
Earnings/(Loss) per Common Share
Basic (in usd per share)	$ 2.97	$ 3.15	$ (3.99)
Diluted (in usd per share)	$ 2.95	$ 3.12	$ (3.99)
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	106,000,000

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	$ 130	$ 2,987
Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag	Derivative assets
Equity investments	$ 1,104	2,019
Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag	Derivative liabilities
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	$ 32	2,264
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	98	320
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	403
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents - money market and other securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liability:	0	0
Level 1 \| Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	424	1,910
Level 1 \| Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability:	5	8
Level 1 \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	0
Level 1 \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	0
Level 1 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents - money market and other securities	7,770	12,225
Derivative assets	305	206
Derivative liabilities	213	25
Contingent consideration liability:	0	0
Level 2 \| Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	680	109
Level 2 \| Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability:	0	0
Level 2 \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	32	2,264
Level 2 \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	98	320
Level 2 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	403
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents - money market and other securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liability:	24	35
Level 3 \| Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	0	0
Level 3 \| Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability:	0	0
Level 3 \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	0
Level 3 \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	0	0
Level 3 \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities, fair value	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Available-for-sale Securities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Amortized Cost	$ 130	$ 2,985
Gross unrealized gains	0	2
Gross unrealized losses	0	0
Marketable debt securities, fair value	130	2,987
Certificates of deposit
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Amortized Cost	32	2,264
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Marketable debt securities, fair value	32	2,264
Commercial paper
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Amortized Cost	98	320
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Marketable debt securities, fair value	98	320
Corporate debt securities
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Amortized Cost	0	401
Gross unrealized gains	0	2
Gross unrealized losses	0	0
Marketable debt securities, fair value	$ 0	$ 403

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Summary of Equity Investments Carrying Amount (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Equity investments with readily determinable fair values	$ 1,104	$ 2,019
Equity investments without readily determinable fair values	537	283
Limited partnerships and other equity method investments	546	666
Total equity investments	$ 2,187	$ 2,968

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity investments with readily determined fair value
Net loss/(gain) recognized	$ 762	$ 403	$ (964)
Net loss/(gain) recognized on investments sold	(17)	(357)	12
Net unrealized loss/(gain) recognized on investments still held	779	760	(976)
Equity investments without readily determinable fair values
Upward adjustments	(80)	(918)	(388)
Impairments and downward adjustments	11	1	204
Equity in net (income)/loss of limited partnerships and other equity method investments	$ 108	$ (231)	$ (72)

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Additional Information (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cumulative upwards adjustments	$ 181
Cumulative impairments and downward adjustments	61
Recognized in Other Comprehensive Income/(Loss)	585	$ 364	$ (216)
Principal Value	$ 38,234	43,095
Variable rate debt, lower range of basis point spread	4.60%			4.60%
London Interbank Offered Rate (LIBOR)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
LIBOR	4.39%			4.39%
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Value	$ 400			€ 375
Foreign exchange contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized in Other Comprehensive Income/(Loss)	592	364	(267)
Cross-currency interest rate swap contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized in Other Comprehensive Income/(Loss)	(7)	0	0
Cross-currency interest rate swap contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	1,200
Treasury Lock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized in Other Comprehensive Income/(Loss)	0	$ 0	51
Treasury Lock \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			$ 2,100
Euro Member Countries, Euro \| Foreign exchange contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	5,300
Euro Member Countries, Euro \| Cross-currency interest rate swap contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	584			€ 575
Japan, Yen \| Foreign exchange contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	1,300
Japan, Yen \| Cross-currency interest rate swap contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	$ 509

FINANCIAL INSTRUMENTS AND FAI_8

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivatives and Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Interest rate swap contracts
Derivatives and Hedging [Line Items]
Derivative liabilities	$ (18)	$ 10
Designated as Hedging Instrument \| Interest rate swap contracts
Derivatives and Hedging [Line Items]
Derivative assets, fair value	0	10
Derivative liabilities	(18)	0
Designated as Hedging Instrument \| Interest rate swap contracts \| Assets
Derivatives and Hedging [Line Items]
Derivative, notional amount	0	255
Designated as Hedging Instrument \| Interest rate swap contracts \| Liability
Derivatives and Hedging [Line Items]
Derivative, notional amount	255	0
Designated as Hedging Instrument \| Cross-currency interest rate swap contracts
Derivatives and Hedging [Line Items]
Derivative, notional amount	1,200
Derivative assets, fair value	1	26
Derivative liabilities	(85)	0
Designated as Hedging Instrument \| Cross-currency interest rate swap contracts \| Assets
Derivatives and Hedging [Line Items]
Derivative, notional amount	72	600
Designated as Hedging Instrument \| Cross-currency interest rate swap contracts \| Liability
Derivatives and Hedging [Line Items]
Derivative, notional amount	1,741	0
Designated as Hedging Instrument \| Foreign exchange contracts
Derivatives and Hedging [Line Items]
Derivative assets, fair value	271	161
Derivative liabilities	(80)	(20)
Designated as Hedging Instrument \| Foreign exchange contracts \| Assets
Derivatives and Hedging [Line Items]
Derivative, notional amount	5,771	3,587
Designated as Hedging Instrument \| Foreign exchange contracts \| Liability
Derivatives and Hedging [Line Items]
Derivative, notional amount	2,281	1,814
Not Designated as Hedging Instrument \| Foreign exchange contracts
Derivatives and Hedging [Line Items]
Derivative assets, fair value	33	9
Derivative liabilities	(19)	(5)
Not Designated as Hedging Instrument \| Foreign exchange contracts \| Assets
Derivatives and Hedging [Line Items]
Derivative, notional amount	1,564	883
Not Designated as Hedging Instrument \| Foreign exchange contracts \| Liability
Derivatives and Hedging [Line Items]
Derivative, notional amount	1,703	568
Not Designated as Hedging Instrument \| Total return swap contracts
Derivatives and Hedging [Line Items]
Derivative assets, fair value	0	0
Derivative liabilities	(11)	0
Not Designated as Hedging Instrument \| Total return swap contracts \| Assets
Derivatives and Hedging [Line Items]
Derivative, notional amount	0	0
Not Designated as Hedging Instrument \| Total return swap contracts \| Liability
Derivatives and Hedging [Line Items]
Derivative, notional amount	$ 322	$ 0

FINANCIAL INSTRUMENTS AND FAI_9

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Derivative Instruments, Gain (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest rate swap contracts \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	$ 0	$ 0	$ 0
Interest rate swap contracts \| Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	(27)	(31)	(29)
Cross-currency interest rate swap contracts \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	0	0	0
Cross-currency interest rate swap contracts \| Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	(52)	(11)	(10)
Foreign exchange contracts \| Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	(492)	96	(18)
Foreign exchange contracts \| Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	$ (96)	$ (21)	$ (23)

FINANCIAL INSTRUMENTS AND FA_10

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Gain/(Loss) on Hedging Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign exchange contracts gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	$ 585	$ 364	$ (216)
Reclassified to Cost of products sold	(524)	95	(54)
Treasury lock hedge contracts gain:
Recognized in Other Comprehensive Income/(Loss)	585	364	(216)
Non U.S. dollar borrowings gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	(183)	(14)	(19)
Designated as Hedging Instrument
Non U.S. dollar borrowings gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	91	83	(105)
Foreign exchange contracts
Foreign exchange contracts gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	592	364	(267)
Treasury lock hedge contracts gain:
Recognized in Other Comprehensive Income/(Loss)	592	364	(267)
Foreign exchange contracts \| Cost of products sold
Foreign exchange contracts gain/(loss):
Reclassified to Cost of products sold	(492)	96	(54)
Treasury Lock
Foreign exchange contracts gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	0	0	51
Treasury lock hedge contracts gain:
Recognized in Other Comprehensive Income/(Loss)	0	0	51
Cross-currency interest rate swap contracts
Foreign exchange contracts gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	(7)	0	0
Reclassified to Cost of products sold	(29)	0	0
Treasury lock hedge contracts gain:
Recognized in Other Comprehensive Income/(Loss)	(7)	0	0
Cross-currency interest rate swap contracts gain/(loss):
Recognized in Other Comprehensive Income/(Loss)	30	38	(11)
Forward starting interest rate swap contracts
Foreign exchange contracts gain/(loss):
Reclassified to Cost of products sold	$ (3)	$ 0	$ 0

Financing Arrangements - Short-

Financing Arrangements - Short-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Non-U.S. short-term borrowings	$ 176	$ 105
Current portion of long-term debt	3,897	4,764
Other	191	79
Total	$ 4,264	$ 4,948

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal Value	$ 38,234	$ 43,095
Unamortized basis adjustment from swap terminations	97	119
Unamortized bond discounts and issuance costs	(284)	(263)
Unamortized purchase price adjustments of Celgene debt	924	1,408
Total	38,953	44,369
Current portion of long-term debt	3,897	4,764
Long-term debt	35,056	39,605
Floating Rate Notes due 2022
Debt Instrument [Line Items]
Principal Value	0	500
2.000% Notes due 2022
Debt Instrument [Line Items]
Principal Value	0	750
2.600% Notes due 2022
Debt Instrument [Line Items]
Principal Value	0	1,500
3.250% Notes due 2022
Debt Instrument [Line Items]
Principal Value	0	1,000
3.550% Notes due 2022
Debt Instrument [Line Items]
Principal Value	0	1,000
0.537% Notes due 2023
Debt Instrument [Line Items]
Principal Value	1,500	1,500
2.750% Notes due 2023
Debt Instrument [Line Items]
Principal Value	750	750
3.250% Notes due 2023
Debt Instrument [Line Items]
Principal Value	500	500
3.250% Notes due 2023
Debt Instrument [Line Items]
Principal Value	890	890
7.150% Notes due 2023
Debt Instrument [Line Items]
Principal Value	239	239
2.900% Notes due 2024
Debt Instrument [Line Items]
Principal Value	2,478	2,478
3.625% Notes due 2024
Debt Instrument [Line Items]
Principal Value	395	395
0.750% Notes due 2025
Debt Instrument [Line Items]
Principal Value	1,000	1,000
1.000% Euro Notes due 2025
Debt Instrument [Line Items]
Principal Value	613	651
3.875% Notes due 2025
Debt Instrument [Line Items]
Principal Value	229	1,925
3.200% Notes due 2026
Debt Instrument [Line Items]
Principal Value	1,750	2,250
6.800% Notes due 2026
Debt Instrument [Line Items]
Principal Value	256	256
1.125% Notes due 2027
Debt Instrument [Line Items]
Principal Value	1,000	1,000
3.250% Notes due 2027
Debt Instrument [Line Items]
Principal Value	512	750
3.450% Notes due 2027
Debt Instrument [Line Items]
Principal Value	534	1,000
3.900% Notes due 2028
Debt Instrument [Line Items]
Principal Value	1,500	1,500
3.400% Notes due 2029
Debt Instrument [Line Items]
Principal Value	2,400	4,000
1.450% Notes due 2030
Debt Instrument [Line Items]
Principal Value	1,250	1,250
2.950% Notes due 2032
Debt Instrument [Line Items]
Principal Value	1,750	0
1.750% Euro Notes due 2035
Debt Instrument [Line Items]
Principal Value	613	651
5.875% Notes due 2036
Debt Instrument [Line Items]
Principal Value	279	279
6.125% Notes due 2038
Debt Instrument [Line Items]
Principal Value	219	219
4.125% Notes due 2039
Debt Instrument [Line Items]
Principal Value	2,000	2,000
2.350% Notes due 2040
Debt Instrument [Line Items]
Principal Value	750	750
5.700% Notes due 2040
Debt Instrument [Line Items]
Principal Value	153	193
3.550% Notes due 2042
Debt Instrument [Line Items]
Principal Value	1,250	0
3.250% Notes due 2042
Debt Instrument [Line Items]
Principal Value	500	500
5.250% Notes due 2043
Debt Instrument [Line Items]
Principal Value	226	280
4.500% Notes due 2044
Debt Instrument [Line Items]
Principal Value	342	500
4.625% Notes due 2044
Debt Instrument [Line Items]
Principal Value	748	748
5.000% Notes due 2045
Debt Instrument [Line Items]
Principal Value	758	1,768
4.350% Notes due 2047
Debt Instrument [Line Items]
Principal Value	1,250	1,250
4.550% Notes due 2048
Debt Instrument [Line Items]
Principal Value	1,272	1,486
4.250% Notes due 2049
Debt Instrument [Line Items]
Principal Value	3,750	3,750
2.550% Notes due 2050
Debt Instrument [Line Items]
Principal Value	1,500	1,500
3.700% Notes due 2052
Debt Instrument [Line Items]
Principal Value	2,000	0
3.900% Notes due 2062
Debt Instrument [Line Items]
Principal Value	1,000	0
6.875% Notes due 2097
Debt Instrument [Line Items]
Principal Value	63	86
0.13% - maturing through 2023
Debt Instrument [Line Items]
Principal Value	15	51
Interest rate swap contracts
Debt Instrument [Line Items]
Fair value of interest rate swap contracts	$ (18)	$ 10

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2027	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2022
Debt Instrument [Line Items]
Long-term debt, fair value						$ 34,900	$ 49,100
Unsecured senior notes, principal amount						6,000		$ 7,000
Proceeds from debt, net of issuance costs						5,900		6,900
Extinguishment of debt						6,000	3,500
Payment for debt extinguishment						6,600	4,000
Loss on debt redemption						(266)	(281)	0
Principal Value						38,234	43,095
Repayments of notes payable						4,800	2,000	2,800
Interest payments						1,400	1,500	$ 1,600
Available financial guarantees						$ 1,400
Forecast
Debt Instrument [Line Items]
Long-term debt, maturity, 2023					$ 3,900
Long-term debt, maturity, 2024				$ 2,900
Long-term debt, maturity, 2025			$ 1,800
Long-term debt, maturity, 2026		$ 2,000
Long-term debt, maturity, 2027	$ 2,000
Interest payment	$ 977	$ 1,000	$ 1,100	$ 1,100	$ 1,200
$5 Billion Maximum Borrowing Capacity
Debt Instrument [Line Items]
Long-term debt, term (in years)						5 years
Line of credit facility, maximum borrowing capacity									$ 5,000
Renewal period									1 year
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Borrowings outstanding						$ 0	$ 0

RECEIVABLES - Schedule of Accou

RECEIVABLES - Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Trade receivables	$ 8,848	$ 8,723
Less charge-backs and cash discounts	(675)	(723)
Less allowance for expected credit loss	(22)	(21)
Net trade receivables	8,151	7,979
Alliance, royalties, VAT and other	1,735	1,390
Receivables	$ 9,886	$ 9,369

RECEIVABLES - Additional Inform

RECEIVABLES - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) wholesaler	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables sold on a nonrecourse basis \| $	$ 1,000	$ 1,500	$ 1,200
The number of the largest pharmaceutical wholesalers in the U.S. \| wholesaler	3
Customer Concentration Risk
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of aggregate total trade receivables due	66%	59%

RECEIVABLES - Receivables Allow

RECEIVABLES - Receivables Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$ 744	$ 663	$ 412
Provision	7,476	7,257	5,839
Utilization	(7,521)	(7,170)	(5,601)
Other	(2)	(6)	13
Balance at end of year	697	744	663
Provision for expected credit loss	$ 7	$ 4	$ 12

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Finished goods	$ 509	$ 543
Work in process	1,850	2,111
Raw and packaging materials	464	350
Total Inventories	2,823	3,004
Inventories	2,339	2,095
Other non-current assets	484	909
Inventory Purchase Price Fair Value Adjustment
Inventories, fair value adjustment	$ 84	$ 508

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Land	$ 162	$ 169
Buildings	5,920	5,897
Machinery, equipment and fixtures	3,284	3,252
Construction in progress	1,053	764
Gross property, plant and equipment	10,419	10,082
Less accumulated depreciation	(4,164)	(4,033)
Property, plant and equipment	6,255	6,049
Depreciation expense	587	559	$ 586
United States
Property, Plant and Equipment [Line Items]
Property, plant and equipment	4,833	4,710
International
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 1,422	$ 1,339

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
ROU asset obtained in exchange for operating lease liability	$ 492
Operating lease payments	203	$ 189	$ 164
Operating leases not yet commenced	$ 754
ROU asset impairment charge			$ 31
Minimum \| Facility Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	1 year
Operating lease, renewal term	1 year
Minimum \| Vehicle Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	1 year
Maximum \| Facility Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	15 years
Operating lease, renewal term	10 years
Maximum \| Vehicle Lease
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	4 years

LEASES - Summary of Components

LEASES - Summary of Components of Lease Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 224	$ 220	$ 194
Variable lease cost	55	44	50
Short-term lease cost	20	17	19
Sublease income	(6)	(7)	(4)
Total operating lease expense	$ 293	$ 274	$ 259

LEASES - Balance Sheet Informat

LEASES - Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Other non-current assets	$ 1,220	$ 919
Other current liabilities	136	169
Other non-current liabilities	1,261	874
Total liabilities	$ 1,397	$ 1,043
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other non-current assets	Other non-current assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other non-current liabilities	Other non-current liabilities

LEASES - Summary of Operating L

LEASES - Summary of Operating Lease Maturity (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2023	$ 187
2024	191
2025	169
2026	149
2027	145
Thereafter	933
Total future lease payments	1,774
Less imputed interest	(377)
Total lease liability	$ 1,397	$ 1,043

LEASES - Supplemental Balance S

LEASES - Supplemental Balance Sheet Information Related To Leases (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term	11 years	10 years
Weighted average discount rate	4%	3%

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Beginning balance	$ 20,502	$ 20,547
Currency translation and other adjustments	(48)	(45)
Ending balance	21,149	20,502
Turning Point
Goodwill [Roll Forward]
Turning Point acquisition	695	$ 0
Ending balance	$ 695

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other intangible assets
Total other intangible assets, gross carrying amounts	$ 68,992	$ 66,010
Accumulated amortization	(33,133)	(23,483)
Other intangible assets, net	35,859	42,527
IPRD
Other intangible assets
IPRD	6,560	3,750
Other intangible assets, net	6,560	3,750
Licenses
Other intangible assets
Finite-lived intangible assets, net	400	307
Accumulated amortization	(128)	(102)
Other intangible assets, net	$ 272	205
Licenses \| Minimum
Other intangible assets
Finite-lived intangible asset, useful life (years)	5 years
Licenses \| Maximum
Other intangible assets
Finite-lived intangible asset, useful life (years)	15 years
Acquired marketed product rights
Other intangible assets
Finite-lived intangible assets, net	$ 60,477	60,454
Accumulated amortization	(31,949)	(22,380)
Other intangible assets, net	$ 28,528	38,074
Acquired marketed product rights \| Minimum
Other intangible assets
Finite-lived intangible asset, useful life (years)	3 years
Acquired marketed product rights \| Maximum
Other intangible assets
Finite-lived intangible asset, useful life (years)	15 years
Capitalized software
Other intangible assets
Finite-lived intangible assets, net	$ 1,555	1,499
Accumulated amortization	(1,056)	(1,001)
Other intangible assets, net	$ 499	$ 498
Capitalized software \| Minimum
Other intangible assets
Finite-lived intangible asset, useful life (years)	3 years
Capitalized software \| Maximum
Other intangible assets
Finite-lived intangible asset, useful life (years)	10 years

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other intangible assets
Amortization of intangible assets	$ 9,700	$ 10,200	$ 9,900
Future estimated amortization, 2023	9,200
Future estimated amortization, 2024	8,400
Future estimated amortization, 2025	2,900
Future estimated amortization, 2026	1,400
Future estimated amortization, 2027	1,300
Impairment of other intangible assets	101	1,200	1,100
Payments to acquire intangible assets		300
Investigational Compound for Hematologic Diseases \| Celgene
Other intangible assets
Impairment of other intangible assets	$ 98	610
Investigational Compound for Fibrotic Diseases \| Celgene
Other intangible assets
Impairment of other intangible assets		230
Inrebic
Other intangible assets
Impairment of other intangible assets		315	575
Inrebic \| Acquired marketed product rights
Other intangible assets
Finite-lived intangible assets, net		$ 385
Orva-cel
Other intangible assets
Impairment of other intangible assets			$ 470

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Supplemental Financial Information [Abstract]
Income taxes	$ 3,547	$ 2,786
Research and development	579	514
Contract assets	504	361
Equity investments	0	255
Restricted cash	148	140
Other	1,017	776
Other current assets	$ 5,795	$ 4,832

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Supplemental Financial Information [Abstract]
Equity investments	$ 2,187	$ 2,713
Inventories	484	909
Operating leases	1,220	919
Pension and postretirement	285	317
Research and development	496	248
Restricted cash	54	197
Other	214	232
Other non-current assets	$ 4,940	$ 5,535

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Supplemental Financial Information [Abstract]
Rebates and discounts	$ 6,702	$ 6,399
Income taxes	942	754
Employee compensation and benefits	1,425	1,375
Research and development	1,359	1,373
Dividends	1,196	1,186
Interest	321	378
Royalties	431	410
Operating leases	136	169
Other	2,074	1,927
Other current liabilities	$ 14,586	$ 13,971

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Supplemental Financial Information [Abstract]
Income taxes	$ 3,992	$ 4,835
Pension and postretirement	402	654
Operating leases	1,261	874
Deferred income	283	326
Deferred compensation	349	427
Other	303	218
Other non-current liabilities	$ 6,590	$ 7,334

EQUITY - Schedule of Stockholde

EQUITY - Schedule of Stockholders Equity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Line Items]
Beginning balance	$ 36,006
Treasury stock, shares (in shares)	825	747
Net loss	$ 6,327	$ 6,994	$ (9,015)
Net earnings attributable to noncontrolling interest	(18)	(20)	(20)
Other Comprehensive Income/(Loss)	(13)	571	$ (319)
Ending balance	$ 31,118	$ 36,006
Dividends declared (in usd per share)	$ 2.19	$ 2.01	$ 1.84
Common Stock
Equity [Line Items]
Beginning balance (in shares)	2,923	2,923	2,923
Beginning balance	$ 292	$ 292	$ 292
Ending balance (in shares)	2,923	2,923	2,923
Ending balance	$ 292	$ 292	$ 292
Capital in Excess of Par Value of Stock
Equity [Line Items]
Beginning balance	44,361	44,325	43,709
Share repurchase program			1,400
Stock compensation	804	36	(784)
Ending balance	45,165	44,361	44,325
Accumulated Other Comprehensive Loss
Equity [Line Items]
Beginning balance	(1,268)	(1,839)	(1,520)
Other Comprehensive Income/(Loss)	(13)	571	(319)
Ending balance	(1,281)	(1,268)	(1,839)
Retained Earnings
Equity [Line Items]
Beginning balance	23,820	21,281	34,474
Net loss	6,327	6,994	(9,015)
Cash dividends declared	(4,644)	(4,455)	(4,178)
Ending balance	25,503	23,820	21,281
Treasury Stock
Equity [Line Items]
Beginning balance	$ (31,259)	$ (26,237)	$ (25,357)
Treasury stock, shares (in shares)	825	747	679	672
Share repurchase program	$ (8,001)	$ (6,240)	$ (2,993)
Stock repurchase program (in shares)	109	102	43
Stock compensation	$ 642	$ 1,218	$ 2,113
Stock compensation (in shares)	(31)	(34)	(36)
Ending balance	$ (38,618)	$ (31,259)	$ (26,237)
Noncontrolling Interest
Equity [Line Items]
Beginning balance	60	60	100
Net earnings attributable to noncontrolling interest	18	20	20
Distributions	(21)	(20)	(60)
Ending balance	$ 57	$ 60	$ 60

EQUITY - Additional Information

EQUITY - Additional Information (Details) - USD ($) shares in Millions, $ in Billions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock repurchase program, remaining authorized repurchase amount	$ 7.2	$ 15.2
Stock repurchased during period (in shares)	40
Stock repurchased during period	$ 3
2022 ASR
Stock repurchase program, authorized amount	$ 5
Stock repurchased during period (in shares)	69

EQUITY - Schedule of Comprehens

EQUITY - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Unrealized gains/(losses), pretax	$ 585	$ 364	$ (216)
Unrealized gains/(losses), tax	(79)	(34)	7
Unrealized gains/(losses), after tax	506	330	(209)
Reclassified to net earnings, pretax	(524)	95	(54)
Reclassified to net earnings, tax	72	(10)	7
Reclassified to net earnings, after tax	(452)	85	(47)
Derivatives qualifying as cash flow hedges, pretax	61	459	(270)
Derivatives qualifying as cash flow hedges, tax	(7)	(44)	14
Derivatives qualifying as cash flow hedges, after tax	54	415	(256)
Actuarial losses, pretax	146	220	(134)
Actuarial losses, tax	(25)	(40)	25
Actuarial losses, after tax	121	180	(109)
Amortization, pretax	21	41	33
Amortization, tax	(6)	(10)	(6)
Amortization, after tax	15	31	27
Settlements, pretax	11	(6)	10
Settlements, tax	(2)	1	(3)
Settlements, after tax	9	(5)	7
Pension and postretirement benefits, pretax	178	255	(91)
Pension and postretirement benefits, tax	(33)	(49)	16
Pension and postretirement benefits, after tax	145	206	(75)
Unrealized (losses)gains, pretax	(2)	(11)	7
Unrealized (losses)gains, tax	0	2	(1)
Unrealized (losses)gains, after tax	(2)	(9)	6
Realized (losses)gains, pretax	0	0	(1)
Realized (losses)gains, tax	0	0	0
Realized (losses)gains, after tax	0	0	(1)
Marketable debt securities, pretax	(2)	(11)	6
Marketable debt securities, tax	0	2	(1)
Marketable debt securities, after tax	(2)	(9)	5
Foreign currency translation, pretax	(183)	(14)	(19)
Foreign currency translation, tax	(27)	(27)	26
Foreign currency translation, after tax	(210)	(41)	7
Other Comprehensive Income/(Loss), pretax	54	689	(374)
Other Comprehensive Income/(Loss), tax	(67)	(118)	55
Other Comprehensive Income/(Loss), after tax	$ (13)	$ 571	$ (319)

EQUITY - Schedule of Accumulate

EQUITY - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Derivatives qualifying as cash flow hedges	$ 232	$ 178
Pension and postretirement benefits	(623)	(768)
Marketable debt securities	0	2
Foreign currency	(890)	(680)
Accumulated other comprehensive loss	(1,281)	(1,268)
Net investment hedges gains	$ 125	$ 30

RETIREMENT BENEFITS - Additiona

RETIREMENT BENEFITS - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Accumulated benefit obligation	$ 2,000	$ 2,900
Pension asset transfer			$ 381
Reversion excise tax			76
Defined contribution plan expense	$ 360	350	290
Equity Securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Investment allocation, percentage	23%
Debt Securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Investment allocation, percentage	66%
Total return swap contracts
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Investment allocation, percentage	11%
Pension Plans, Defined Benefit
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Net periodic benefit cost of defined benefit pension plans	$ 27	28	42
Benefit obligation	$ 1,976	$ 2,935	$ 3,242
Discount rate	4%	1.60%
Other Postretirement Benefits Plan
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Benefit obligation	$ 187	$ 237
Discount rate	5%	2.50%

RETIREMENT BENEFITS - Schedule

RETIREMENT BENEFITS - Schedule Of Defined Benefit Obligations And Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan, Change in Fair Value of Plan Assets
Fair value of plan assets at beginning of year	$ 2,815
Fair value of plan assets at end of year	2,027	$ 2,815
Other non-current assets	285	317
Other non-current liabilities	(402)	(654)
Pension Plans, Defined Benefit
Defined Benefit Plan, Change in Benefit Obligation
Benefit obligations at beginning of year	2,935	3,242
Service cost—benefits earned during the year	36	51
Interest cost	42	35
Settlements and curtailments	(58)	(101)
Actuarial (gains)/losses	(760)	(153)
Benefits paid	(68)	(46)
Foreign currency and other	(151)	(93)
Benefit obligations at end of year	1,976	2,935
Defined Benefit Plan, Change in Fair Value of Plan Assets
Fair value of plan assets at beginning of year	2,815	2,807
Actual return on plan assets	(570)	125
Employer contributions	76	87
Settlements	(53)	(83)
Benefits paid	(68)	(46)
Foreign currency and other	(173)	(75)
Fair value of plan assets at end of year	2,027	2,815
Funded status	51	(120)
Other non-current assets	285	317
Other current liabilities	(21)	(24)
Other non-current liabilities	(213)	(413)
Funded status	51	(120)
Net actuarial losses	869	1,015
Prior service credit	(25)	(29)
Total	$ 844	$ 986

RETIREMENT BENEFITS - Schedul_2

RETIREMENT BENEFITS - Schedule Of Accumulated And Projected Benefit Obligation In Excess Of Fair Value Of Plan Assets (Details) - Pension Plans, Defined Benefit - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Projected benefit obligation	$ 728	$ 1,274
Fair value of plan assets	495	836
Accumulated benefit obligation	728	1,245
Fair value of plan assets	$ 495	$ 832

RETIREMENT BENEFITS - Actuarial

RETIREMENT BENEFITS - Actuarial Assumptions (Details) - Pension Plans, Defined Benefit	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Discount rate	4%	1.60%
Rate of compensation increase	1.20%	1%
Interest crediting rate	2.50%	2.10%
Discount rate	1.60%	1.20%	1.60%
Expected long-term return on plan assets	3.60%	3.60%	4.10%
Rate of compensation increase	1%	1.30%	1.30%
Interest crediting rate	2.10%	2.20%	2.20%

RETIREMENT BENEFITS - Fair Valu

RETIREMENT BENEFITS - Fair Value of Pension Plan Assets by Asset Category (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	$ 2,027	$ 2,815
Level 1
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	44	91
Level 1 \| Equity securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	1	44
Level 1 \| Equity funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 1 \| Fixed income funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 1 \| Corporate debt securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 1 \| U.S. Treasury and agency securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 1 \| Insurance contracts
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 1 \| Cash and cash equivalents
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	43	47
Level 1 \| Other
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 2
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	1,531	2,216
Level 2 \| Equity securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 2 \| Equity funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	368	625
Level 2 \| Fixed income funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	697	815
Level 2 \| Corporate debt securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	376	485
Level 2 \| U.S. Treasury and agency securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	75	67
Level 2 \| Insurance contracts
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 2 \| Cash and cash equivalents
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 2 \| Other
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	15	224
Level 3
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	158	172
Level 3 \| Equity securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| Equity funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| Fixed income funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| Corporate debt securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| U.S. Treasury and agency securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| Insurance contracts
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	123	130
Level 3 \| Cash and cash equivalents
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	0	0
Level 3 \| Other
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	35	42
Fair Value, Inputs, Level 1, 2 and 3
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	1,733	2,479
Fair Value, Inputs, Level 1, 2 and 3 \| Equity securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	1	44
Fair Value, Inputs, Level 1, 2 and 3 \| Equity funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	368	625
Fair Value, Inputs, Level 1, 2 and 3 \| Fixed income funds
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	697	815
Fair Value, Inputs, Level 1, 2 and 3 \| Corporate debt securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	376	485
Fair Value, Inputs, Level 1, 2 and 3 \| U.S. Treasury and agency securities
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	75	67
Fair Value, Inputs, Level 1, 2 and 3 \| Insurance contracts
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	123	130
Fair Value, Inputs, Level 1, 2 and 3 \| Cash and cash equivalents
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	43	47
Fair Value, Inputs, Level 1, 2 and 3 \| Other
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	50	266
Plan assets measured at NAV as a practical expedient \| Plan assets measured at NAV as a practical expedient
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Fair value of pension and postretirement plan asset	$ 294	$ 336

EMPLOYEE STOCK BENEFIT PLANS -

EMPLOYEE STOCK BENEFIT PLANS - Stock Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 457	$ 583	$ 779
Income tax benefit	91	120	158
Excess tax benefits from share-based compensation awards	74	38	35
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	41	57	37
Marketing, selling and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	195	241	332
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	221	272	339
Other (income)/expense, net
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 0	$ 13	$ 71

EMPLOYEE STOCK BENEFIT PLANS _2

EMPLOYEE STOCK BENEFIT PLANS - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 457	$ 583	$ 779
Closing share price (in usd per share)	$ 71.95
Celgene
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 96	192	382
Share-based payment arrangement, accelerated cost		$ 13	$ 71
Stock Options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Equity awards outstanding (in shares)	21.9	47
Award vesting period	4 years
Award expiration period	10 years
MSUs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Award vesting period	4 years
MSUs \| Minimum \| Vesting Condition One
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Payout factor percentage	60%
MSUs \| Maximum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Payout factor percentage	225%	200%
MSUs \| Maximum \| Vesting Condition One
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Payout factor percentage	80%
PSUs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Award vesting period	3 years
PSUs \| Minimum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Payout factor percentage	0%
PSUs \| Maximum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Payout factor percentage	200%
RSUs \| Minimum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Award vesting period	3 years
RSUs \| Maximum
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Award vesting period	4 years
2021 Stock Incentive Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Shares to be authorized for grants (in shares)		85
Shares available to be granted for active plans (in shares)	81
Equity awards outstanding (in shares)	44

EMPLOYEE STOCK BENEFIT PLANS _3

EMPLOYEE STOCK BENEFIT PLANS - Summary of Stock Compensation Activity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted-average exercise price per stock
Total intrinsic value of stock options exercised	$ 526	$ 512	$ 556
Stock Options
Stock compensation activity, shares
Stock options, beginning balance (in shares)	47
Stock options, granted (in shares)	0
Stock options, released/exercised (in shares)	(24.3)
Stock options, adjustments for actual payout (in shares)	0
Stock options, forfeited/canceled (in shares)	(0.8)
Stock options, ending balance (in shares)	21.9	47
Weighted-average exercise price per stock
Stock options, weighted-average exercise price at the beginning of the period (in dollars per share)	$ 53
Stock options, granted, weighted-average exercise price at the beginning of the period (in dollars per share)	0
Stock options, released/exercised, weighted-average exercise price at the beginning of the period (in dollars per share)	50.79
Stock options, adjustments for actual payout, weighted-average exercise price at the beginning of the period (in dollars per share)	0
Stock options, forfeited/canceled, weighted-average exercise price at the beginning of the period (in dollars per share)	58.70
Stock options, weighted-average exercise price at the end of the period (in dollars per share)	$ 55.25	$ 53
RSUs
Stock compensation activity, shares
Other than options, beginning balance (in shares)	19.1
Other than options, granted (in shares)	8.7
Other than options, released/exercised (in shares)	(8.2)
Other than options, adjustments for actual payout (in shares)	0
Other than options, forfeited/canceled (in shares)	(2.7)
Other than options, ending balance (in shares)	16.9	19.1
Weighted-average exercise price per stock
Other than options, weighted average grant date fair value at the beginning of the period (in usd per share)	$ 54.92
Other than options, granted, weighted average grant date fair value (in usd per share)	64.12	$ 56.58	$ 53.65
Other than options, released/exercised, weighted average grant date fair value (in usd per share)	55.12
Other than options, adjustments for actual payout, weighted average grant date fair value (in usd per share)	0
Other than options, forfeited/canceled, weighted average grant date fair value (in usd per share)	57.43
Other than options, weighted average grant date fair value at the end of the period (in usd per share)	$ 59.17	$ 54.92
Other than options, expected to vest (in shares)	14.9
Other than options, expected to vest, weighted average grant date fair value (in usd per share)	$ 58.97
Unrecognized compensation cost	$ 734
Expected weighted-average period in years of compensation cost to be recognized	2 years 6 months
Fair value of awards that vested during the year	$ 300	$ 246	$ 122
RSUs \| Legacy Celgene Plans
Weighted-average exercise price per stock
Fair value of awards that vested during the year	$ 152	$ 519	$ 777
MSUs
Stock compensation activity, shares
Other than options, beginning balance (in shares)	1.8
Other than options, granted (in shares)	1
Other than options, released/exercised (in shares)	(0.8)
Other than options, adjustments for actual payout (in shares)	0.1
Other than options, forfeited/canceled (in shares)	(0.3)
Other than options, ending balance (in shares)	1.8	1.8
Weighted-average exercise price per stock
Other than options, weighted average grant date fair value at the beginning of the period (in usd per share)	$ 56.51
Other than options, granted, weighted average grant date fair value (in usd per share)	60.74	$ 58.04	$ 53.92
Other than options, released/exercised, weighted average grant date fair value (in usd per share)	56.95
Other than options, adjustments for actual payout, weighted average grant date fair value (in usd per share)	54.26
Other than options, forfeited/canceled, weighted average grant date fair value (in usd per share)	57.63
Other than options, weighted average grant date fair value at the end of the period (in usd per share)	$ 58.25	$ 56.51
Other than options, expected to vest (in shares)	1.6
Other than options, expected to vest, weighted average grant date fair value (in usd per share)	$ 58.12
Unrecognized compensation cost	$ 49
Expected weighted-average period in years of compensation cost to be recognized	2 years 9 months 18 days
Fair value of awards that vested during the year	$ 44	$ 37	$ 37
PSUs
Stock compensation activity, shares
Other than options, beginning balance (in shares)	3.4
Other than options, granted (in shares)	1.4
Other than options, released/exercised (in shares)	(1.3)
Other than options, adjustments for actual payout (in shares)	0.4
Other than options, forfeited/canceled (in shares)	(0.4)
Other than options, ending balance (in shares)	3.5	3.4
Weighted-average exercise price per stock
Other than options, weighted average grant date fair value at the beginning of the period (in usd per share)	$ 55.38
Other than options, granted, weighted average grant date fair value (in usd per share)	66.76	$ 59.04	$ 55.61
Other than options, released/exercised, weighted average grant date fair value (in usd per share)	49.99
Other than options, adjustments for actual payout, weighted average grant date fair value (in usd per share)	49.99
Other than options, forfeited/canceled, weighted average grant date fair value (in usd per share)	60.26
Other than options, weighted average grant date fair value at the end of the period (in usd per share)	$ 60.88	$ 55.38
Other than options, expected to vest (in shares)	3.2
Other than options, expected to vest, weighted average grant date fair value (in usd per share)	$ 60.45
Unrecognized compensation cost	$ 89
Expected weighted-average period in years of compensation cost to be recognized	1 year 8 months 12 days
Fair value of awards that vested during the year	$ 68	$ 61	$ 59

EMPLOYEE STOCK BENEFIT PLANS _4

EMPLOYEE STOCK BENEFIT PLANS - Summary of Significant Outstanding and Exercisable Options (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding (in shares) \| shares	21.9
Number of options exercisable (in shares) \| shares	21.9
Options outstanding, weighted average remaining contractual life (years)	2 years 9 months 18 days
Options exercisable, weighted average remaining contractual life (years)	2 years 9 months 18 days
Options outstanding, weighted-average exercise price per share (in usd per share)	$ 55.25
Options exercisable, weighted-average exercise price per share (in usd per share)	$ 55.25
Options outstanding, aggregate intrinsic value \| $	$ 366
Options exercisable, aggregate intrinsic value \| $	$ 366
$10 - $40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding (in shares) \| shares	2.2
Options outstanding, weighted average remaining contractual life (years)	1 year
Options outstanding, weighted-average exercise price per share (in usd per share)	$ 35.02
Options outstanding, aggregate intrinsic value \| $	$ 80
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	$ 10
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit	$ 40
$40 - $55
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding (in shares) \| shares	7.7
Options outstanding, weighted average remaining contractual life (years)	3 years 3 months 18 days
Options outstanding, weighted-average exercise price per share (in usd per share)	$ 48.92
Options outstanding, aggregate intrinsic value \| $	$ 177
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	$ 40
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit	$ 55
$55 - $65
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding (in shares) \| shares	8
Options outstanding, weighted average remaining contractual life (years)	2 years 8 months 12 days
Options outstanding, weighted-average exercise price per share (in usd per share)	$ 59.45
Options outstanding, aggregate intrinsic value \| $	$ 100
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	$ 55
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit	$ 65
$65 +
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding (in shares) \| shares	4
Options outstanding, weighted average remaining contractual life (years)	3 years 2 months 12 days
Options outstanding, weighted-average exercise price per share (in usd per share)	$ 70.02
Options outstanding, aggregate intrinsic value \| $	$ 9
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	$ 65

LEGAL PROCEEDINGS AND CONTING_2

LEGAL PROCEEDINGS AND CONTINGENCIES (Details) $ in Millions, $ in Millions	1 Months Ended
	Feb. 28, 2021 USD ($)	Apr. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2015 patent	Mar. 31, 2010 USD ($)	Mar. 31, 2010 AUD ($)	Dec. 31, 2022 USD ($) lawsuit plaintiff	Jun. 30, 2022 claim	Apr. 01, 2022	Mar. 30, 2022 lawsuit	Jun. 30, 2021 USD ($)
Legal Proceedings And Contingencies [Line Items]
Running royalty									0.015
Damages sought \| $	$ 834
Obligation to holders of the contingent value rights \| $											$ 6,400
Future costs \| $							$ 91
Anti-PD-1 Antibody Litigation
Legal Proceedings And Contingencies [Line Items]
Number of patents \| patent				6
Onglyza Product Liability Litigation
Legal Proceedings And Contingencies [Line Items]
Pending claims \| lawsuit										18
Abilify Product Liability Litigation
Legal Proceedings And Contingencies [Line Items]
Dismissed cases \| lawsuit							2,700
Number of plaintiffs, dismissed cases \| plaintiff							3,900
Abilify Product Liability \| CANADA
Legal Proceedings And Contingencies [Line Items]
Pending claims \| lawsuit							11
Class action claims \| lawsuit							4
Individual injury claims \| lawsuit							7
Pending claims, active \| lawsuit							2
Plavix Australia Intellectual Property \| Australia, Dollars
Legal Proceedings And Contingencies [Line Items]
Maximum damages \| $						$ 449
Plavix Australia Intellectual Property \| United States of America, Dollars
Legal Proceedings And Contingencies [Line Items]
Maximum damages \| $					$ 304
CAR T Kite Litigation
Legal Proceedings And Contingencies [Line Items]
Payments for royalties \| $		$ 1,200	$ 585
Running royalty		0.276	0.276
Molina Litigation
Legal Proceedings And Contingencies [Line Items]
Dismissed cases \| claim								4
Class action claims \| claim								63
Opt-Out Entities
Legal Proceedings And Contingencies [Line Items]
Class action claims \| lawsuit							2
Bristol-Myers Squibb
Legal Proceedings And Contingencies [Line Items]
Damages sought \| $	$ 417